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Abstract 
 
Introduction: Chronic sustained hypoxia (CH) induces functional weakness, 
atrophy, and mitochondrial remodelling in the diaphragm muscle. Animal models of 
CH present with changes similar to patients with respiratory-related disease. 
Elucidating the molecular mechanisms that drive diaphragm adaptations to CH is 
clinically important. Reactive oxygen species (ROS) are produced by – and 
contribute to – damaged mitochondria while hypoxia and increased muscle 
contractile activity also promote ROS formation. We hypothesize that ROS are 
pivotal in diaphragm muscle adaptation to CH. 
 
Method: C57BL6/J mice were exposed to CH (FiO2=0.1) for one, three, and six 
weeks. Sternohyoid (upper airway dilator), extensor digitorum longus (EDL), and 
soleus were studied as reference muscles as well as the diaphragm which was the 
major focus of this thesis. The diaphragm was profiled using a redox proteomics 
approach followed by mass spectrometry. Following this, redox-modified metabolic 
enzyme activities and atrophy signalling were assessed using spectrophotometric 
assays and ELISA. Diaphragm isotonic performance was assessed after six weeks of 
CH ± chronic antioxidant supplementation. 
 
Results: Protein carbonyl and free thiol content in the diaphragm were increased and 
decreased respectively after six weeks of CH – indicative of protein oxidation. These 
changes were temporally modulated and muscle specific. Extensive remodelling of 
metabolic proteins occurred and the stress reached the cross-bridge. Metabolic 
enzyme activities in the diaphragm were, for the most part, decreased by CH and 
differential muscle responses were observed. Redox sensitive chymotrypsin-like 
proteasome activity of the diaphragm was increased and atrophy signalling was 
observed through decreased phospho-FOXO3a and phospho-mTOR. Phospho-p38 
MAPK content was increased and this was attenuated by antioxidant treatment. 
Hypoxia decreased power generating capacity of the diaphragm and this was 
restored by N-acetyl-cysteine (NAC) but not by tempol. 
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Conclusion: Redox remodelling is pivotal for diaphragm adaptation to chronic 
sustained hypoxia. Muscle changes are dependent on duration of the hypoxia 
stimulus, activity profile of the muscle, and molecular composition of the muscle. 
The working respiratory muscles and slow oxidative fibres are particularly 
susceptible. Atrophy signalling through FOXO3a is likely mediated by p38MAPK 
and not Akt. NAC (antioxidant) may be useful as an adjunct therapy in respiratory-
related diseases characterised by hypoxic stress. 
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1.1 Hypoxia 
 
Hypoxia is a condition of insufficient O2 delivery to – or utilisation by – the body’s 
cells and tissues such that metabolic demands are not adequately met. An abrupt or 
rapid depletion in available oxygen (acute hypoxia) may result from exercise, 
asphyxia, airway obstruction or acute haemorrhaging. In comparison, chronic 
sustained hypoxia (CH) is encountered in chronic respiratory disease or upon ascent 
to high altitude – although there may be overlap between chronic and acute under 
some circumstances such as exacerbations of disease. Hypoxia is also featured 
during embryonic development, ischaemia and tumours. Of course these generally 
present focal hypoxia as opposed to widespread hypoxaemia (low blood oxygen 
content/partial pressure). Approximately 90-100mmHg constitutes the normal range 
of partial pressure of oxygen in arterial blood (PaO2). Clinically, the PaO2 in chronic 
obstructive pulmonary disease (COPD) patients can drop below 60mmHg [1,2]. 
PaO2 has been reported as low as 28mmHg near the summit of Mt Everest [3]. 
 
Hypoxia is classified into five distinct types: hypoxic, anaemic, stagnant, histotoxic, 
and genetic. Hypoxic hypoxia is attributable to insufficient O2 in inspired air, 
decreased oxygen partial pressure (PO2) in the alveolus or inadequate O2 transfer 
from the alveoli into pulmonary capillaries. It may transpire by means of ascent to 
high altitude, hypoventilation, diffusion abnormalities, pulmonary shunting or 
ventilation/perfusion mismatch. Anaemic hypoxia is an abnormally low O2 carrying 
capacity of the blood due to either a lack of haemoglobin (Hgb) (e.g. during 
hypovolaemia) or poor Hgb-oxygen binding capacity (e.g. carbon monoxide 
poisoning). Stagnant hypoxia is a result of poor blood perfusion such as occurs in 
several cardiovascular pathologies. Histotoxic hypoxia arises when tissues cannot 
metabolise sufficient oxygen despite adequate PO2 and oxygen delivery (e.g. sepsis). 
Genetic hypoxia can arise from mutations in genes responsible for degradation of 
hypoxia-responsive proteins in normoxic conditions (e.g. congenital polycythaemia) 
and can lead to dysfunction of oxygen utilisation and homeostasis in cells. 
 
The physiological response to hypoxia depends on the rate and degree of exposure 
e.g. a mountain climber who has spent some weeks at high altitude is able to remain 
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conscious and continue on his upward route whereas a pilot in an unpressurised 
aircraft at the height of the summit of Mt. Everest (8848m) who loses his oxygen 
supply would lose consciousness in a matter of minutes [4]. Classic hypoxia 
acclimatisation responses include reflex hyperventilation followed by progressive 
decline before ventilation plateaus at a higher level than in normoxia. Increases in 
[Hgb], capillary density and heart rate also occur. These changes may be considered 
beneficial but CH can result in pathologies such as hypoxic pulmonary 
vasoconstriction, pulmonary hypertension, and cor pulmonale. These result from 
vascular wall remodelling including thickening of vessel walls and extension of 
smooth muscle cells into previously non-muscular arterioles. Elevated pulmonary 
arterial pressures result in increased right heart workload which can lead to right 
heart failure. Polycythaemia is considered contributory to Monge’s disease in 
Andean populations and elevated blood viscosity can lead to left heart problems. 
High altitude is defined as >2,500m above sea level and full acclimatisation can take 
up to three weeks or more [5]. 
 
1.2 Skeletal Muscle 
 
Skeletal muscle, as the name suggests, is connected at one or both ends to the 
skeleton and is the main effector organ of the locomotor system with an attendant 
role in thermoregulation, excretory functions, and more recently a role in endocrine 
physiology.  It consists of bundles of long, multinucleated, thick or thin, fused fibres 
that appear transversely striated under a microscope. Muscle fibres differ in their 
abilities to generate power and carry out mechanical work thus resulting in the 
heterogeneity observed in skeletal muscles. Thin, slow, oxidative fibres are designed 
for endurance activities such as postural control whereas thick, fast, glycolytic fibres 
are required where more powerful contractions against heavy loads are necessary. 
There are several classifications of fibre type – the most common classifications 
being by myosin heavy chain (MHC) isoform composition (types I, IIa, IIx and IIb; 
slow to fast respectively) or by kinetics and metabolic activities (slow oxidative, fast 
oxidative and fast glycolytic). Intermediate fibre types also occur and fibre type 
classification may vary with the technical approach used. MHC isoforms are the 
main determinant of contractile properties; the most abundant protein in skeletal 
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muscle; and several methods may be used to identify MHC isoform composition 
including immunofluorescent imaging and polyacrylamide gel electrophoresis 
(PAGE). Muscle fibre type composition is regulated by gene expression and 
microarray studies have revealed significant gene expression differences in fast and 
slow muscles [6]. At the protein level, mitogen activated protein kinase (MAPK) 
pathways, calcineurin, calmodulin (CaM) kinase IV, peroxisome proliferator γ co-
activator 1-α (PGC1-α) and hypoxia-inducible factor (HIF) transcription factors are 
involved [7–15] in regulating fibre type composition. HIF-1α and HIF-2α 
transcription factors are hypoxia-responsive and considered regulatory in fast and 
slow muscle fibre differentiation respectively [13–15]. 
 
Ultimately, the molecular compositions of slow and fast fibre types are 
heterogeneous and thus respond differently to different stimuli. Furthermore, skeletal 
muscle is an extremely malleable tissue. Hypertrophy/atrophy, metabolic activity 
and molecular composition changes and even fibre-type switching can occur as a 
result of training and/or disuse [16–21]. This becomes obvious when comparing 
professional weight lifters with long distance runners and sedentary individuals. 
Hypoxia, both short and long term exposures of different paradigms, induces 
differential muscle remodelling [22–27], ostensibly linked to molecular composition 
and functional role of the muscle. The sum total of skeletal muscle in the human 
body consumes approximately 20% of available oxygen and more than this during 
exercise. The effects of CH exposure on skeletal muscle and the molecular 
mechanisms that drive adaptation to CH, specifically in the diaphragm muscle for 
reasons that will become clear in the following paragraphs, will be explored in this 
thesis. 
 
1.2.1 The Respiratory Muscles 
The respiratory muscles, or muscles of breathing, are unique as continuous rhythmic 
activity without rest is required to sustain human life. Despite this, they have the 
same general structure and operational manner as limb muscles. The respiratory 
muscles encompass the diaphragm, the extrinsic and intrinsic intercostals and 
approximately 20 upper airway skeletal muscles. 
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1.2.2 The Diaphragm 
The diaphragm, the primary inspiratory pump muscle critical for respiration, is 
composed of a mixture of fibre types [22], is present in some form in more than 5000 
mammalian species, and is almost a completely unique trait of mammals [28]. 
Diaphragmatic contraction increases thoracic volume and subsequent negative 
pressure in the airways allows air at atmospheric pressure to flow from the external 
environment into the lungs. Upon relaxation, air can be drawn out passively by 
elastic recoil. Both force generation and fatigue resistance are important functional 
parameters for the diaphragm given its unique anatomical shape, continuous 
rhythmic activity (even during sleep), and its requirement to produce faster 
contractions such as during tachypnoea. This is reflected by its mixed fibre type 
distribution. Passive, involuntary breathing uses slow fibre types while specific 
recruitment of fast fibres occurs in the diaphragm of heat-induced rapidly ventilating 
rabbits [29]. The diaphragm is a dome-shaped membrane separating the thoracic and 
the abdominal cavities. It is innervated exclusively from the phrenic nerves 
originating from C3, C4 and C5 which provide both motor and sensory control. It is 
under both voluntary and involuntary control from the central nervous system. In 
addition to breathing, the diaphragm has physiological roles in excretion through 
increasing intra-abdominal pressure and acid reflux control through exerting pressure 
on the lower oesophageal sphincter. The major arterial blood supply comes from the 
left and right phrenic arteries. In hypoxia, blood flow is diverted away from several 
vascular beds to the diaphragm but not to other skeletal muscles [30–32], thus 
highlighting the importance of the diaphragm in hypoxic conditions. 
 
We are also interested in other respiratory and limb muscles from a comparative 
point of view and so the other muscles studied in this thesis alongside the diaphragm, 
and their functional roles, are described below.  
 
1.2.3 The Sternohyoid 
Pharyngeal dilator muscles regulate upper airway patency during breathing [33]. As 
the pharyngeal airway is not supported by bone or cartilage, it would collapse with 
the negative pressures associated with the initial phase of inspiration were it not for 
the activity of these muscles [34]. The pharyngeal dilator muscles provide much 
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needed support to the structure by contracting synchronously with the diaphragm 
[35]. The transition from wakefulness to sleep is associated with decrements in 
pharyngeal muscle tone, thus functional changes in these muscles will be of 
physiological consequence [33,36–39]. The sternohyoid, a representative upper 
airway dilator muscle which we study in parallel to the diaphragm, is composed 
almost entirely of fast type IIb fibres in rodents [22] (note: there is no information 
available regarding the composition of this muscle in humans). Sternohyoid muscle 
length has been shown to be inversely proportional to pharyngeal airway volume 
[40]. 
 
1.2.4 Hind-limb muscles 
The extensor digitorum longus (EDL) and soleus hind-limb muscles are useful for 
study alongside the diaphragm for consideration of muscle adaptations resulting 
from muscle specificity or related to the molecular composition or activity profile of 
a given muscle under a particular stimulus – CH in this case. The EDL is a powerful, 
fast glycolytic muscle, located along the anterolateral side of the leg and deep to the 
tibialis anterior, whose function involves dorsiflexion of the foot. It is composed 
predominantly of fast glycolytic fibres. In comparison, the soleus is a highly 
enduring muscle located deep to the gastrocnemius in the posterior compartment of 
the leg, composed of a very high proportion of slow oxidative fibres, and plays an 
important functional role in postural maintenance. 
 
1.3 Clinical Relevance 
 
Respiratory muscles increase their workload against hypoxic insult through reflex 
hyperventilation. The respiratory frequency of CH rats is 30–40% greater than 
normoxic controls [41]. In contrast, there may be deconditioning of limb muscles 
due to reduced activity [42]. Muscle remodelling is a feature of high altitude and 
respiratory-related diseases where hypoxia is featured [43–46], but the role of CH in 
these processes is not clear at present. 
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1.3.1 Chronic Lung Diseases 
Asthma, bronchopulmonary dysplasia, and COPD (COPD is an umbrella term for 
emphysema and bronchitis) constitute chronic lung diseases. These lung diseases 
perturb breathing and are progressive. COPD alone is the 12
th
 leading cause of death 
worldwide, 5
th
 leading cause in Western countries and, according to reports by the 
World Health Organisation, is predicted to climb to the 3
rd
 leading global cause of 
death by 2030. The main symptoms include sputum production, chronic and 
sometimes severe coughing, and shortness of breath. Co-conditions and morbidities 
can include hypertension, ischaemic heart disease, diabetes, muscle wasting and 
malaise. The primary cause of COPD is tobacco smoking but there are genetic and 
environmental risk factors. There is no cure. Respiratory muscle dysfunction is 
implicated in the pathogenesis and/or progression of COPD. Maximum inspiratory 
pressure is correlated with survival in COPD patients [47–49], thus functional 
remodelling in the diaphragm muscle is clinically relevant. Furthermore, the COPD 
diaphragm is more susceptible to muscle injury after inspiratory loading [50].  
 
1.3.2 Obstructive Sleep Apnoea 
Obstructive sleep apnoea (OSA) is a condition of sleep-disordered breathing, 
characterised by repetitive airway collapse, increased airway resistance, acute 
intermittent periods of hypoxia and is associated with upper airway muscle 
dysfunction that is thought to contribute to its progression [36,37,51,52]. It is known 
to affect 9-24% of the population although it is considered that this number may be 
significantly larger with many patients undiagnosed. Prevalence is increasing with 
obesity recognised as a significant risk factor. Comorbidities include obesity, 
hypertension and cognitive impairments. OSA in conjunction with COPD (overlap 
syndrome) is more common than OSA alone [53]. Nocturnal oxygen desaturation 
develops in COPD independent of apnoea and is more severe in the overlap 
syndrome [54]. 
 
COPD and OSA represent two of the most prevalent chronic respiratory diseases 
[55]. Elucidating molecular mechanisms that underpin respiratory muscle adaptation 
to CH will be important in shaping new therapeutic strategies in diseases where 
hypoxia and/or muscle dysfunction are featured. This is especially important given 
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that exercise programmes are increasingly being considered as adjunct-therapies in 
respiratory disease. There is also interest in mechanisms controlling respiratory 
muscle performance and adaptation to hypoxia from the fields of exercise 
physiology, high altitude physiology and aviation. 
 
We cannot consummately say that COPD-induced functional adaptations in 
respiratory muscle are a direct result of hypoxia and/or reflex hyperventilation as 
there may be other disease-related confounding influences (e.g. hypercapnia and 
inflammation). However, the observed functional adaptations are very similar to 
adaptations observed in animal models of CH. COPD patients have a lower trans-
diaphragmatic pressure generating capacity as well as improved fatigue tolerance in 
their diaphragm muscle [43,44,56,57] or at least, fatigue tolerance is not reduced 
despite them being at a mechanical disadvantage [45]. Hypoxia-induced functional 
adaptations in respiratory muscles are discussed below in section 1.5. 
 
1.4 Mechanism of Muscle Contraction 
 
The stimulus for muscle activity are neural impulses. Muscle fibres themselves are 
excitable cells. At the neuromuscular junction, electrical impulses from neurons are 
amplified chemically to raise the motor endplate voltage above threshold and initiate 
excitation-contraction (E-C) coupling. Upon reaching threshold voltage, Na
+
 
channels, abundant in the sarcolemma, spread the electrical signal across the muscle 
and down through invaginations called transverse-tubules which run perpendicular to 
the sarcolemma. These t-tubules carry the signal to voltage ‘sensors’ that transduce 
and transmit the signal to the structures responsible for contraction. Dihydropyridine 
receptors (DHPRs) concentrated in the t-tubules undergo a voltage-dependent 
conformational change resulting in their interaction with ryanodine receptors (RyRs) 
of the sarcoplasmic reticulum (SR – intracellular Ca2+ store). The RyRs are Ca2+ 
release channels whose pores open with DHPR interaction allowing Ca
2+
 to flood 
down its concentration gradient into the myoplasm. Ca
2+
, and ATP from metabolism, 
are the cofactors required for sarcomere shortening [58,59].  
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The Sarcomere and Sliding-Filament Theory 
The sarcomere is the basic unit of muscle function and is composed of thick myosin 
and thin actin filaments arranged in parallel. In 1954, using high resolution 
microscopy to visualise the action of actin and myosin, Huxley, Hanson, and 
Niedergerke proposed the sliding-filament theory of muscle contraction [60,61]. 
They describe the action of actin, which is tethered to protein (termed the ‘Z’ disc) at 
the lateral end of each sarcomere, sliding past stationary myosin at various stages of 
contraction. As actin moves, it pulls the Z-discs closer together resulting in 
sarcomere, and thus muscle, shortening. This theory has since been refined after the 
observation that myosin ‘heads’ (globular domains at the ends of filamentous 
myosin) can bind to actin, forming a cross-bridge, and pull upon the actin to shorten 
the sarcomere [62]. 
 
Cross-bridge Cycling 
In a resting sarcomere, the tropomyosin protein blocks the myosin head binding sites 
on actin. Ca
2+
, introduced from the SR, can bind to troponin which is attached to 
tropomyosin and cause a conformational change in the tropomyosin that in turn 
exposes the myosin head binding sites [58,63]. ATP which has bound to myosin is 
hydrolysed by the myosin-ATPase (mATPase) enzyme into ADP and inorganic 
phosphate (Pi). The energy released by this reaction activates the myosin head into 
its extended position where it binds to exposed binding sites on actin. Myosin 
releases ADP, returning the myosin head to its unextended position. As it returns, it 
is still attached to actin and pulls the actin filament along (‘the power stroke’). ATP 
can now bind to myosin which breaks the actin-myosin bond. ATP hydrolysis by 
mATPase will again facilitate binding if binding sites on actin are available. The 
collective binding of numerous myosin heads to actin combine to move the actin 
relative to the myosin filaments. 
 
1.5 Functional Adaptations in Hypoxia 
 
Dissecting the information from ex vivo muscle bath studies is complicated. The role 
of temperature in skeletal muscle performance assessment ex vivo must be taken into 
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account. At 37
o
C metabolic activity is greatest and therefore muscle viability in a 
tissue bath will diminish faster. There is evidence supporting an increase in O2
-
 
production in mammalian skeletal muscle as temperature increases between 32 and 
37
o
C resulting in irreversible force depression [64]. However, at lower temperatures 
metabolic activity is not occurring at a physiological rate and the complexion of 
muscle function may be altered somewhat because of this. Clearly, there is a trade-
off in reducing ex vivo muscle rundown with physiological redox signalling. It is 
debatable as to what temperature gives more physiological results. Differences in 
hypoxic intensity, exposure times and different experimental paradigms employed 
may also account for discrepancies in the literature e.g. reduced air density in 
hypobaric hypoxia will reduce the work of breathing and may affect rates of 
diffusion in airways differential to normobaric hypoxia. Moreover, isometric 
contractions in respiratory muscle, particularly the diaphragm, would not result in 
thoracic volume and pressure changes which are required for breathing, yet most 
studies have focussed on isometric properties of the muscle. There has been no study 
to date on isotonic function in CH animal models. Nevertheless, isometric 
performance capacities of muscle are still a good indicator of potential in vivo 
performance and serve to link performance changes to molecular changes. 
 
Twitch Tension and Kinetics 
Peak twitch tension in rat diaphragm after six weeks of CH exposure to 0.1 fraction 
of inspired O2 (FiO2=0.1; equivalent to 5800-6200m above sea level) has been 
observed to significantly increase, remain the same and significantly decrease at 
25
o
C [26], 30
o
C [22] and 37
o
C [65] respectively. There were no significant changes 
in contractile kinetics. There was no change in twitch tension or contraction kinetics 
in rat sternohyoid after six weeks of CH exposure at 30
o
C [22], however a significant 
increase in twitch tension was observed at 25
o
C [26]. Similar temperature-dependent 
results were seen in EDL and soleus muscles of both rats and mice [65–67].  
 
Force-frequency relationship 
Four weeks of CH had no effect on the force-frequency relationship (F-F) in mouse 
diaphragm at 37
o
C [67]. Six weeks of CH depressed the F-F in rat diaphragm at 
37
o
C [65] and 30
o
C [22] but enhanced F-F at 25
o
C [26]. After six weeks of CH, 
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there was no change to F-F in rat sternohyoid muscle at 30
o
C [22] or 25
o
C [26], nor 
was there any change in the soleus at 37
o
C, however F-F was depressed in rat EDL 
at 37
o
C [65]. Four weeks of CH had no effect on F-F in mouse soleus at 37
o
C [67].  
 
Fatigue Tolerance 
Fatigue tolerance in rat diaphragm significantly increased after six weeks of CH at 
30
o
C [22], however it was unchanged at 37
o
C [65] and 25
o
C [26]. Four weeks of CH 
had no effect on fatigue tolerance in mouse diaphragm at 37
o
C [67]. Six weeks of 
CH exposure decreased fatigue tolerance in rat sternohyoid at 25
o
C [26], however no 
change was observed at 30
o
C [22]. After four weeks of CH, the post-stimulation 
relaxation time/peak force in rat soleus was significantly decreased indicating a 
reduced tolerance to fatigue at 25
o
C [66] although no change was observed at 37
o
C 
[65] with the same results observed in the EDL muscle at 37
o
C.  
 
Muscle Performance in Acute Hypoxia 
Acute hypoxia has severe detrimental effects on respiratory muscle function ex vivo. 
Force production, shortening velocity, total shortening and fatigue tolerance are all 
impaired [68,69]. 
 
Single-Fibre Function 
Single fibre studies on diaphragm and soleus muscle from animals exposed to four 
weeks of CH reveal significant reductions in force generating capacity of type I and 
type II fibres from both muscles, with the type II fibres apparently more severely 
affected [70]. No changes were observed to shortening velocities but power 
production was significantly decreased.  
 
The general consensus is that CH-induced functional adaptations in the diaphragm 
appear to maintain/improve performance [67] in comparison to limb muscles. 
However, force generating capacity in the diaphragm at 35-37
o
C is compromised and 
thus there is diaphragm muscle weakness following CH exposure. Unpublished 
results from our laboratory also show that respiratory muscle from CH animals 
performs better in acute hypoxic conditions than muscles from normoxic control 
animals i.e. there is hypoxic tolerance. This is potentially beneficial to the muscle in 
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the short-term however structural and metabolic adaptations may result in poor 
clinical outcomes in the chronic diseased state (years), particularly with respiratory 
disease exacerbations and periods of dyspnoea. 
 
1.6 Molecular Adaptations in Hypoxia 
 
As outlined in section 1.5, there are several specific compartments and/or signalling 
cascades of the muscle fibre that may be affected in hypoxia. We must also be aware 
of secondary and tertiary stimuli resulting from hypoxia that may even 
compete/interact with hypoxia to influence phenotype changes in a hypoxic 
environment e.g. increased demands placed on the diaphragm. As mammals are 
generally less active in hypoxia [42], power-generating limb muscle (EDL) activity 
may be decreased compared to tonically active postural limb muscles (soleus) and 
may account for differences observed here. 
 
1.6.1 Structural Adaptations 
Fibre Type: Muscle fibre type proportions vary in accordance with activity. Slower 
fibres are more energy efficient, however they require a higher O2 quantity to 
produce requisite ATP than fast fibres. Type II fibre transformation into the more 
enduring type I fibres has been observed in the severe COPD diaphragm [71,72] 
along with other slow sarcomere related proteins. There is contrasting literature 
regarding fibre type transitions in intercostal muscles [73,74]. Fibre type shifts in 
mild COPD are not as pronounced suggesting the adaptive process is time-
dependent. Fatigue tolerance studies from our laboratory suggest that CH-induced 
respiratory muscle functional adaptations are time-dependent [22]. However, there is 
no significant change in fibre type proportions in diaphragm muscle after six weeks 
of CH [22,65,75]. Even from birth, when muscle plasticity is greatest, type I, IIa, IIb 
and IIx fibres remained unaltered in rat diaphragm after six weeks of CH; however, 
MHC isoforms changed significantly after thirty-nine weeks [76]. Hypoxia exposure 
in humans does not produce fibre type changes in vastus lateralis muscle [77]. Even 
high altitude natives do not present with differential fibre type distributions in vastus 
lateralis muscle compared to lowlanders [78]. Unfortunately, there are no studies to 
date on human respiratory muscle tissue fibre type composition after CH/high 
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altitude exposure. Early-life exposure to CH can result in functional changes that 
persist into adulthood without fibre type adaptation [79]. Longer exposures may be 
necessary to induce detectable fibre type change. None the less, functional 
adaptations are observed in the respiratory muscles of animal models of CH prior to 
any potential fibre-type change. Moreover, the HIF transcription factors which are 
sensitive to hypoxia and influence fibre type transitions may have only minor roles 
in respiratory muscle functional adaptation to CH. 
 
Fibre cross-sectional area: Fibre cross-sectional area (FCSA) modifications are 
consistently reported in the literature on hypoxia and the diaphragm muscle. 
McMorrow et al., report rat diaphragm fibre atrophy following six weeks of CH in 
type I, IIa, IIb, and IIx fibres (1410  38 vs. 1232  25; 1422  26 vs. 1384  23; 
2565  80 vs. 2040  75; 5024  177 vs. 3424  85µm2 mean  SEM for control vs. 
CH respectively) [22] alongside no change in numerical density or areal density. 
Gamboa and Andrade report mouse diaphragm fibre atrophy following four weeks of 
CH (656  59 vs. 488  55 µm2 mean  SEM for control vs. CH respectively) [67]. 
Degens et al., report rat diaphragm fibre atrophy following four weeks of CH (data is 
presented in graphs rather than tables). This is especially interesting given that we 
might expect atrophy in non-working limb muscles compared to working respiratory 
muscles in hypoxia. Of course, decreases in FCSA will serve to reduce O2 diffusion 
distances but may also decrease force generating capacity should myofibrils also 
decrease. Muscle fibre atrophy is observed in the diaphragm and limb muscles of 
severe COPD patients and animal models of CH [22,44,67,80,81] and in limb 
muscles of lowlanders who travel to high altitude [82], with the slow oxidative and 
fast oxidative type I and type II fibres affected most. In severe COPD patients, this 
phenotype in diaphragm muscle appears to be driven by reduced MyoD mRNA, 
increased MAFbx mRNA, and decreased Nedd4 mRNA (E3 ubiquitin ligases; 
MAFbx is up-regulated during muscle atrophy, Nedd4 is up-regulated during disuse 
but not catabolic states), and decreased myostatin mRNA but increased myostatin 
protein levels (inhibits muscle differentiation and growth) [81]. The atrophy signals 
are observed to be greater in limb muscles compared to the diaphragm in COPD 
patients [83] and not in controls indicating a role for local factors in hypoxia-induced 
atrophy. There is no difference between limb and diaphragm in hypertrophy signals 
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in COPD or normal lung function patients with the exception of phosphorylated-
(phospho)-protein 70 ribosome S6 kinase (p70S6K) content being greater in the 
COPD diaphragm. The limb muscles are clearly more at risk of atrophying than the 
diaphragm in COPD patients, however this may be due to decreased voluntary 
activity of the limb muscles in exercise intolerant patients. Unloading-induced 
atrophy is rapid, especially in weight-bearing muscles [84]. The proteasome complex 
degrades idle or damaged proteins. Increased proteasome activity has also been 
reported in the COPD diaphragm without a change in proteasome content indicating 
increased activity of individual proteasomes [85]. Furthermore, a proteasome 
inhibitor significantly improved contractile function and reduced myosin protein loss 
in emphysematous hamsters [86]. No significant changes to numerical fibre density 
or areal density have been reported for the diaphragm after six weeks of CH 
exposure [22,65]. Six weeks of CH induces hypertrophy of type IIa and IIx fibres in 
rat sternohyoid but no changes in EDL or soleus FCSA have been observed [22]. No 
change in mouse gastrocnemius and soleus FCSA was observed after four weeks of 
CH but a significant decrease was observed for diaphragm muscle [67]. The latter 
study [67] also presents a CH-induced left-shift in the frequency distribution of 
diaphragm fibres as functions of FCSA (i.e. larger to smaller CSA) while the 
frequency distribution for limb muscles became more concentrated at the centre (i.e. 
decreased number of smaller and larger CSA fibres and increased mid-range CSA 
fibres). Other studies have reported a significant decrease in the FCSA of type IIb 
fibres in rat EDL and soleus [65]. After three weeks of CH, there was no change in 
FCSA in rat EDL, soleus or tibialis anterior [75]. Neither was there any change to 
FCSA in mouse gastrocnemius, plantaris and soleus after four weeks of CH [67], 
however the FCSA of type IIa fibres was significantly decreased in rat soleus as was 
FCSA of type IIx fibres in rat EDL [66]. Four weeks of CH induced an overall 
decrease in FCSA, regardless of fibre type, in rat plantaris muscle [87]. It is clear that 
six weeks of CH induces fibre atrophy in the diaphragm muscle and plausible that 
the fibre type composition and workload influence the degree of fibre atrophy and 
the mechanism (mechanism is currently unknown).  
 
Protein regulators of muscle fibre type composition, including MAPKs are 
mentioned in section 1.4. Muscle fibre size is also a defining feature of fibre type 
15 | P a g e  
 
and regulation of fibre size and type are intrinsically coupled by cross-talk between 
the MAPKs and the Akt signalling cascade. Progressive phosphorylation of the Akt 
protein and downstream targets such as mammalian target of rapamycin (mTOR) 
drives hypertrophy and forkhead box (FOXO)3a places a brake on atrophy [88–91]. 
The contribution of atrophic mRNA signals to COPD diaphragm atrophy suggests 
that the FOXO3a transcription factor and p38MAPK, which drive atrogin gene 
expression, will be activated in hypoxia. Hypoxia has also been shown to induce 
FOXO1 activity and expression, and a downstream activator of autophagy in the 
form of BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3) [80]. 
Furthermore, hypoxia increases Redd1 mRNA transcription, an inhibitor of the 
mTOR(C1) complex 1 pathway [92,93] suggesting that muscle atrophy is a 
combination of both active and inactive processes. However, others have shown that 
decreased protein synthesis does not appear to be a factor in hypoxia related muscle 
atrophy [94]. In fact protein synthesis rates are increased according to a study by 
Chaudhary et al. [94] although protein breakdown will provide substrate for protein 
synthesis. The ubiquitin-proteasome pathway’s activity accounts for the majority of 
muscle degradation in cancer cachexia where hypoxia-induced changes may play a 
role. Atrophy likely contributes to the functional adaptations discussed above and is 
a hypoxia-induced mechanism we explore further in the CH diaphragm (Chapter 5).  
 
1.6.2 Metabolic Adaptations 
Chronic increased sub-maximal activity of respiratory muscles in CH might be 
expected to increase their capacity for oxidative metabolism. Mitochondria, which 
are the major energy producers of the muscle cell, require oxygen to produce ATP 
and are likely to be affected in hypoxia. To complicate matters further, hypoxia and 
HIF-1α have been shown to promote a more glycolytic phenotype in cells [95]; and 
with the blood flow changes and body weight changes that occur, nutritional status 
and metabolic substrate availability could further confound metabolic regulation. 
Atrophy and protein degradation will also free amino acids which can substitute for 
more typical metabolic substrates when required. Ultimately, alterations to match 
energy production and expenditure are likely to occur to support the functional 
changes observed in animal models of CH.  
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ATP Production – Lowlanders spending time at high altitude/simulated high 
altitude present with reduced mitochondrial content and signs of muscle wasting and 
lipofuscin granule accumulation [80,94,96–99]. Curiously, superior aerobic 
performance is observed in human and animal populations native to high altitude 
despite paradoxical lower skeletal muscle oxidative capacity [100,101]. Cellular 
respiration is also lower in animal models of CH. State 3 respiration rates in CD1 
mouse hind-limb skeletal muscle mitochondria were significantly lower compared to 
control after two days of CH exposure. This infers that ATP production is reduced 
after two days of hypoxia exposure. The altered respiratory control ratio values 
(RCR – ratio between state 3 and state 4 respiration) and impaired uncoupled 
respiration [102] indicates the electron transport chain itself must be damaged [103]. 
In contrast to acute hypoxia, mitochondrial respiration values after four weeks of CH 
are indicative of mitochondrial integrity in mouse diaphragm and hind-limb muscles, 
although state 3 respiration and oxygen consumption was significantly lower. There 
was no change in the RCR or uncoupled respiration [67]. Four weeks of CH 
decreased uncoupling protein (UCP)3 content in mouse diaphragm but not triceps 
surae [80]. Decreased UCP3 will decrease thermogenesis and facilitate optimisation 
of oxygen consumption by decreasing dissipation of the proton gradient. 
Mitochondria in diaphragm muscle are unquestionably distressed in times of CH 
albeit still functional. 
 
Endurance training increases oxidative enzyme activity in skeletal muscle without 
major shifts in fibre type [18]. Consistent with the hypothesis of hypoxia-induced 
endurance training of the diaphragm – advanced COPD diaphragm fibres have 
higher succinate dehydrogenase (SDH) activity than controls but there is also a 
significant increase in type I fibres and decrease in type IIx fibres [104]. There is no 
change in oxidative/glycolytic ratio in the mild-to-moderate COPD diaphragm with 
the exception of the glycolytic enzyme lactate dehydrogenase (LDH), whose activity 
was decreased [105]. Severe, acute hypoxia decreases aconitase activity in mouse 
hind-limb [102]. Six weeks of CH has no effect on SDH or nicotinamide adenine 
dinucleotide phosphate reduced form (NADPH)-diaphorase enzyme activity in rat 
diaphragm or sternohyoid muscles [22]. Four weeks of CH exposure increases SDH 
activity in rat plantaris glycolytic fibres but not oxidative fibres [87], while a shift 
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from an oxidative to glycolytic phenotype was observed with high altitude exposure 
in the type 1 fibres from human vastus lateralis muscle [100]. Evidently, changes in 
metabolic enzyme activities are specific to the type, intensity and duration of the 
hypoxia stimulus and the muscle in which activity is measured. Regional-adaptations 
in metabolism and ATP production could occur but remain hidden in global tissue 
measurements. Hypoxia in exercise decreases phosphocreatine recovery as well as 
decreasing pH levels in human gastrocnemius muscle [106,107]. Both of these 
stimuli will also cause fatigue in skeletal muscle [108]. Earlier recruitment of 
glycolytic fibres may be required inducing an increase in their oxidative capacity 
through activation. An additional 5% duration of recruitment has been shown to 
increase the oxidative capacity of a muscle cell [109]. Also, training during hypoxia 
increases the oxidative capacity of limb muscle [110–112]. While these studies use 
different metabolic enzymes as a measure of oxidative/glycolytic capacity, these 
enzymes may not be maximally active in vivo and a reserve capacity may be present 
should more metabolic substrate present itself. Furthermore, the catalytic activity of 
an enzyme under saturating conditions may not change while substrate flux 
according to availability and up-stream enzyme activity in metabolic pathways may 
be important. 
 
In the diaphragm after CH, adaptations occur to improve ATP production despite 
damage to the mitochondria; however the full mechanism behind this is yet to be 
delineated. The effects of hypoxia on upstream metabolic pathways are particularly 
unclear and require elucidating. Overall, hypoxia decreases ATP production in 
respiratory muscle but given blood-flow changes, there isn’t likely to be a 
detrimental change in substrate availability. A thorough evaluation of key metabolic 
enzyme activities from a single study is required (Chapter 4).  
 
ATP Utilisation – Hypoxia decreases ATP production in skeletal muscle, thus, 
tighter constraints on ATP usage will be important. Reflex hyperventilation makes 
the constraints on ATP usage of greater importance to the diaphragm muscle. 
Skeletal muscle ion pump ATPases are the largest consumers of ATP in the muscle 
cell and are thus candidate sites for regulation. The Na
+
/K
+
 ATPases establish the 
ionic concentration balance across the cell membrane, maintaining myocyte 
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excitability and regulating myoplasmic volume. Increased pump activity improves 
skeletal muscle endurance [113] whereas ouabain inhibition of the pump can 
accelerate muscle fatigability [114]. Six weeks of CH increased Na
+
/K
+
 ATPase 
pump content in rat diaphragm and EDL but not in sternohyoid or soleus muscles 
[22]. A decrease in pump content in human vastus lateralis was observed after a 
three weeks at high altitude [115] and eight weeks at high altitude which included 
intermittent exercise [112]. Changes in pH regulation including the requirement of 
the Na
+
/K
+
 ATPase to pump out excess Na
+
 that enters the cell via the Na
+
/H
+
 
exchanger (NHE) may also be important given that in a working muscle such as the 
diaphragm in hypoxia, local acidity is controlled for by NHE removing the produced 
H
+
. The sarco/endoplasmic reticulum Ca
2+
 ATPase (SERCA) resides in the SR 
membrane. SERCA pumps transfer Ca
2+
 from the myoplasm to the lumen of the SR 
at the expense of ATP hydrolysis during muscle relaxation. SERCA1 is 
predominantly found in fast glycolytic fibre types and SERCA2a in slow oxidative 
fibres. Overload and chronic electrical stimulation increases SERCA2 and decreases 
SERCA1 protein expression in fast skeletal muscle [116,117]. Fatigue alterations in 
½-relaxation time also implicate the SERCA pumps in the fatigue process [118]. We 
might expect an increase in SERCA2 content in the CH diaphragm given the 
observed improved endurance [22]. One theory suggests fibre type transformation 
including SERCA isoform transformation: SERCA1/MHC IIa SERCA1+2/MHC 
IIa+MHC I SERCA2/MHC I. This fits with measurements of SERCA protein in 
severe COPD patient diaphragm [119]. Our laboratory has reported no significant 
difference in the areal density of fibres expressing SERCA2 in rat diaphragm after 
six weeks of CH exposure [22]. Myosin ATPase activity employs ATP hydrolysis to 
move myosin heads and pull actin filaments, thus shortening cross-bridges and 
generating force. This is regulated by the troponin complex. The troponin complex 
consists of three subunits: troponin C (TnC), troponin I (TnI), and troponin T (TnT). 
Ca
2+
 binding to the N-terminus of TnC triggers contraction by removing TnI 
inhibition of the mATPase. TnT is needed for Ca
2+
-dependent regulation of the 
troponin complex as well as complete inhibition of mATPase activity. Significant 
decreases in TnC and TnI were observed in acute hypoxic mouse diaphragm 
preparations fatigued ex vivo compared to unfatigued control. The extraction of 
endogenous troponins from control fibres reduces maximal Ca
2+
-activated force and 
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adding recombinant troponins to hypoxic-fatigued fibres improves maximal Ca
2+
-
activated force [68,120]. Hypoxaemia can induce post-translational modification of 
diaphragm TnI in anesthetized, spontaneously breathing canines [121]. Cross-bridge 
modifications may play a role in muscle adaptation to CH from both metabolic and 
functional perspectives. 
 
Na
+
/K
+ 
ATPase and mATPase content are more likely candidates of adaptation with 
CH. The lack of fibre-type change, SERCA2a density change, and contractile kinetic 
changes [22] is in opposition to SERCA content changes or structural modifications. 
While Na
+
/K
+ 
ATPase content increases are in contrast to required metabolic 
modifications, the observed fibre atrophy is suggestive of mATPase decreases. 
However, as will be discussed in Section 1.7, structural modifications can occur to 
proteins that may limit their energy consumption. 
 
1.6.3 Calcium Handling 
Ca
2+
 is released through the RyR channels for contraction and re-uptake is through 
the SERCA proteins of the SR for muscle relaxation. There are a number of 
important intra-SR proteins that can signal information to the ion channels about the 
[Ca
2+
] in the SR and bind Ca
2+
 to reduce to intra-SR free [Ca
2+
]. As well as being 
essential to contractile function, Ca
2+
 can initiate many myocellular signalling events 
through Ca
2+
 binding proteins such as CaM and calcineurin. Hypoxia significantly 
alters Ca
2+
 transients in C2C12 myotubes [122]. Ca
2+
 signalling events and Ca
2+
-
protein interactions may indirectly affect muscle function. Increased intracellular 
[Ca
2+
] induces Na
+
/K
+
 ATPase α1 mRNA expression via the calcineurin and CAM 
kinase II (CamKII) signalling cascades in rat skeletal muscle oxidative fibres [123]. 
This transcriptional response occurs through the nuclear factor of activated T cells 
(NFAT). NFAT also controls activity-dependent muscle fibre type specification 
[124], however there is no change observed to muscle-fibre type composition before 
functional changes emerge in CH.  
 
1.6.4 The Sarcomere 
The sarcomere is the cellular compartment where Ca
2+
 and ATP combine with a 
structure consisting of several regulatory proteins to produce muscle contraction. As 
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Ca
2+
 release and re-uptake are further down our list of candidates to be the direct 
mechanism behind respiratory muscle dysfunction in hypoxia, the cross-bridge 
becomes the logical cellular target, with altered sensitivity to Ca
2+
, less available 
ATP, and atrophy being the likely mechanisms. Degens et al., (2010) show a small 
change in Ca
2+
 sensitivity in the CH diaphragm so there may be sarcomere protein 
modification [70]. Muscle fibre atrophy, too, may affect the cross-bridge. Indeed, we 
have mentioned already the intricate links between hypoxia, Ca
2+
, sarcomere 
proteins, mATPase and muscle contraction. 
 
1.6.5 Myokines 
As mentioned in section 1.2, skeletal muscle is increasingly recognised for its role as 
a regulator of endocrine signalling. It has been suggested that secretion of myokines 
may facilitate the beneficial effects of exercise in chronic disease patients  [125]. 
However, there is no literature to date on the role of myokines in hypoxia-induced 
diaphragm adaptations and thus are not a focus of this thesis. 
 
1.7 Redox Homeostasis 
 
Undoubtedly, there are a vast number of potential target sites for functional 
manipulation in skeletal muscle. Ultimately, adaptation will come down to 
modification of the protein component of the cell, whether through expression, 
structural alterations or manipulating a protein’s environment (pH, temperature etc.) 
to change sensitivity, activity or functional role to govern growth, metabolic activity 
and of course contractile performance. The field has considered fibre-type changes, 
fibre atrophy, metabolic changes including glycolytic/oxidative capacity and 
integrity of the respiratory chain in mitochondria, constraints on ATP usage, Ca
2+
 
signalling, actin-myosin interactions in the sarcomere and pH. However, the 
mechanisms driving CH-induced molecular and functional remodelling including 
those upstream of processes already elucidated remains unclear. Moreover, the data 
is fragmented and in some parts contradictory, while some studies place too much 
physiological significance on stand-alone data e.g. a single metabolic enzyme’s 
activity as an index of metabolic capacity. If we simply ask the question of where the 
effect of hypoxia is likely to manifest in the first instance, the main candidates would 
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be the HIF transcription factors (O2 results in degradation vs. hypoxic stabilisation) 
and mitochondria (O2 is the ultimate electron acceptor in the respiratory chain). HIF-
1α levels are unchanged following 7-9 days at high altitude in human vastus lateralis 
muscle [97] and potentially will not change in the long term given that the perceived 
hypoxia stimulus will decrease following acclimatisation. Fibre-type changes would 
also be driven by HIF, especially after chronic sustained HIF activation, yet these do 
not occur. Therefore, hypoxia effects are more likely to be observed at the 
mitochondrial level, which include increasing reactive oxygen species (ROS) 
formation [96,97,102,126], albeit somewhat paradoxically. A reduction in oxygen 
availability leads to a prevention of flow of electrons along the electron transport 
chain, subsequent stockpile of electrons and the ensuing release of O2
-
 from 
mitochondria [127–130] whereas anoxia prevents radical production as there is 
simply no oxygen to take part in the reaction. Furthermore, increased muscle activity 
increases ROS production [131–133] and the reflex hyperventilatory response to 
hypoxia increases diaphragm muscle activity. 
 
1.7.1 Reactive Oxygen Species 
Oxygen is one of the most electronegative elements. When partially reduced, as 
occurs in various chemical reactions, it forms ROS. Basic cellular components such 
as proteins, lipids and DNA are all at risk of damage from oxidative stress. ROS is 
linked to many debilitating diseases and are thought to be the main reason of aging. 
Some proteins are damage resistant and instead use oxidative modifications to 
change their activity and even protect the cells from oxidative stress. O2
-
 and nitric 
oxide (NO) are the primary reactive species. Despite their high reactivity, ROS also 
undergo chemical change to alleviate reactivity via antioxidant defence mechanisms 
e.g. O2
- 
has a higher reactivity with superoxide dismutase (SOD) than most 
molecules which catalyses the formation of H2O2 (Fig.1.1). ROS and redox 
homeostasis changes, which have been associated with functional changes in CH and 
other models (and will be discussed in this section), represent a way in which 
function, metabolism and fibre atrophy processes may all be manipulated and are 
thus best candidates for driving CH-induced remodelling in the diaphragm muscle. 
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Figure 1.1: Superoxide and nitric oxide pathways of protein oxidation and 
antioxidant-induced reduction. O2
- 
may 1) be converted into hydrogen peroxide by 
the enzyme superoxide dismutase; 2) actively modify proteins by direct interaction; 
or 3) combine with nitric oxide to form the derivative peroxynitrite. Hydrogen 
peroxide may 1) chemically modify proteins directly; 2) be reduced to water and 
oxygen by the enzyme catalase or the cyclical antioxidant GSH system; or 3) take 
part in Fenton reactions to form the hydroxyl radical which is extremely reactive. 
GSH can also form disulphide bridges with oxidised protein thiols (glutathionylation 
– not shown in diagram); GSH = glutathione; GSSG = oxidised glutathione; GPx = 
glutathione peroxidase; GR = glutathione reductase; 
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Figure 1.2: Generators of reactive species in the skeletal muscle cell. XO = 
xanthine oxidase; NOX = NADPH oxidase; NOS = nitric oxide synthase. 
 
Mitochondria are not the only source of ROS in the muscle cell (Fig. 1.2). Different 
models of skeletal muscle adaptation reveal a role for ROS generated from cytosolic 
oxidases such as xanthine oxidase and NADPH oxidase [90,134–137]. Several 
proteins using or producing NAD(P)H co-enzymes as reducing equivalents can 
produce ROS when substrate availability is altered or the proteins themselves 
become modified e.g. 2-oxoglutarate-dehydrogenase can produce ROS [138–141]. 
However, mitochondria in the hypoxic diaphragm are compromised [67,80] and as 
such are candidate to increase ROS production in the CH diaphragm.  
 
Different paradigms of hypoxic stress have revealed an integral role for ROS in the 
respiratory control system. It has been reported that HIF and ROS play an important 
role in regulating the carotid body response to hypoxia [142–144]. Furthermore, 
there is a significant role for NADPH oxidase in chronic intermittent hypoxia 
induced modulation of the respiratory control centres in the brainstem and the 
phrenic nuclei [145]. It is entirely plausible that the main effector organs of 
respiratory control, the respiratory muscles, would be manipulated by alterations in 
redox balance in hypoxia. The pathogenesis and/or progression of several models of 
respiratory muscle dysfunction, such as sepsis, mechanical ventilation, muscular 
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dystrophy etc., are also thought to be, at least in part, ROS mediated [16,146,147]. 
Atrophy, which is common to all of these models, is also closely associated with 
changes in ROS levels. For instance, FOXO3a and p38 MAPK transcription factors 
of atrophy genes are closely associated with ROS [148,149] and proteasome activity 
may be up-regulated with ROS [150]. Increased contractile activity will also 
stimulate ROS production [131–133]. We know that basal levels of ROS are 
required for function and even a slight shift toward a more oxidising environment is 
beneficial to performance [151] but too much ROS are detrimental to function [152] 
(see Fig. 1.3 below). 
 
Redox modification of proteins affects their function. For example, actin oxidation is 
observed in several disease settings including COPD, Alzheimer’s disease and 
cardiac ischaemia [153–155]. Despite its complexity [156–160], however, actin-α 
oxidation is explicitly known to disrupt actomyosin interaction [161,162] and thus 
may affect muscle contraction directly. 
 
1.7.2 ROS and Hypoxia 
Further evidence to support the hypothesis of redox modifications in the diaphragm 
following CH exposure include mitochondrial morphological changes such as 
swelling and cristae degeneration which have been observed in rat [163] and human 
[102] skeletal muscle exposed to hypoxia. Four weeks of CH exposure increased 
activity of auto-phagocytic proteins (BNIP-3) and decreased PGC-1α and 
peroxisome proliferator-activated receptor gamma (PPARγ) protein resulting in 
decreased mitochondrial density and associated proteins in mouse diaphragm [80]. 
Both damage and resulting autophagy of mitochondria is potentially ROS mediated. 
Mitochondrial aconitase (an O2
-
 sensitive enzyme due to an iron-sulphur cluster) 
activity can be measured as an index for O2
-
 generation from mitochondria. Two 
days of hypoxia significantly decreased mitochondrial aconitase activity in CD-1 
mice [102]. Additionally, Vitamin E, GSH and mitochondrial protein thiol content 
were decreased alongside increases in GSSG concentration, protein carbonylation 
and mitochondrial heat shock protein (HSP)-60 indicating the antioxidant defence 
system has been overwhelmed. Chronic nitric oxide synthase (NOS) blockade 
decreases Na
+
/K
+
 pump content and prevents CH-induced improved muscle 
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endurance in the rat diaphragm [22]. NO has both oxidant properties itself and 
antioxidant properties through the formation of peroxynitrite and as an O2
-
 
scavenger. Potentially it is through Ca
2+
 modulation that NO induces changes in 
Na
+
/K
+
 ATPase activity [123]. However, no change in protein nitrosylation has been 
observed in rat diaphragm muscle after six weeks of CH exposure [70]. In the COPD 
diaphragm and other respiratory muscles, oxidative stress and redox modification to 
key proteins whose function may be altered by redox modification has been observed 
[72,153,165,166] including those involved in metabolism, pH regulation and in 
contractile function directly.  
 
 
Figure 1.3: Hypothesised and experimentally demonstrated relationship 
between isometric force of skeletal muscle and cellular redox state.  
Image adapted and redrawn from [167]. 
 
In vivo and ex vivo pro/anti-oxidant drug treatment provides clues as to how exactly 
ROS influence muscle function. Tiron and tempol (exogenous antioxidants) prevent 
the increased rate of fatigue and reduction in force in Flexor Digitorum Brevis 
muscle measured ex vivo at 37
o
C compared to 22
o
C [168] through alterations in Ca
2+
 
sensitivity. Temperature alone is not enough to alter Ca
2+
 sensitivity – a fatiguing 
stimulation is required. Also, application of dithiothreitol (DTT), a reducing agent, 
could reverse Ca
2+
 sensitivity changes [169]. Similar results have been observed in 
our laboratory in rat sternohyoid with tempol and tiron improving muscle 
performance ex vivo in hyperoxia and hypoxia [170]. Tiron improves rat diaphragm 
26 | P a g e  
 
endurance during acute hypoxia [171]. N-acetyl-cysteine (NAC) administration 
improves endurance in human respiratory and limb muscle and abolishes GSH 
oxidation [172,173]. NAC pre-treatment also attenuates the rise in plasma [K
+
] after 
exercise suggesting oxidative stress contributes to K
+
 deregulation. However, NAC 
treatment does not seem to inhibit high frequency fatigue in either reduced muscle 
preparations or human limb muscle [174]. Chronic NOS blockade decreases 
diaphragm Na
+
/K
+
 ATPase pump content and prevents CH-induced functional 
remodelling in the rat diaphragm [22]. Prolonged activity in skeletal muscle leads to 
an increase in nNOS expression [175]. After six weeks of CH exposure from birth, 
nNOS and eNOS protein expression increase in rat diaphragm [176] although after 
thirty-nine weeks of CH exposure from birth, they had decreased to approximately 
20% and 15% of control levels respectively. Transgenic over-expression of catalase, 
CuZn-SOD or Mn-SOD causes morphological alterations in mouse diaphragm 
including an increase in non-contractile material and alterations to muscle fibre type. 
Specific force production is diminished yet fatigue tolerance during prolonged 
submaximal contractions is not improved [177]. However, improved fatigue 
tolerance has been reported in single muscle fibres of Mn-SOD overexpressing mice 
[178]. Although there is pharmacological evidence in favour of a role for NO in 
hypoxia-induced adaptation [22], no change in protein nitrosylation has been 
observed in CH muscle single fibres [70]. NO has also been shown to attenuate force 
production without altering Ca
2+
 sensitivity [179]. Of course, O2
-
 interacts with NO 
to form peroxynitrite and so pharmacological modifications of NO availability would 
in turn affect the role of O2
-
 in hypoxia. There is also conflicting evidence showing 
that NO reduces myofibril Ca
2+
 sensitivity in mouse skeletal muscle fibres via non-
cGMP mediated pathways [180]. Conditions designed to block endogenous 
production of NO will also shift the voltage dependence of SR Ca
2+
 release 
activation towards more negative values [181]. In contrast, excess NO applied to 
isolated muscle preparation raises the [Ca
2+
]i at rest with some SR Ca
2+
 release 
channels remaining locked open, which can be reversed with DTT [182]. NO is 
involved in altering the sensitivity of the SR Ca
2+
 release channel, in agreement with 
findings from other groups [183,184]. Decreases in SR Ca
2+
 release may be 
understood to be a safety mechanism. If SR Ca
2+
 release remains high when ATP 
levels are depleted due to increased activity, ATP might fall to a critical level where 
27 | P a g e  
 
functional mATPase, SERCA and Na+/K+ ATPase is lost resulting in rigor, 
breakdown of Ca
2+
 reuptake and loss of myocyte excitability respectively. 
Interestingly, PO2 appears to be a regulator of NO induced alterations in SR Ca
2+
 
release channel activation with the redox state of several thiol residues acting as PO2 
sensors [184]. Different concentrations of NO influence ryanodine effects on the SR 
Ca
2+
 release channel at different PO2 levels. Voltage dependence of RyR channel 
activation also occurs in the presence of H2O2 [181]. H2O2 induces inter-subunit 
cross-link disulphide bonds. Low levels of NO donors inhibit these cross-links and 
prevent activation of the RyR channel [185]. The two phenomena may be linked 
with NO providing protection against the effects of oxidation as is suggested by the 
study. Changes to Ca
2+
 sensitivity and decreased release of Ca
2+
 from the SR depend 
on ROS metabolism and SOD activity. In rats and Mn-SOD overexpressing mice, 
the decreased force observed after fatigue stimulation was due to decreased 
myofibrillar sensitivity as opposed to decreased Ca
2+
 release form the SR in wild 
type NMRI mice (~50% lower SOD activity) [178]. More intense oxidative insults 
were required to induce changes in calcium regulation and these changes could be 
abolished by adding a non-specific ROS scavenger [180,186]. ROS can also impede 
actin-myosin interactions [158,187].  
 
It is clear that ROS can have widespread effects in regulating muscle function and 
tissue homeostasis. ROS are produced in hypoxia and with increased muscle 
contractile activity. They are also produced by – and contribute to – damaged 
mitochondria. The working diaphragm muscle in CH, unlike limb muscles, is 
potentially challenged by ROS on two fronts – by hypoxia per se and increased 
contractile activity. However, there have been no studies to date pursuing potential 
redox alterations to respiratory muscle proteins in an animal model of CH. 
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1.8 Hypothesis  
 
We hypothesize that redox remodelling is pivotal in diaphragm muscle adaptation to 
CH.  
 
The aim of this thesis is to elucidate molecular mechanisms driving diaphragm 
muscle adaptations to CH. A mouse model was utilised, exposed to different 
durations of CH in the presence or absence of chronic antioxidant supplementation. 
The sternohyoid, EDL, and soleus muscles were analysed alongside the diaphragm 
for comparative purposes. Protein redox changes and antioxidant changes are 
described in chapter 3. Redox-modified metabolic enzyme activity adaptations are 
described in chapter 4 alongside, metabolic enzyme activities at key substrate flux 
gating points, HIF-1α content, and succinate dehydrogenase activity at the muscle 
fibre level in a rat model of CH. Atrophy signalling and mechanism adaptations are 
described in chapter 5 and diaphragm muscle isotonic functional changes are 
described in chapter 6. 
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Chapter 2: Methods 
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2.1 Animal Model 
 
All protocols involving animals described in this thesis were approved by local 
ethics committee and performed under licence from the Irish Government 
Department of Health and Children in accordance with EU legislation. 
 
C57Bl6/J mouse models of CH were generated using environmental chambers 
(Oxycycler Model A84, BioSpherix Ltd, USA) where ambient oxygen levels can be 
tightly regulated (Fig. 2.1A). A reduction in the fractional volume of oxygen within 
the chamber results in a reduction in the fractional volume of oxygen in inspired air, 
airways, alveolus and ultimately blood with consequent hypoxemia for the animals. 
The Oxycycler permits user defined protocols to be used in several chambers 
simultaneously. A combination of oxygen and nitrogen gases are fed into the 
chambers and used to maintain the desired oxygen concentration. The chambers 
themselves contain oxygen sensors that continuously relay information back to the 
system software which facilitates immediate and appropriate gas infusion should 
oxygen concentration deviate from the user defined set-point. Animals are 
unrestrained and housed in their normal cages within the specialised chambers. Food 
and water were available ad libitum, and the chambers were maintained at room 
temperature with a 12/12 hour light/dark cycle. Once a week, the chambers were 
briefly opened to weigh animals and for cage cleaning. Soda lime and a molecular 
sieve (Sigma-Aldrich, Ireland) were placed inside the chambers to prevent CO2 and 
condensation accumulation. An interesting note on the use of mouse models of CH: 
mice, like humans, but unlike rats (to the best of my knowledge), can be found at 
altitudes as high as 4,347m [188], and so mice and humans may be evolutionarily 
better equipped to deal with hypoxic insult. 
 
2.1.1 Sample Size Calculation 
Based on published work from McMorrow et al., (2011), a diaphragm fatigue index 
of ~72.5±6% from animals exposed to six weeks of CH was measured as 
significantly increased from the control animal fatigue index of ~50% ± 6% with n=6 
animals per group [22]. The signal we want to be able to detect is ~22.5% and the 
standard deviation is ~14%. For experimental power to be 80% and sure of a 
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difference at the 5% significance level, the sample size required per group is ~7 
(calculation below; 8 is used in case of animal loss during the experimental 
procedure). 
Sample size = (2*SD
2
)*(Z
a/2
 + Z
β
)
2
/(d
2
) 
Where:  
SD = standard deviation;  
Z
a/2
 = Z
0.05/2
 = 1.96 taken from Z tables 
Z
β
 = Z
0.2 
= 0.842 taken form Z tables 
d = effect size 
(2*14
2
)*(1.96+0.842)
2
/(22.5
2
) = 
392*7.85/506.25 = 6.1 
n = ~7 
 
2.1.2 Groups 
Two independent CH exposure trials were carried out: 
Group 1) Forty-eight (6 groups; n=8 per group) age- and weight-matched 
C576Bl/J mice (Charles River Laboratories, UK) were exposed to one, three, 
or six weeks of CH (FiO2=0.1) or normoxia (3 separate groups for each of the 
time-points). The CH exposure trial for each group was completed as animals 
reached 12-13 weeks of age.  
 
Group 2) The second cohort of thirty-two age- and weight-matched C576Bl/J 
mice (Harlan, UK) were exposed six weeks of CH (FiO2=0.1) with/without 
chronic antioxidant supplementation (either tempol or NAC) in drinking 
water or normoxia (n=8 per group). Five fatalities were recorded during this 
second hypoxia trial: 2 x hypoxia, 2 x hypoxia + NAC, 1 x hypoxia + tempol. 
All fatalities occurred in different cages and different chambers and were the 
lightest mice of their respective cages. Furthermore, there were no signs of 
distress or fighting. We suspect a combination of the stress of hypoxia and 
being the runt of the group as the potential cause.  
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Figure 2.1: Oxyycler set-up and chamber oxygen profiles for treatment period.  
Gas, Oxycycler, and Animal Chamber Set-Up are illustrated in (A); and (B) Oxygen 
profiles and durations of experimental groups. 
 
 
 
A. 
B. 
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2.1.3 Tempol and NAC 
Tempol is a membrane-permeable antioxidant drug with properties similar to the 
enzyme SOD. It disproportionates the superoxide radical into hydrogen peroxide and 
water. Tempol has been observed to reverse the chronic intermittent hypoxia-
induced decreased fatigue tolerance in rat diaphragm muscle [189] and reverse the 
chronic intermittent hypoxia-induced muscle weakness in the sternohyoid muscle 
[25]. It also increases force production in the sternohyoid muscle in acute hypoxia 
conditions [170,190]. In control conditions, tempol has no effect on/increases 
sternohyoid muscle force production [170,190]. NAC is a thiol-containing 
antioxidant drug that has intrinsic antioxidant properties itself and increases the 
cellular reserve of free radical scavengers by increasing GSH levels. It can be used to 
replenish GSH stores when they are depleted. It is sold as a nutritional supplement 
and used medically to treat paracetamol overdose. Furthermore, NAC is thought to 
possess some anti-inflammatory effects. NAC has been shown to reverse the chronic 
intermittent hypoxia-induced decreased fatigue tolerance and decreased peak specific 
force in rat diaphragm muscle [189]. NAC has no effect on sternohyoid muscle force 
in control conditions [170]. 
 
At the end of the gas treatment period, animals were anaesthetised by 5% isoflurane 
inhalation in air and euthanized by cervical dislocation. Diaphragm, sternohyoid, 
EDL and soleus muscles were excised, snap frozen in liquid nitrogen and stored at -
80
o
C until further processing. Blood samples were taken in capillary tubes for 
haematocrit determination and the heart was removed for right and left (incl. septum) 
ventricular weight determination as indices of hypoxic (mal)adaptation. Results are 
presented in appendix 1.  
 
2.2 Muscle Tissue Preparation 
 
Frozen muscle samples were thawed on ice, weighed (for preparation only, muscle 
weights not recorded), and homogenised in ice-cold 10% w/v modified radio-
immunoprecipitation assay (RIPA) buffer (1X RIPA, 200mM sodium fluoride, 1mM 
phenylmethylsulfonyl fluoride (PMSF), protease inhibitor cocktail, phosphatase 
inhibitor cocktail (Fisher Scientific, Ireland) using a General Lab Homogeniser 
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(Omni-Inc., Kennesaw, Georgia, USA) followed by centrifugation in a U-320R 
centrifuge (Boeckel & Co, Hamburg, Germany) at 13,000g for 15 min at 4
o
C to 
separate insoluble fractions from crude protein homogenate. Insoluble fractions 
(pellet) were discarded and crude protein homogenate (supernatant) was separated 
into aliquots and frozen at -80
o
C. Protein concentrations were evaluated using a 
bicinchoninic (BCA) protein assay (Pierce Biotechnology (Fisher Scientific), 
Ireland) against bovine serum albumin protein standards of known concentration. 
Samples are kept ice-cold throughout processing. 
 
2.3 Redox Proteomics 
 
2.3.1 Total Protein Carbonyl and Free Thiol Content  
As previously described [191–193], muscle homogenates were incubated with either 
2mM fluorescein-thiosemicarbazide (FTSC) or 2mM iodoacetamidofluorescein 
(IAF) (Sigma-Aldrich, Ireland) for two hours in the dark on ice for detection of free 
protein carbonyl and thiol groups respectively. Samples were then precipitated with 
20% trichloroacetic acid (TCA) in acetone, followed by centrifugation at 11,000g for 
3 min. Protein pellets were then washed with ice-cold excess 1:1 ethylacetate/ethanol 
or acetone (for FTSC and IAF respectively) to remove excess TCA, interfering salts 
and non-protein contaminants. Samples were dried, re-suspended in sample buffer 
(12.5% 0.5M Tris pH6.8, 25% glycerol, 2% sodium-dodecyl sulfate (SDS), a few 
grains of bromophenol blue) containing 5% beta-mercaptoethanol and heated at 95
o
C 
for 5min before electrophoretic separation on a 12% polyacrylamide gel. Fluorescent 
images of the gels were captured on a Typhoon Trio+ Variable-Mode Imager (GE 
Healthcare, UK). Protein bands were visualised by colloidal coomassie [194] and 
coomassie images were captured on a calibrating image densitometer (GS-800, 
Biorad, USA). This assay was performed on diaphragm, sternohyoid, EDL and 
soleus muscle samples from C57Bl6/J mice exposed to one, three, and six weeks of 
CH and normoxia controls. 
 
2.3.2 2D Redox Proteomics 
As previously described [191–193], this method separates proteins according to their 
isoelectric point and molecular mass such that they appear as spots when stained on 
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polyacrylamide gels; protein spots can be analysed independently. Samples were 
treated as described above for 1D preparation until re-suspension in sample buffer. 
Samples were instead re-suspended in rehydration buffer (7M urea, 2M thiourea, 2% 
(w/v) 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate, 4% (v/v) 
ampholytes (Pharmalyte 3-10, Amersham, UK), 1% (v/v) destreak reagent 
(Amersham) and a trace amount of bromophenol blue) and loaded onto 70mm pH3-
10 non-linear immobilised pH gradient (IPG) strips (GE Healthcare) in the dark and 
overnight. IPG strips were focused on a Protean isoelectric focusing (IEF) cell 
(Biorad) with linear voltage increases: 250V for 15min; 4000V for 2h; then up to 
20,000Vh. Following IEF, strips were equilibrated (20 min) in equilibration buffer 
(6M urea, 0.375M Tris, pH 8.8, 2% (w/v) SDS, and 20% (v/v) glycerol) containing 
2% (w/v) DTT, and then for 20 min in equilibration buffer containing 2.5% (w/v) 
iodoacetamide. Equilibrated strips were then subjected to gel electrophoresis. 
Fluorescent and colloidal coomassie stained gel images were captured as described 
above. This assay was performed on diaphragm and sternohyoid muscle samples 
from C57Bl6/J mice exposed to six weeks of CH and normoxia controls. 
 
2.3.3 Image Analysis  
Quantity One image analysis software (Bio-Rad) was used to subtract background 
and quantify optical density for FTSC, IAF and colloidal coomassie labelling using 
the ‘rolling-disk’ method. For each sample, intensity of fluorescence was normalised 
to intensity of coomassie staining. For 2D separations, alignment of gels, spot 
matching, and quantification of spot volumes was carried out using Progenesis 
SameSpots image analysis software (Version 4.5; Non-linear Dynamics, Durham, 
NC, USA).  
 
2.3.4 Protein Digestion and Identification 
Gel spot selection criteria included statistical thresholding, separation, resolution, 
abundance and overlap in fluorescence-stain and muscle separations. Gel spots were 
used for in-gel protein digestion with trypsin. The extracted peptides were loaded 
onto a R2 micro column (RP-C18 equivalent) where they were desalted, 
concentrated and eluted directly onto a MALDI plate using -cyano-4-
hydroxycinnamic acid (5mg/ml) as matrix solution in 50% (v/v) acetonitrile and 5% 
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(v/v) formic acid. Mass spectra of the peptides were acquired with positive reflectron 
mass spectrometry (MS) and MS/MS modes using MALDI-TOF/TOF MS 
instrument (4800plus MALDI TOF/TOF analyser). The collected MS and MS/MS 
spectra were analysed in combined mode using Mascot (version 2.2; Matrix Science, 
Boston, MA) search engine and SwissProt (release 02_2013, 539 165 entries) 
database restricted to 50 ppm peptide mass tolerance for the parent ions, an error of 
0.3 Da for the fragments, one missed cleavage in peptide masses, and 
carbamidomethylation of Cys and oxidation of Met as fixed and variable amino acid 
modifications, respectively. No taxonomy restrictions were applied. The identified 
proteins were only considered if a MASCOT score above 95% confidence was 
obtained (p < 0.05) and at least one peptide was identified with a score above 95% 
confidence (p < 0.05). This analysis was conducted by the Analytical Services Unit, 
Instituto de Tecnologia Química e Biológica (ITQB), New University of Lisbon, 
Lisbon, Portugal. 
 
2.3.5 Statistical Analysis 
Statistically significant differences in the total mean fluorescence intensity for 1D 
preparations and FTSC/IAF- and coomassie-labelled spot volumes (2D) were 
measured using Student’s t-test, Mann-Whitney test, or one-way ANOVA after 
testing for normality and equal variance in the data sets using Graph-Pad Prism 
(Graph-Pad Software Inc., CA, USA) and Progenesis SameSpots software for 1D 
and 2D preparations respectively. P<0.05 was the criterion for statistical 
significance. 
 
2.4 Spectrophotometry   
 
Light intensity at a specific wavelength, either changed by absorption (A) or 
produced by emission of light, can be measured by means of spectrophotometry. 
Different molecules absorb light with absorption peaks at specific wavelengths; thus, 
changes in the amount of molecules which absorb at a specific wavelength will be 
relative to the difference in light intensity (Io-It) at that wavelength before and after 
passing through them. Increases in product or decreases in substrate related to an 
enzymes activity may be measured by this method, and when measured under 
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optimal conditions for that enzyme (e.g. pH, temperature, and saturating substrate) 
they may be used to compare a particular enzyme’s maximal catalytic activity in 
different tissues and in response to different stimuli, assuming the light-path length 
and volume of liquid is kept the same. Fig. 2.2A illustrates a simple 
spectrophotometer measuring absorption. The Beer-Lambert Law takes into account 
molar absorptivity and light-path length and can be used to calculate specific units of 
activity (Fig 2.2B). Molar absorptivity is a measurement of intrinsic absorption 
strength that depends on the nature of the absorbing species and the wavelength of 
the incident light. Further biochemical reactions can be used to form coloured 
products with strong absorbencies or to react with fluorescent or luminescent 
substrates that emit light which can amplify signals and provide greater experimental 
specificity. There are many enzymatic reaction substrates/products that peak in 
absorbance at a specific wavelength and are widely used e.g. common co-substrates 
for several metabolic enzyme reactions include dinucleotides such as NADH, which 
may be oxidised to form NAD
+ 
or
 
produced by reduction of NAD
+
. NADH readily 
absorbs light at 339nm whereas NAD
+
 does not (Fig. 2.2C). Antioxidants, metabolic 
enzymes, proteasome and phospho-protein activities and content assays described 
below make use of these techniques. Unless otherwise stated, the Spectramax M3 
(Molecular Devices, CA, USA) is the spectrophotometer used in the following 
experiments. Optimal protein concentrations were pre-determined by varying the 
protein concentration to find the appropriate linear range for enzyme activity 
measurements as a function of protein concentration. 
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Figure 2.2: Workflow and principles of spectrophotometry 
A simplified diagram of a spectrophotometer measuring absorbance change is 
illustrated in (A); The Beer-Lambert Law is illustrated in (B); and peak absorbance 
wavelengths for the NAD
+
 and NADH are illustrated in (C). 
  
A. 
B. 
C. 
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2.4.1 Antioxidants 
2.4.1.1 Catalase Activity 
The decomposition of H2O2 into oxygen and water in cells is catalysed by catalase, 
preventing both oxidative damage by H2O2 and the formation of the highly reactive 
hydroxyl radical. H2O2 peaks in absorbance at 240nm, and thus, the reaction in Fig. 
2.3 can be followed by ultra-violet absorption spectrophotometry [195]. One unit of 
catalase activity decomposes one micromole of H2O2 per minute at 25
o
C and pH 7.0; 
43.6 is the millimolar extinction coefficient of peroxide at 240nm. 30% H2O2 
(Pharmacy Brand) was diluted in pH 7 phosphate buffer (0.75% v/v) and added to 
dH2O, incubated for 5min in the spectrophotometer to achieve temperature 
equilibration. Sample was then added (33% H2O2 in final dH2O and sample) and 
decreasing absorbance was recorded for 2-4min. The reaction velocity was taken 
from the initial linear part of the curve. Mouse liver sample and purified catalase 
(Sigma Aldrich) were used as positive controls and sodium azide (a catalase 
inhibitor) (Sigma Aldrich) was used as a negative control. This assay was performed 
on diaphragm muscle samples from C57Bl6/J mice exposed to one, three, and six 
weeks of CH and normoxia controls. 
 
 
 
Figure 2.3: Decomposition of hydrogen peroxide by the enzyme catalase 
 
2.4.1.2 Total Glutathione Content 
GSH, the tri-peptide L-γ-glutamyl-L-cysteinylglycine, is an endogenous antioxidant 
and the most abundant non-protein thiol containing compound in cells. It is involved 
in amino acid transport, the formation of DNA precursors, the detoxification of 
xenobiotics, and protection from oxidative damage. It functions as a co-enzyme and 
can conjugate with many endogenous and foreign thiol radicals. It operates in a 
cyclical manner with the enzymes GPx and GR converting the oxidised GSH radical 
to the disulfide dimer form and reduction back to the singular compound form 
respectively. Total GSH content was measured using a colorimetric reaction in 
accordance with the kit manufacturer’s instructions (Caymen Chemical, USA). The 
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sulfhydryl group of GSH in the sample is reacted with 5-5-dithio-bis-2-nitrobenzoic 
acid (DTNB or Ellman’s Reagent) to produce 5-thio-nitrobenzoic acid (TNB) and 
the mixed disulfide GSTNB. GSTNB is reduced by GR to recycle the GSH and 
produce more TNB. The rate of TNB production is directly proportional to the 
recycling reaction which is directly proportional to the amount of GSH in the system 
(Fig. 2.4). The absorbance of TNB at 410nm provides an accurate estimation of GSH 
in the sample. To avoid interference from proteins containing sulfhydryl groups, 
samples are first deproteinated by addition of an equal volume of 10% 
metaphosphoric acid (Sigma Aldrich), incubation for 5min and centrifugation at 
2,500g for 2 min with collection of the deproteinated supernatant at the end. 4M 
Triethanolamine (Sigma Aldrich) is added 1:20 to the sample to increase the pH 
before assaying. GSSG standards and samples are added to wells of a 96-well plate 
followed by addition of the assay cocktail (MES Buffer, Co-Factor mixture, Enzyme 
mixture and DTNB). Absorbance is measured after 25 min incubation in the dark on 
an orbital shaker. This assay was performed on diaphragm and sternohyoid muscle 
samples from C57Bl6/J mice exposed to six weeks of CH and normoxia controls. 
 
 
 
 
 
 
Figure 2.4: Recycling mechanism of total glutathione assay 
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2.4.2 Metabolic Enzymes 
 
2.4.2.1 Glucose-6-Phosphate Dehydrogenase Activity 
Glucose-6-Phosphate Dehydrogenase (G6PD), which shuttles metabolic substrate 
between the glycolysis and pentose phosphate pathways to increase reducing 
equivalent availability for cells, is unique as it possesses dual co-substrate 
specificity. The G6PD assay is a modified version of that described by [196] and 
[197]. The reaction velocity is determined by measuring the increase in absorbance 
at A339nm/min resulting from the reduction of NAD or NADP. 55mM Tris⋅HCl 
buffer (pH 7.8) containing 3.3mM MgCl2 was added to a 96-well plate (25% v/v) 
along with 60mM NAD (25% v/v) and 0.1M glucose-6-phosphate (25% v/v). The 
plate was incubated in a spectrophotometer at 30
o
C for 10min. Sample was added 
(25% v/v) and the increase in A339nm was recorded for 10min. ΔA339/min was 
calculated from the initial linear portion of the curve. One unit reduces one 
micromole of NAD per minute at 30°C and pH 7.8; 6.22 is the millimolar extinction 
coefficient of NADH. This assay was performed on diaphragm muscle samples from 
C57Bl6/J mice exposed to one, three and six weeks of CH and normoxia controls. 
 
 
 
Figure 2.5: G6PD catalyses the reversible oxidation of D-glucose-6-phosphate 
into 6-phospho-D-glucono-1,5-lactone 
 
2.4.2.2 Fructose-1, 6-bisphosphate Aldolase A Activity 
Fructose-1, 6-bisphosphate Aldolase A (aldolase) is the isoform of the enzyme found 
predominantly in skeletal muscle, composed of four identical subunits, and is the 4
th
 
enzyme of the glycolysis pathway. It catalyzes the conversion of fructose-1-6-
bisphosphate into both 3-phosphoglyceraldehyde and dihydroxyacetone phosphate 
(Fig. 2.5). This assay is based upon Boyer’s modification of the hydrazine assay 
[198] where 3-phosphoglyceraldehyde reacts with hydrazine to form a hydrazone 
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which absorbs at A240nm. 4mM fructose-1,6-bisphosphate (pH 7.5) (25% v/v), 
0.03mM EDTA pH 7.5 (25% v/v), and 2.3mM hydrazine sulphate (25% v/v) were 
added to a 96-well plate and absorbance was recorded for 10min. Samples and a 
dH2O blank (25% v/v) were then added to the plate and absorbance was recorded for 
another 10min. Using the linear portions of the curve, the ΔA240/min of the blank 
was subtracted from the ΔA240/min of the test. One unit is described as a change in 
absorbance of 1.00 per minute at 25°C and pH 7.5. This assay was performed on 
diaphragm muscle samples from C57Bl6/J mice exposed to one, three and six weeks 
of CH and normoxia controls. 
 
 
 
Figure 2.6: Aldolase catalyses the reversible reduction of fructose-1-6-
bisphosphate into both 3-phosphoglyceraldehyde and dihydroxyacetone 
phosphate 
 
2.4.2.3 Glycerol-3-Phosphate Dehydrogenase Activity 
Glycerol-3-Phosphate Dehydrogenase (G3PD) serves as a major link between 
carbohydrate and lipid metabolism as well as maintaining the inner mitochondrial 
membrane redox potential and being a major contributor of electrons to the 
respiratory chain. It catalyzes the reversible redox conversion of dihydroxyacetone 
phosphate to glycerol-3-phosphate (Fig. 2.6). 25mM Triethanolamine⋅HCL (pH7.5) 
containing 0.65mM EDTA and 0.025mM 2-mercaptoethanol (25% v/v) was added 
to a 96-well plate with sample (25% v/v) and dihydroxyacetone phosphate (25% v/v) 
and incubated for 10min in a spectrophotometer at 25
o
C. 0.03mM NADH (25% v/v) 
was then added to the mixture and ΔA339 was recorded for 20min. ΔA339/min is taken 
from the linear portion of the curve. This assay was performed on diaphragm, muscle 
samples from C57Bl6/J mice exposed to one, three weeks and six of CH and 
normoxia controls.  
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Figure 2.7: G3PD catalyzes the reversible reduction of dihydroxyacetone 
phosphate into glycerol-3-phosphate 
 
2.4.2.4 Glyceraldehyde-3-phosphate Dehydrogenase Activity 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is the 6
th
 enzyme in the 
glycolysis pathway. Its activity catalyzes the conversion of glyceraldehyde-3-
phosphate into D-glycerate-1,3-bisphosphate (Fig. 2.7). GAPDH activity was 
measured in a modified version of the assay described by [199,200]. Samples were 
added to 13.5mM sodium pyrophosphate buffer (pH8.5) containing 30mM sodium 
arsenate, 0.25mM NAD with 3.325mM DTT. Samples were incubated at 25
o
C for 
10min to achieve temperature equilibration and to establish a blank rate, if any. 
0.5mM DL-glyceraldehdye-3-phosphate was added and absorbance was recorded for 
10min at A339nm. All chemicals above are described as final concentrations in the 
well. Measured rates were corrected by measuring the blank rate of the reaction. One 
unit is defined as 1µmol NADH generated/minute/mg sample. One unit is defined 
1umol NADH generated/minute/mg sample. This assay was performed on 
diaphragm, sternohyoid, EDL and soleus muscle samples from C57Bl6/J mice 
exposed to one and three weeks of CH and normoxia controls.  
 
 
 
Figure 2.8: GAPDH catalyzes the reversible reduction of glyceraldehyde-3-
phosphate into D-glycerate-1,3-bisphosphate 
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2.4.2.5 Lactate Dehydrogenase Activity 
LDH catalyzes the reversible reaction of pyruvate to lactate oxidising the co-
substrate NADH to the by-product NAD
+
 in the process (Fig. 2.9). Total activity is 
contributed to by five different isozymes which derive from two gene loci coding for 
two different polypeptides which combine together in groups of four to produce five 
different isozymes. LDH-4 and LDH-5 predominate in skeletal muscle. Total LDH 
activity was calculated as the decreasing absorbance at A339nm produced by 
oxidation of NADH at 25
o
C and pH 7.3 in 0.2M Tris-HCL buffer containing 1mM 
sodium pyruvate and 0.22mM NADH. All chemicals above are described as final 
concentrations in the well. After 5min temperature equilibration and establishing a 
blank rate, if any, sample is then added and the reaction is recorded kinetically at 
339nm for 10min. ΔA339/min was taken from the linear portion of the curve. This 
assay was performed on diaphragm, sternohyoid, EDL and soleus muscle samples 
from C57Bl6/J mice exposed to one and three weeks of CH and normoxia controls. 
Diaphragm muscle from six week groups was also assayed. 
 
Figure 2.9: LDH catalyzes the reversible reduction of pyruvate into lactate 
 
2.4.2.6 Aconitase Activity 
Aconitase activity was measured using a colorimetric reaction in accordance with the 
kit manufacturer’s instructions (Abcam, Cambridge, UK). Aconitase is a TCA cycle 
enzyme that catalyzes the isomerisation of citrate to isocitrate. Isocitrate, in this 
assay, undergoes further biochemical reaction resulting in a product that converts a 
nearly colourless probe into an intensely coloured form with a peak absorbance at 
A450nm. Samples are incubated in an activating solution containing cysteine-HCL 
and (NH4)2Fe(SO4)2 on ice for one hour before addition to a 96-well plate in 
duplicate along with isocitrate standards. One half of the duplicate wells receive the 
sample reaction mixture (containing assay buffer, enzyme mix and substrate) and the 
other half the background mixture (containing assay buffer and enzyme mix only) 
and samples are incubated for 60min at 25
o
C. Developer is then added to each well 
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and samples are incubated for a further 10min. Absorbance is measured at A450nm 
and background is subtracted from the test sample. One unit of Aconitase activity is 
the amount of enzyme that will isomerize 1 mmol of isocitrate per minute at pH 7.4 
and 25
o
C. This assay was performed on diaphragm muscle samples from C57Bl6/J 
mice exposed to one, three, and six weeks of CH and normoxia controls.  
 
 
 
Figure 2.10: Aconitase catalyzes the reversible reduction of citrate into 
isocitrate 
 
2.4.2.7 Creatine Kinase Activity 
In order to maintain an immediately accessible energy reservoir in skeletal muscle, 
creatine kinase (CK) catalyzes the phosphorylation of creatine. The highest catalytic 
concentration of CK is found in skeletal muscle. CK activity was measured using a 
colorimetric reaction in accordance with the kit manufacturer’s instructions 
(Abcam). In this assay, the generated phosphocreatine reacts with the CK enzyme 
mix to form an intermediate, which reduces a colourless probe to a coloured product 
with strong absorbance at A450nm. Standards, samples and positive controls are 
added in duplicate to a 96-well plate. One half of each duplicate pair is incubated 
with a reaction mixture (containing assay buffer, enzyme mix, developer, ATP and 
substrate) and the other with a background mixture (containing assay buffer, enzyme 
mix, developer and ATP only) for 1hour at 37
o
C and absorbance is recorded 
kinetically at A450nm. Background is subtracted from test samples. One unit of CK is 
the amount of enzyme that will generate 1 mmol of NADH per minute at pH9 and 
37
o
C. This assay was performed on diaphragm muscle samples from C57Bl6/J mice 
exposed to one, three, and six weeks of CH and normoxia controls. 
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Figure 2.11: Creatine Kinase catalyzes the reversible phosphorylation of 
creatine into phosphocreatine 
 
2.4.3 Hypertrophy/Atrophy Signalling 
 
2.4.3.1 Chymotrypsin-Like Proteasome Activity 
Chymotrypsin-like activity of the 20S proteasome was measured by fluorometric 
spectrophotometry in accordance with the kit manufacturer’s instructions (Abcam). 
The reaction uses an AMC-tagged peptide substrate that releases highly fluorescent 
AMC in the presence of proteolytic activity. Jurkat cell lysate with high proteasome 
activity is supplied as the positive control and the proteasome specific inhibitor MG-
132 permits differentiation of proteasome activity from other proteolytic activity 
which may be present in the sample. All samples and positive controls were assayed 
with/without the proteasome specific inhibitor on a white, 96-well plate. Samples, 
standards and positive controls are added to the plate. One half of each pair received 
the inhibitor and all wells except the standards received the substrate. Samples were 
incubated at 37
o
C and readings were taken kinetically for 1hour at Ex/Em = 
350/440nm. The first few minutes of the readings are discarded due to the time lag of 
the samples in reaching 37
o
C. Non-proteasome activity is subtracted from total 
activity and one unit of proteasome activity is defined as the amount of proteasome 
which generates 1 nmol of AMC per minute at 37
o
C. This assay was performed on 
diaphragm, sternohyoid, EDL and soleus muscle samples from C57Bl6/J mice 
exposed to six weeks of CH and normoxia controls. Diaphragm muscle samples 
from the one week exposure groups were also assayed. 
 
2.4.3.2 Phospho-FOXO3a (Thr32) content 
FOXO3a is a transcription factor which regulates multi-transcriptional targets 
involved in various cellular processes. This assay was performed in accordance with 
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the manufacturer’s instructions (Mesoscale Discovery, Gaithersburg, USA). Sample 
is loaded onto a 96-well plate containing specific capture antibodies bound to 
electrodes at the well bottom and the protein of interest is captured. The sample is 
then incubated in solution containing the detection antibody which is conjugated to 
an electrochemiluminescent label. Excess detection antibody is washed away and a 
read buffer is added to the wells which provide the optimum chemical environment 
for electrochemiluminescence emission and recording at 620nm. A specialised 
‘Mesoscale’ spectrophotometer (MSD Sector Imager) was used to measure intensity 
of emitted light to provide a quantitative measure of phospho-FOXO3a in the 
sample. Inside the imager, a voltage applied to the plate electrodes causes the labels 
bound to the electrode surface to emit light. As a mild and acute oxidative stress has 
been shown to induce activation of Akt signalling in neurons [201,202] and thus 
phosphorylation of FOXO3a, cultured primary Sprague-Dawley rat hippocampal 
neurons treated for 10min with H2O2 (courtesy of a neighbouring laboratory) were 
used as a positive control. Care was taken to use measurements in the dynamic range 
of the signal. This assay was performed on diaphragm muscle samples from 
C57Bl6/J mice exposed to one, three, and six weeks of CH and normoxia controls. 
 
2.4.3.3 mTOR and phospho-mTOR (Ser2448) content 
The ‘Mesoscale Discovery’ technology facilitates the ability to quantify more than 
one protein in a single 96-well at one time. Several arrays of capture antibodies can 
be present in a well and light emitted based on temporal and spatial differences in the 
voltage applied to wells facilitate this multi-plex design. Using multi-plex assays, 
total mTOR and phospho-mTOR content were quantified in a similar method as 
phospho-FOXO3a. This assay was performed on diaphragm muscle samples from 
C57Bl6/J mice exposed to one, three, and six weeks of CH and normoxia controls. 
 
2.4.3.4 Phospho-Akt, phospho-p70S6K, phospho-GSK-3β, phospho-S6RP 
content 
 The phosphorylated content of Protein Kinase B (Akt), p70S6K, glycogen synthase 
kinase-3β (GSK-3β) and ribosomal protein S6 (S6RP) signalling proteins of Akt 
signalling cascade were measured using the Mesoscale multi-plex format. This assay 
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was performed on diaphragm muscle samples from C57Bl6/J mice exposed to one, 
three, and six weeks of CH and normoxia controls. 
 
2.4.3.5 Phospho-ERK 1/2, phospho-p38, phospho-JNK content 
The phosphorylated content of extracellular signal related kinase (ERK) 1/2, p38, 
and C-Jun-N-terminal kinase (JNK) MAPK was assessed using the Mesoscale 
multiplex format already described. Lysate from Jurkat cells treated with 1µmol 
rapamycin for three hours to activate MAPK phosphatase 1 was used as negative 
control and lysate from Jurkat cells treated with 50nM calyculin A and 200nM PMA 
for 15min to stimulate phosphorylation was used as a positive control. This assay 
was performed on diaphragm muscle samples from C57Bl6/J mice exposed to six 
weeks of CH in the presence or absence of chronic supplementation with tempol or 
NAC and normoxia controls. 
 
2.4.4 HIF-1α content 
This assay was performed on diaphragm muscle samples from C57Bl6/J mice 
exposed to six weeks of CH ± chronic supplementation with tempol or NAC and 
normoxia controls using the Mesoscale multiplex format already described. Negative 
and positive controls are HeLa cells and HeLa cells treated with cobalt chloride 
(activates HIF) for 16 hours respectively. 
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Figure 2.12: Representation of method of protein content determination using 
the ‘Mesoscale’ assays 
 
2.4.5 Statistical Analysis  
Significant differences in enzyme activity and protein content assays were measured 
using Student’s t-test, Mann-Whitney test, one-way analysis of variance (ANOVA) 
followed by Tukey’s post-hoc multiple comparison tests, or the Kruskal-Wallis test 
followed by Dunn’s post-hoc multiple comparison tests after testing for normality 
and equal variance in the data sets. P<0.05 was the criterion for statistical 
significance. 
 
2.5  Isotonic Muscle Function 
 
2.5.1 Ex Vivo Muscle Preparation 
Animals were anaesthetised by 5% isoflurane inhalation in air and euthanized by 
cervical dislocation. The diaphragm and sternohyoid muscles were excised and 
placed in a bath of Krebs solution (NaCl 120mM, KCl 5mM, Ca
2+
 gluconate 2.5mM, 
MgSO4 1.2mM, NaH2PO4 1.2mM, NaHCO3 25mM, glucose 11.5mM, and 25mM d-
tubocurarine) at room temperature and gassed with high oxygen (95% O2/5% CO2) 
before mounting in the test bath for performance assessment. Diaphragm muscle 
bundles (2-3mm at the rib end and slightly narrower at the central tendon end) were 
arranged with fibres running vertically between plate electrodes, anchored at the rib 
end to a fixed base and connected at the central tendon to a dual mode force 
transducer (Aurora Scientific, Canada) using thread. Whole mouse sternohyoid 
muscle bundles (1-2mm in diameter) were arranged between the electrodes with 
sternum anchored at the fixed base and at the hyoid bone to the force transducer so 
fibres are orientated vertically. Upon placement in the test bath, bundles were 
incubated at 35
o
C in Krebs solution gassed with high oxygen (95% O2/5% CO2). 
Muscle performance has previously been shown to be optimal under hyperoxic 
conditions (95% O2) compared to normoxic conditions (21% O2). Bundles were 
equilibrated for five minutes in gassed Krebs solution prior to initiating the 
experimental protocol. Sternohyoid was assessed first because unlike the diaphragm, 
50 | P a g e  
 
performance of the sternohyoid deteriorates when left for a prolonged period in the 
Krebs bath at room temperature (unpublished observation). 
 
2.5.2 Protocol 
Peak isometric twitch and tetanic force and twitch contractile kinetics Bundles were 
set to optimum length (Lo – length at which peak twitch force occurs) by adjusting 
the position of the force transducer with a micro-positioner and stimulating with a 
single pulse until peak twitch force was reached. Twitch kinetics (time to peak (TTP) 
and half-relaxation time (T50) were measured from the peak twitch force recording. 
After five minutes equilibration time, the force transducer was set to maximum 
rigidity (~500mN; >100% load) and a tetanic contraction was elicited by stimulating 
the bundle with supra-maximal voltage at 100Hz for 300ms. Shortening length and 
velocity The force transducer was set to minimum rigidity and contractions were 
elicited in incremental steps from 0-100% with one minute rest between each step. 
For example, when load was set to 20%, the muscle could only shorten when force 
production reached 20% of peak tetanic force. At the end of contraction, the muscle 
started to lengthen when force fell back below 20%. Shortening was determined as 
the maximum distance shortened over the whole contraction and shortening velocity 
was determined as distance shortened per the initial 30ms of shortening as this is 
when velocity is greatest. Peak shortening and peak shortening velocity were 
measured at 0% load. Work and Power Work and Power were determined at each 
step as the product of force x shortening and force x shortening velocity respectively. 
Peak work and peak power performance parameters were determined from the work-
load and power-load relationship. Fatigue Five minutes after the step-test, muscle 
endurance was tested by repeated stimulation of the muscle at 100 Hz with 300ms 
trains every 2 seconds for a period of 5 minutes in isotonic conditions at 33% load. 
33% load has previously been shown to elicit maximum power. 
 
2.5.3 Data Analysis 
Peak specific force (Fmax) was calculated in N/cm
2
 of muscle CSA. CSA was 
calculated as the blotted dry muscle bundle weight divided by the product of Lo and 
the specific density, assumed to be 1.056g/cm
3
. Peak specific shortening (Smax) was 
calculated as length shortened per optimal length (L/Lo). Peak specific shortening 
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velocity (Vmax) was calculated as Lo/s. Peak specific mechanical work (Wmax) was 
calculated as Joules/cm
2
 and peak specific power (Pmax) as Watts/cm
2
. For the 
assessment of isotonic fatigue, shortening, shortening velocity, work, and power 
were measured every 10s for the initial 2min and every 30s thereafter. After testing 
for normality and equal variance in the data sets, statistical comparisons were 
performed between groups using one-way ANOVA, Kruskal-Wallis test, two-way 
ANOVA, Tukey’s post-hoc multiple comparison tests, Bonferroni’s post-hoc 
multiple comparison tests, Dunn’s multiple comparison tests as appropriate using 
Graph-Pad Prism. P<0.05 was the criterion for statistical significance. 
 
2.6 Succinate Dehydrogenase Histochemistry Analysis 
 
SDH is a TCA cycle enzyme and also part of complex II of the respiratory chain. 
SDH catalyses the conversion of succinate into fumurate, with reduced flavin 
adenine dinucleotide (FADH2) produced as a by-product of this reaction. FADH2 
and, thus electrons are thereby provided to the respiratory chain for oxidative 
phosphorylation. In a previous study by our laboratory, diaphragm and sternohyoid 
muscle SDH activity in a rat model of CH was determined for the whole muscle 
composite section on slides by histochemistry and optical density measurement [22]. 
No significant differences were observed between control and CH in diaphragm or 
sternohyoid muscles. We sought to re-examine these slides as changes may have 
occurred at the fibre level that may be hidden in whole muscle analysis. Male Wistar 
rats were exposed to hypobaric CH (380mmHg) for six weeks [22]. Post treatment, 
diaphragm and sternohyoid muscles were excised and snap frozen. Transverse 
sections from each muscle were cryo-sectioned and SDH histochemistry was 
performed [22]. Scion Image was the software used for determination of SDH 
activity optical density per fibre cross sectional area.  
 
K-means cluster analysis was performed on area-density plots of muscles from 
control and CH animals. K-means clustering partitions ‘x’ number of observations 
into ‘k’ number of clusters by iterative fine-tuning until all observations are grouped 
into the cluster of the nearest mean. Three means/clusters (k=3) were decided 
appropriate (small, middle, and large FCSAs). Three means are selected at random 
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and data points are grouped accordingly. The centroid of each cluster becomes the 
new mean and data points are grouped according to these new means. This process is 
repeated until the cluster centroids no longer change with the three most spatially 
distinct clusters remaining. SDH activity of fibre clusters in normoxic and CH 
sternohyoid and diaphragm muscles were compared. 
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Chapter 3: Redox remodelling in 
diaphragm muscle following chronic 
sustained hypoxia  
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3.1 Chapter Introduction 
 
Mitochondria in the hypoxic diaphragm are compromised [67,80] and as such may 
be producing increased ROS – progressive to mitochondrial damage. Hypoxia 
increases ROS formation in several tissues [102,126] through increased electron leak 
from mitochondria [129,130]. Increased contractile activity will also stimulate ROS 
production [131–133]. Perturbations to ROS and redox homeostasis, which are 
associated with muscle functional changes in CH and other models, represent a 
process whereby function, metabolism and fibre atrophy in the diaphragm may all be 
manipulated (discussed in chapter 1). Oxidative stress correlation with human 
disease is widely accepted. COPD patients present with redox remodelling in their 
diaphragm muscle [72,153]. Increased protein oxidation has also been detected in 
respiratory muscles in response to chronic resistive loading, after several hours of 
mechanical ventilation, and in response to sepsis [16,19,203,204]. However, there is 
a paucity of information concerning how and where ROS mediate their effects.  
 
Proteins represent the major non-water constituent of the cell and thus absorb the 
majority of ROS produced by the cell. This in turn will alter protein expression, 
through gene induction or targeted degradation, and/or affect catalytic function by 
altering a given protein’s covalent structure, both of which could impact homeostasis 
in the muscle proteome in times of oxidative stress. Protein oxidation may occur in a 
number of ways, with carbonylation being the most common form and free thiol 
oxidation being quite specific [159,205]. Many structural, metabolic, and stress 
response proteins can have their expression and functions modified by oxidation 
[72,102,184,204,206–211]. They may not all strictly be maladaptive as advantageous 
adaptations have been observed in models of oxidative stress e.g. metabolic enzymes 
in yeast that experience oxidant stress [212].  
 
Carbonyls are functional groups of amino acids that contain a carbon atom double-
bonded to an oxygen atom (C=O) e.g. ketones and aldehydes. Carbonylation is for 
the most part irreversible and carbonylated proteins are targeted for degradation by 
the 20S proteasome [213–218]. It has even been suggested that proteolysis might be 
a better indicator of oxidative stress than lipid peroxidation [216]. Further 
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carbonylation can result in aggregate formations that cannot be degraded, as occurs 
with aging [219,220]. Despite carbonylation being the most common form of protein 
oxidation [159,221], specificity can occur in many cases and consequently be 
conducive to protein quality control. Carbonylation may be physiologically 
important in targeting irreparably damaged protein for degradation rather than 
chaperoning and re-folding [159]. Enzymes that are idle due to a lack of substrate 
also appear more prone to carbonylation e.g. there is specific carbonylation of 
glutamine synthetase during nitrogen starvation [213,214,222]. A thiol is a carbon 
bonded sulfhydryl group (-SH). Free thiols are sulfhydryl groups that are exposed 
and oxidant sensitive. They are often found in enzyme catalytic sites and contribute 
to catalytic activity. Oxidation of protein thiol groups to reversible and irreversible 
protein disulphide bridges (R-SS-R), glutathionylated thiols (R-SSG), nitrosothiols (-
SNO), and sulphoxides (thiol radical (-S
-)→ sulfenic acid (-SOH) → sulfinic acid (-
SO2H) → sulfonic acid (-SO3H); with progressive oxidation) is highly specific in 
accordance with the low abundance of the amino acid cysteine in comparison to 
other amino acids [205]. 
 
In this chapter we describe protein carbonyl and free thiol oxidation in respiratory 
and limb muscles after one, three and six weeks of hypoxia compared to controls. 
We use redox proteomics to identify proteins that are redox modified in the 
diaphragm and sternohyoid after six weeks CH (a collaborative study with Prof Dave 
Sheehan’s Proteomic Research Group in the School of Biochemistry & Cell Biology, 
University College Cork). The approach also facilitates the assessment of protein 
expression changes. We hypothesize that differential and temporal changes in 
protein oxidation occur in respiratory and limb muscles. Furthermore, proteins key to 
muscle function will be redox modified in the respiratory muscles. 
 
Protein redox changes may result from either increased production of ROS, decline 
in the antioxidant defence system, diminished capacity for removal of oxidized 
proteins, increased susceptibility of proteins to oxidative attack or increased proteins 
available for carbonylation such as those containing metals like Ferritin. Of course, 
these possibilities are not mutually exclusive [205]. A diminished capacity for 
protein removal is unlikely given that fibre atrophy is observed in this model, while 
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Ferritin will be required for increased haematocrit levels in hypoxia. Bearing this in 
mind, we are also interested in what happens to the antioxidant defence system of the 
cell. 
 
Cells have evolved a host of antioxidant defence mechanisms including utilising 
specific enzyme activities (e.g. catalase) and non-protein reducing agents (e.g. GSH, 
Vitamin E) as well as having antioxidant responsive genes. Antioxidants inhibit 
reactive intermediates by being oxidised themselves. 
 
We measured total GSH content in the respiratory muscles after six weeks of CH and 
catalase activity in the diaphragm after one, three and six weeks of CH. GSH is the 
most abundant non-protein thiol in mammalian cells and is present in concentrations 
of 0.5–10mM. It plays a role in many biological processes, including synthesis of 
proteins and DNA, transport of amino acids, and as an antioxidant. It may also form 
disulphide bridges with other oxidised thiols of proteins and lipids, in some cases 
conferring protection against further oxidative stress. It may also be used as a 
reductant in keeping other endogenous antioxidants such as Vitamin E in their 
reduced form. Catalase reduces H2O2 to water and oxygen and has an extremely high 
turnover rate. Catalase can be differentially expressed or activated in times of 
oxidative stress. We hypothesized that hypoxia increases antioxidant defences to 
combat oxidative stress.  
 
3.2 Chapter Results 
 
3.2.1 Section A: Total Protein Carbonyl and Free Thiol Content 
Fig. 3.1 illustrates the differences in the redox proteome between diaphragm and 
sternohyoid muscles in control animals before quantitative measurement. It is 
entirely plausible that exposure to hypoxia will result in differences in protein redox 
modification in respiratory and in limb muscles. 
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Figure 3.1: Representative images of 1D gel protein separations 
The gel images are of labelled protein free thiols in control diaphragm samples (A) 
and control sternohyoid samples (B). Molecular weights cannot be displayed for the 
protein free thiol gel image - only the coomassie stained gel image. Despite this, the 
same range of protein weights which are displayed on each gel facilitates noting 
differences in protein free thiol content densities at different weights between both 
muscles. 
A. 
 
B. 
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3.2.1.1 Diaphragm 
Temporal changes in diaphragm protein carbonyl and free thiol content are shown in 
Fig. 3.2. There are significant increases in diaphragm protein carbonylation after 
three and six weeks of CH (121.66 ± 16.91 vs. 91.32 ± 13.09, 81.09 ± 25.19 vs. 
229.36 ± 35.46*, 70.72 ± 11.71 vs. 526.752 ± 72.42*** mean ± SEM normalised 
fluorescence intensity; control vs. CH; diaphragm protein carbonyl content after one, 
three, and six weeks of CH respectively; n=5-8 per group; *p<0.05, ***p<0.001) – 
indicative of progressive protein oxidation. Changes in diaphragm protein free thiol 
content, in contrast to carbonyl content, are bi-phasic. There are significant increases 
after one and three weeks of CH however this is significantly lower than control after 
six weeks (30.77 ± 5.33 vs. 281.65 ± 32.18***, 11.36 ± 1.34 vs. 142.61 ± 17.18***, 
16.71 ± 1.8 vs. 9.97 ± 0.86** mean ± SEM normalised fluorescence intensity; 
control vs. CH; diaphragm protein free thiol content after one, three, and six weeks 
of CH respectively; n=7-8 per group; **p<0.01, ***p<0.001) – further indication of 
progressive oxidation although the findings observed after one week are suggestive 
of an early antioxidant response. 
 
3.2.1.2 Sternohyoid  
Sternohyoid protein carbonyl content and free thiol content changes after one, three, 
and six weeks of CH are shown in Fig. 3.3. Similar to diaphragm muscle, there are 
significant progressive increases in sternohyoid protein carbonyl content after three 
and six weeks of CH (313.88 ± 54.78 vs. 197.40 ± 46.90, 341.01 ± 96.95 vs. 1035.41 
± 38.92***, 222.94 ± 28.37 vs. 930.04 ± 75.72*** mean ± SEM normalised 
fluorescence intensity; control vs. CH; sternohyoid protein carbonyl content after 
one, three, and six weeks of CH respectively; n=5-8 per group; ***p<0.001). 
Changes in sternohyoid protein free thiol content are also bi-phasic. There are 
significant increases after one and three weeks of CH however this is significantly 
lower than control after six weeks (82.07 ± 9.87 vs. 203.91 ± 30.53*, 68.72 ± 4.91 
vs. 128.69 ± 15.06*, 71.79 ± 2.02 vs. 13.92 ± 1.63** mean ± SEM normalised 
fluorescence intensity; control vs. CH; sternohyoid protein free thiol content after 
one, three, and six weeks of CH respectively; n=7-8 per group; *p<0.05, **p<0.01). 
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Figure 3.2: Diaphragm protein carbonyl and free thiol content after one, three 
and six weeks of sustained hypoxia compared to normoxic controls. (A) 
Diaphragm protein carbonyl content (mean ± SEM) after one, three, and six weeks 
of normoxia or sustained hypoxia expressed as normalised fluorescence intensity; 
n=5-8 per group; (B) Diaphragm protein free thiol content (mean ± SEM) after one, 
three, and six weeks of normoxia or sustained hypoxia expressed as normalised 
fluorescence intensity; n=7-8 per group; *p<0.05, **p<0.01, ***p<0.001, ns=not 
significant; Student’s t-test or Mann-Whitney test as appropriate; Ctrl = normoxic 
control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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Figure 3.3: Sternohyoid protein carbonyl and free thiol content after one, three 
and six weeks of sustained hypoxia compared to normoxic controls. (A) 
Sternohyoid protein carbonyl content (mean ± SEM) after one, three, and six weeks 
of normoxia or sustained hypoxia expressed as normalised fluorescence intensity; 
n=5-8 per group; (B) Sternohyoid protein free thiol content (mean ± SEM) after one, 
three, and six weeks of normoxia or sustained hypoxia expressed as normalised 
fluorescence intensity; n=7-8 per group; *p<0.05, **p<0.01, ***p<0.001, ns=not 
significant; Student’s t-test or Mann-Whitney test as appropriate. Ctrl = normoxic 
control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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3.2.1.3 EDL  
Unlike the respiratory muscles, there are no significant changes to protein carbonyl 
content in EDL muscle after CH exposure (Fig. 3.4A) (113.04 ± 11.32 vs. 92.22 ± 
14.94, 137.05 ± 49.04 vs. 219.19 ± 43.39, 86.35 ± 8.01 vs. 104.86 ± 20.75 mean ± 
SEM normalised fluorescence intensity; control vs. CH; EDL protein carbonyl 
content after one, three, and six weeks of CH respectively; n=4-8 per group). There 
are, however, significant increases in EDL free thiol content after one, three, and six 
weeks of CH (79.39 ± 24.18 vs. 491.25 ± 101.6**, 74.69 ± 12.59 vs. 232.87 ± 
32.87***, 55.69 ± 3.39 vs. 185.33 ± 17.64*** mean ± SEM normalised fluorescence 
intensity; control vs. CH; EDL protein free thiol content after one, three, and six 
weeks of CH respectively; n=6-8 per group; **p<0.01, ***p<0.001) – the magnitude 
of the increase is seen to decrease over time (Fig. 3.4B).  
 
3.2.1.4 Soleus 
Similar to the respiratory muscles, but unlike the EDL, there is no change in protein 
carbonyl content in the soleus muscle after one week of CH but significant increases 
are observed after three and six weeks of CH (Fig. 3.5A) (227.73 ± 87.88 vs. 188.54 
± 46.96, 376.21 ± 28.46 vs. 613.59 ± 103.50*, 251.52 ± 76.81 vs. 980.61 ± 145.10** 
mean ± SEM normalised fluorescence intensity; control vs. CH; soleus protein 
carbonyl content after one, three, and six weeks of CH respectively; n=4-8 per 
group; *p<0.05, **p<0.01). Soleus free thiol content is significantly increased after 
one, three and six weeks of CH compared to controls (Fig. 3.5B) (175.33 ± 39.11 vs. 
1874.80 ± 271.14**, 198.29 ± 24.35 vs. 615.65 ± 110.05***, 115.06 ± 9.51 vs. 
279.62 ± 20.16*** mean ± SEM normalised fluorescence intensity; control vs. CH; 
soleus protein free thiol content after one, three, and six weeks of CH respectively; 
n=8 per group; **p<0.01, ***p<0.001); consistent with EDL there is a decline in 
increased free thiol content in the soleus with progressive CH. 
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Figure 3.4: EDL protein carbonyl and free thiol content after one, three and six 
weeks of sustained hypoxia compared to normoxic controls. (A) EDL protein 
carbonyl content (mean ± SEM) after one, three, and six weeks of sustained hypoxia 
expressed as normalised fluorescence intensity; n=4-8 per group; (B) EDL protein 
free thiol content (mean ± SEM) after one, three, and six weeks of sustained hypoxia 
expressed as normalised fluorescence intensity; n=6-8 per group; *p<0.05, **p<0.01, 
***p<0.001, ns=not significant; Student’s t test or Mann-Whitney test as 
appropriate; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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Figure 3.5: Soleus protein carbonyl and free thiol content after one, three and 
six weeks of sustained hypoxia compared to normoxic controls. (A) Soleus 
protein carbonyl content (mean ± SEM) after one, three, and six weeks of sustained 
hypoxia expressed as normalised fluorescence intensity; n=4-8 per group; (B) Soleus 
protein free thiol content (mean ± SEM) after one, three, and six weeks of sustained 
hypoxia expressed as normalised fluorescence intensity; n=8 per group; *p<0.05, 
**p<0.01, ***p<0.001, ns=not significant; Student’s t test or Mann-Whitney test as 
appropriate; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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3.2.1.5 Total Protein Carbonyl and Free Thiol Content expressed as percentage 
of control  
As illustrated in Fig. 3.6, one week of CH has no effect on protein carbonyl content 
in any of the respiratory or limb muscles studied, while three and six weeks induces 
progressive increases in both respiratory muscles and the soleus muscle. Taking the 
respiratory muscles as a separate group, there is greater carbonylation observed in 
diaphragm which has the greater complement of slow oxidative fibres (~7.5 fold and 
~4.2 fold change in diaphragm and sternohyoid after six weeks of CH respectively) 
and greatest carbonylation is observed in the slow oxidative soleus muscle within the 
limb group (~3.9 fold vs. ~1.2 fold change in soleus and EDL after six weeks of CH 
respectively). Considering respiratory versus limb muscles, there is greater 
carbonylation observed in the working respiratory muscles than in the non-working 
limb muscles. A combination of muscle fibre type composition and workload are 
evidently involved in determining protein carbonylation in muscle after CH. 
  
As illustrated in Fig. 3.7, one week of CH significantly increases protein free thiol 
content in each of the respiratory and limb muscles studied suggesting this may be a 
direct consequence of hypoxia per se. The greater fold change (~10.7, ~9.2, ~6.2, 
and ~2.5) is observed in soleus>diaphragm,>EDL>sternohyoid – again indicative of 
slow vs. fast fibre differences and respiratory vs. limb muscle differences. After 
three weeks of CH, protein free thiol content is significantly increased in all muscles 
although the fold change has decreased in all muscles except the diaphragm. After 
six weeks of CH, a respiratory vs. limb muscle difference is again observed with the 
respiratory group presenting with evidence of protein oxidation compared to 
controls. 
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Figure 3.6: Skeletal muscle protein carbonyl content expressed as a percentage 
of control after one, three, and six weeks of chronic sustained hypoxia. 
Diaphragm, sternohyoid, EDL and soleus protein free thiol content (mean ± SEM) 
expressed as percentage of control after one (A), three (B), and six (C) weeks of CH; 
Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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Figure 3.7: Skeletal muscle protein free thiol content expressed as a percentage 
of control after one, three, and six weeks of chronic sustained hypoxia.  
Diaphragm, sternohyoid, EDL and soleus protein free thiol content (mean ± SEM) 
expressed as percentage of control after one (A), three (B), and six (C) weeks of CH; 
Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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3.2.2 Section B: Redox Proteomics 
In the diaphragm, 498, 264 and 996 resolved spots were matched in FTSC-, IAF-
labelled and coomassie-stained separations respectively. A significant relative 
volume difference is observed in 34 FTSC, 23 IAF and 32 coomassie spots 
comparing control and CH groups (p<0.05). In the sternohyoid, 498, 264 and 996 
resolved spots were matched in FTSC-, IAF-labelled and coomassie-stained 
separations respectively. A significant relative volume difference is observed in 87 
FTSC, 51 IAF and 156 coomassie spots comparing control and CH groups (p<0.05). 
Proteins were selected for MS analysis based on separation, resolution, abundance, 
and overlap in fluorescence-stain and muscle separations. Protein smears and gel 
defects were excluded. Results for diaphragm and sternohyoid protein remodelling 
are presented in Table 3.1 and Table 3.2 respectively with proteins grouped 
according to cellular location and/or function. Selected spots can be visualised on the 
representative coomassie stained gels shown in Fig. 3.8. A change in FTSC and IAF 
fluorescence intensity signal independent of, or differential to, coomassie signal is 
indicative of protein redox remodelling. 88 spots were picked in total; 9 FTSC, 15 
IAF, 16 coomassie - diaphragm; 12 FTSC, 12 IAF, 24 coomassie – sternohyoid; 63 
spots were sent for identification with 59 successful identifications. Proteins 
identified include metabolic enzymes; stress response proteins that are associated 
with the mitochondria, the cytoplasm and the cross-bridge apparatus; as well as 
cross-bridge proteins and Ca
2+
 handling proteins. It should also be noted that just 
because a specific protein is not accounted for in the tables below, it does not mean 
that it is not being redox modified in CH. 
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Figure 3.8: Representative image of 2D-PAGE protein profiles after Coomassie 
staining of proteins. Diaphragm protein profile is presented in (A) and sternohyoid 
in (B). A molecular mass marker ranging from 14-116kDa is shown for size 
reference and isoelectric point is indicated along the range pH 10-3. Spot numbers 
match those presented in table 3.1 and table 3.2. 
A. 
 
B. 
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Table 3.1: Identifications of proteins undergoing significant redox remodelling in 
the diaphragm muscle after six weeks of sustained hypoxia. 
 Mw = molecular weight 
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Table 3.2: Identifications of proteins undergoing significant redox remodelling in 
the sternohyoid muscle after six weeks of sustained hypoxia. 
Mw = molecular weight 
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3.2.3 Section C: Antioxidants 
Total basal GSH content was higher in the diaphragm control compared to 
sternohyoid (Fig. 3.9) but this would be expected owing to the greater oxidative 
capacity of the diaphragm muscle. Six weeks of CH exposure increased diaphragm 
total GSH content (Fig. 3.9A) approaching statistical significance (5.40 ± 0.8 vs. 
9.09 ± 1.76 mean ± SEM nmol/µg protein; control vs. CH; diaphragm tGSH after six 
weeks of CH; n=8 per group; p=0.07) and significantly increased sternohyoid total 
GSH content (3.02 ± 0.62 vs. 8.13 ± 1.9 mean ± SEM nmol/µg protein; control vs. 
CH; sternohyoid tGSH after six weeks of CH; n=7-8 per group; p<0.05) (Fig. 3.9B).  
 
Diaphragm catalase activity (Fig. 3.10) is significantly increased after one, three and 
six weeks of CH compared to control (281.65 ± 21.89 vs. 512.73 ± 39.93***, 250.19 
± 26.12 vs. 363.10 ± 28.88*, 300.38 ± 42.55 vs. 565.65 ± 112.93* mean ± SEM 
Units/mg protein; control vs. CH; diaphragm catalase activity after one, three and six 
weeks of CH respectively; n=8 per group; *p<0.05, ***p<0.001). 
 
 
 
Figure 3.9: Diaphragm and sternohyoid total GSH content after six weeks of 
sustained hypoxia compared to normoxic control. Diaphragm (A) and sternohyoid 
(B) total GSH (mean ± SEM) expressed nmol/μg protein; n=7-8 per group; *p<0.05; 
Student’s t test; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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Figure 3.10: Diaphragm catalase activity after one, three, and six weeks of 
sustained hypoxia compared to normoxic control. Diaphragm catalase activity 
(mean ± SEM) after one, three, and six weeks of normoxia or sustained hypoxia 
expressed as Units/mg protein; n=8 per group; *p<0.05, ***p<0.001; Student’s t test 
or Mann-Whitney test as appropriate; Ctrl = normoxic control; Hypoxia = sustained 
hypoxia (FiO2 = 0.1). 
 
3.3 Chapter Discussion 
 
These results support the hypotheses of 1) differential and temporal changes in 
respiratory and limb muscle protein carbonyl and free thiol content; 2) key proteins 
being redox modified; and 3) of increased antioxidant defences following CH exposure. 
 
3.3.1 Total Protein Carbonyl and Free Thiol Content 
Protein oxidation in diaphragm muscle is progressive. It is conceivable that the 
diaphragm becomes more susceptible to injury with progressive hypoxia exposure 
just as diaphragm injury is a cause of death in COPD patients. Similar changes are 
observed in the sternohyoid and to a lesser extent in limb muscles meaning hypoxia-
induced protein redox remodelling is likely exacerbated by increased contractile 
activity in hypoxia. Differential protein oxidation in response to CH has previously 
been reported in human limb muscles following high altitude hypoxia exposure [96]. 
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Increased protein free thiol content after one week, observed in all four muscles 
studied, is suggestive of an early antioxidant response independent of workload or 
fibre type composition although the greatest increases are observed in the soleus and 
diaphragm which have the greater complement of slow oxidative fibres. Regardless, 
this potential antioxidant response is likely an effect of hypoxia per se, especially 
when considered that these changes are witnessed before classic acclimation 
responses such as increased haematocrit. Within the respiratory and limb muscle 
groups, the diaphragm and soleus muscles present with greatest fold decreases when 
comparing the effects of CH after one week with that of six weeks indicating an 
inherent susceptibility of the slow oxidative fibre phenotype. The temporal fold 
change differences in protein carbonylation are further indicative of this. This makes 
physiological sense given that 1) the slow oxidative muscles rely more on 
mitochondria to produce required ATP and would be subjected to greater electron 
leak and subsequent superoxide formation and protein oxidation if this process is 
disrupted; but also have a faster response to stress that is also greater in magnitude; 
and 2) greater activity would produce greater amounts of ROS; thus, the greater 
complement of slow oxidative fibre types in a given muscle and increased muscle 
activity places the muscle at greater risk of protein oxidation. 
  
Soleus and EDL control values for protein carbonyl and free thiol content are 
comparatively more in concert with what would be expected from slow oxidative 
and fast glycolytic fibre type muscles than the diaphragm and sternohyoid muscles 
comparatively (i.e. more protein carbonyl content and less free thiol content in the 
slow oxidative muscles compared to fast glycolytic muscles). The respiratory 
muscles, in particular the diaphragm, are clearly unique in this regard. The soleus has 
a greater density of protein free thiol groups in control samples in comparison to the 
EDL and both respiratory muscles which may also be reflective of its fibre type 
distribution. 
 
Curiously, after three weeks of CH, the increase in diaphragm protein free thiol 
content is substantially greater than in the other muscles studied. This may confer a 
greater degree of protein thiol protection and/or be indicative of greater protein 
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turnover in the diaphragm in and around this time point. If endurance capacity is 
correlated with protein free thiol content and ROS production is the principle reason 
behind diminishing muscle performance ex vivo, this change may give the diaphragm 
an advantage over other muscles in terms of muscle endurance at this time point (or 
equivalent in other rodents), in hypoxia, while the muscle is being studied ex-vivo.  
 
An interesting side-note: oxidative stress does not appear to affect protein structure 
and function in the naked-mole rat who lives underground in hypoxic conditions 
[223]. 
 
3.3.2 Redox Proteomics 
Our aim for this study was to identify what proteins are subject to change by using a 
redox proteomics approach. We hypothesized that proteins key to muscle function 
will be redox modified in the respiratory muscles after six weeks of CH. Given that 
muscle metabolism, homeostasis and function are inextricably linked, and that 
specific oxidation of several of the proteins we have identified have been shown by 
other groups to have their catalytic activity or functional capability modified by 
oxidation (e.g. actin; discussed below); the results of this study support our 
hypothesis.  
 
Curiously, although we observe extensive global changes to protein carbonyl and 
free thiol content in both respiratory muscles, there is an apparent specificity given 
the somewhat similar changes observed in the respective muscles despite their 
intrinsic molecular differences. This draws attention to a potential role of redox 
signalling in respiratory muscles in animals exposed to CH. Indeed, global 
phosphatase activity in muscle is reported as altered with redox modulation [224]. 
However, whilst many of the proteome changes are similar between diaphragm 
(table 3.1) and sternohyoid (table 3.2) e.g. it is clear that metabolic proteins are 
extensively modified in both, it is also evidently clear that there is a unique redox 
fingerprint for both muscles after six weeks of CH, potentially a result of proteome 
composition i.e. the sternohyoid consists of a greater relative abundance of 
glycolysis enzymes to TCA cycle enzymes in comparison to the diaphragm. 
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2-oxo-glutarate dehydrogenase, actin, and the electron transport chain (ETC) 
proteins (when taken together) present with greatest remodelling in the diaphragm 
and 2-oxo-glutarate dehydrogenase, glycogen phosphorylase, and carbonic 
anhydrase III (CAIII) present with greatest remodelling in the sternohyoid. Redox-
remodelling of 2-oxo-glutarate dehydrogenase, a TCA cycle enzyme, is likely to 
limit ROS production by both its own oxidoreductase activity and by mitochondria 
[139]. CAIII rehydrates CO2; a potential role for this enzyme in lactate shuttling 
through monocarboxylate transporters and other transporters has also been suggested 
[225]. Interestingly, redox remodelling of this protein is also observed in respiratory 
muscle of COPD patients [153] and CAIII has been shown to be significantly up-
regulated after exercise in humans, but only in hypoxia [226]. Furthermore, CAIII 
has been shown to have important anti-apoptotic effects in oxidatively stressed cells 
[227] and may confer protection for the upper-airway dilator muscle in hypoxia as 
both an antioxidant and pH regulator. Glycogen phosphorylase regulates glycogen 
breakdown, and is increased more than 4-fold after CH exposure in the sternohyoid. 
Of interest, no change is observed for this enzyme in human vastus lateralis with 
ascent to high altitude [228], potentially indicative of selective importance to the 
sternohyoid. The large up-regulation would be expected to increase carbohydrate 
substrate availability for energy production, required to maintain the increased 
continuous rhythmic function in the sternohyoid during CH-induced hyperactivity. 
Furthermore, the ATP-producing capacity of the “second” part of the glycolytic 
pathway may be enhanced through the increased expression of phosphoglycerate 
kinase, phosphoglycerate mutase and the pyruvate kinase isozymes. This enhanced 
step 2 of glycolysis, alongside increased glycogen phosphorylase content is 
potentially fundamental to the maintenance of enhanced sternohyoid contractile 
activity in hypoxia. In comparison, the enduring phenotype of the diaphragm is 
perhaps best suited to increased expression and reduction/turnover of ETC proteins. 
Despite reduced mitochondria content, an improved working capacity of individual 
mitochondria in the murine diaphragm after CH exposure has been suggested to be 
due to decreased UCP3 expression [67] and increased expression of complexes IV 
and V. In line with this finding, we observe increases in cytochrome bc-1 complex 
subunit 1 and ATP Synthase subunit β as well as increased free thiol content in ATP 
Synthase subunit α and a subunit of the electron transfer flavoprotein in the CH 
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diaphragm. The increased free thiol content is potentially due to increased turnover 
of protein or folding changes as there is also an increase in 60kDa heat shock protein 
(HSP) content.  
 
Redox modifications at the level of the cross-bridge can directly facilitate functional 
modifications between muscle fibres of the same type [160,186,229–234]. Figure 
3.12 (unpublished pilot study data from Persson, M., 2013; shown here with 
permission) illustrates how actin oxidation can affect cross-bridge sliding velocity 
in-vitro. This is potentially very important given the lack of fibre type change in 
respiratory muscles in animal models of CH [22,65,67]. When there is an increase in 
the oxidising environment in muscle, it is likely that the cross-bridge will be affected 
as a result of the abundance and size of these proteins [187,204,235–237]. Oxidative 
damage to sarcomeric proteins is observed after mitochondrial dysfunction in the 
heart [237]. However, it is difficult to observe actomyosin and auxiliary protein 
signals during proteomic investigations [238]. Despite this difficulty, we observe 
oxidation of actin-α alongside an expression increase in the diaphragm muscle, and 
also oxidation of α-crystallin B chain and CK m-type in both diaphragm and 
sternohyoid muscles. Actin is a critical component for cross-bridge formation and 
muscle contraction, CK m-type supplies ATP for mATPase activity and α-crystallin 
B chain is a sarcomere localised chaperone protein [239]. Actin oxidation is also 
observed in several disease settings including COPD, Alzheimer’s disease and 
cardiac ischemia [153–155]. 
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Figure 3.12 In-vitro motility assay for control and oxidised (H2O2) treated F-
actin (unpublished pilot study data from Persson, M., 2013 and shown here with 
permission). (A) Sliding velocity data of actin over myosin. The number of filament 
paths for velocity measurements in each run is 2-6. (B) Fraction of motile filaments 
in the assay. The images on the bottom are micrographs of untreated and H2O2 
treated F-actin (left and right respectively). The sliding velocities for the oxidized F-
actin were reduced compared to the untreated F-actin (7.750 ± 0.2902 vs. 4.347 ± 
0.9561; untreated vs. oxidised; mean ± SEM; n=3 per group (n is the number of 
different flow cells used i.e. different salinization batches)). Furthermore, the 
fraction of motile filaments was also reduced. Both untreated and H2O2-treated actin 
filaments had remained in their filamentous form and phalloidin labelling was not 
affected by the oxidation. In one control experiment, normal untreated F-actin 
labelled with Alexa-488-phalloidin was incubated in the same flow cell as 
Rhodamine-phalloidin labelled H2O2-treated F-actin. The normal F-actin exhibit 
good motility while the oxidized F-actin (H2O2-treated) did not. The sliding velocity 
and fraction motile filaments from the control experiments are included. This shows 
that the myosin heads are not affected by any possible difference in actin solutions 
e.g., H2O2 residuals. The actin filament lengths influence on the sliding velocity is 
not taken into consideration in the data presented here.  
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There is extensive redox remodelling of metabolic proteins in both muscles. The 
localisation of these proteins coupled with remodelling of the mitochondrial 
respiratory chain and stress responsive proteins leads us to believe the mitochondria 
are the source of the remodelling stress. Diminishing electron transfer between 
respiratory chain complexes assists the upstream modules becoming predisposed to 
autoxidation. This is supported with the findings of mitochondrial remodelling and 
‘mitophagy’ in CH-murine diaphragm [67,80], in limb muscles of humans at high 
altitude [97], in COPD patient diaphragm muscle [165] and in COPD and 
hypoxaemic patient limb muscles [240,241]. 
 
CK, and aconitase are metabolic proteins susceptible to oxidation and this is 
observed in the present study. Oxidation of these enzymes correlates with negative 
regulation of their activities [153,204] and CK is oxidised in the diaphragm of 
COPD patients [153]. Aconitase is often measured as a marker of oxidative stress. 
CK deficiency is associated with deficiencies in burst activity of muscle [242] and 
this may have particular relevance to the sternohyoid from a functional perspective 
as this activity is required to reopen the airway when occlusions occur during sleep. 
There is less mitochondrial CK content and an increase in cytoplasmic CK oxidation 
in the six week CH diaphragm as well as less cytoplasmic CK content with increased 
oxidation in the sternohyoid. This, along with the observed oxidation of adenylate 
kinase in the diaphragm, will impact upon cytosolic adenosine monophosphate 
(AMP):ADP:ATP levels in these muscles, which will in turn affect AMP Kinase (K) 
activity – an important determinant of many cellular processes including the balance 
between energy production and utilisation. Indeed, hypoxia has previously been 
shown to regulate AMPK in a ROS dependent manner [243]. Further muscle specific 
regulation of metabolic enzymes includes aldolase and β-enolase which are 
significantly and differentially modified in diaphragm and sternohyoid muscles after 
six weeks of CH.  
 
Carbonylation of α-crystallin B chain, a cross-bridge chaperone described as 
essential to myofilament maintenance [244], is observed in both muscles. Forms of 
CRYAB gene-linked myopathy can be suppressed by altering availability of 
reducing equivalents such as NADPH, supporting a role for ROS regulation [245]. 
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Furthermore, α-crystallin B chain is described as having antioxidant-like properties 
[246]. Of note, strength training increases its expression [247]. Just as the 
maintenance of proper folding of cross-bridge proteins in working muscle is 
fundamental to function, α-crystallin B chain may be an important player 
downstream of ROS in the differential functional adaptations observed in respiratory 
and limb muscles [22,26,27,67,79]. 
 
Myoglobin is an oxygen binding protein with a ferrous core that is expressed in 
skeletal muscle and presents with decreased carbonyl content and expression in 
diaphragm and sternohyoid respectively which may be important in reducing the 
formation of the extremely reactive hydroxyl radical by decreasing Fenton reactions. 
Decreased myoglobin expression has been previously observed in skeletal muscle in 
response to hypoxia [122].  
 
In addition to α-crystallin B chain, several stress response proteins involved in 
homeostasis maintenance and oxidant buffering present with redox/expression 
modifications including HSPs, serotransferrin, albumin, and aldehyde 
dehydrogenase. HSPs are correlated with skeletal muscle fibre type [248] and are 
involved in maintaining mitochondrial integrity [249], so their respective modulation 
may have a role in differential functional outcomes in respiratory and limb muscles. 
Small HSPs have been shown to modulate ROS, raise GSH levels, prevent apoptosis 
signalling derived from stressed mitochondria, and activate the proteasome 
[150,250,251] while it is also plausible that oxidative modification and/or expression 
changes of protein chaperones facilitates atrophy instead of re-folding [252]. 
Alterations to HSPs are likely to affect atrophy and thus function following CH. 
 
GAPDH is carbonylated after six weeks of CH in the diaphragm muscle with no 
detectable change in its expression. While expression is decreased in the sternohyoid 
after CH, reductive redox remodelling is observed similar to glycogen phosphorylase 
which suggests lesser oxidation, protection, or both increased translation and ROS 
induced degradation occurring simultaneously albeit at different rates, – potentially 
as a result of HIF and ROS. GAPDH is a key metabolic switch protein. With 
oxidation, GAPDH relocates to the nucleus [253] and metabolic substrate flux is 
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directed toward the pentose phosphate pathway to increase reducing power of the 
cell by NAD(P)H formation [212,254,255]. 
 
Redox remodelling of fatty acid binding protein (FABP) and glycerol-3-phosphate 
dehydrogenase [NAD
+
] cytoplasmic along with the increased catalase activity are 
suggestive of a redox effect on fatty-acid utilisation – a change which is known to 
occur in cardiac tissue after CH [256]. In control conditions there is differential 
expression of lipid and carbohydrate metabolism genes within the respiratory 
muscles with the diaphragm favouring lipid metabolism in comparison to the 
sternohyoid [257]. 
 
Differential remodelling of Ca
2+
 buffering proteins and Ca
2+
 activated chaperones in 
the SR may be involved in affecting Ca
2+
 signalling in muscle. Muscle bundle twitch 
contractile kinetics are unaltered by CH [22] as are single fibre shortening velocities 
[70] so release and re-uptake are unlikely affected. Hypoxia has been observed to 
alter Ca
2+ 
signalling in certain circumstances [70,122,184,243,258–260], and 
oxidised calreticulin and decreased expression of calsequestrin in diaphragm and 
sternohyoid muscles respectively may have a role in this [261,262]. 
 
3.3.3 Antioxidants 
We measured a significant increase in catalase activity in the diaphragm that 
remained elevated after three and six weeks of exposure – evidence of an early 
antioxidant response (correlating with increased protein free thiols). There is also an 
increase in the total GSH content after six weeks of CH in both respiratory muscles, 
reaching statistical significance in the sternohyoid and approaching it in the 
diaphragm. Conflicting with these findings, it has been reported that hypoxia 
exposure decreases mitochondrial ROS scavenging proteins [97]. While 
carbonylation is indicative of structural damage, increased tGSH may contribute to 
decreased free thiol content in the respiratory muscles after six weeks of CH through 
formation of disulphide bridges with proteins (RS-SG) providing protection from 
ROS. With the data from the proteomic study highlighting extensive remodelling to 
mitochondrial and metabolic proteins and the increase in antioxidant capacity 
81 | P a g e  
 
reported here, we hypothesize that ROS from mitochondria are causing these redox 
changes and oxidative stress is not the result of a decrease in antioxidant status.  
  
3.3.4 Conclusion 
In conclusion, our findings show that CH induces differential redox remodelling of 
the murine respiratory and limb muscle proteome; proteins key to muscle function 
are affected in the diaphragm and sternohyoid, and antioxidant status is not 
compromised. Many protein carbonyl changes we observe are similar to those 
observed in human COPD diaphragm and LPS injected rat diaphragm tissue 
[72,204]. Mitochondria are the candidate source of stress following CH. 
Antioxidants may be useful as an adjunct therapeutic option in diseases where CH is 
featured, however selectivity is required as to the type of antioxidant and its target 
given the potential role for redox signalling in these muscles [224]. This study also 
highlights the potential of the redox proteomics approach [263] to be extended to 
other models of disease featuring oxidative/reductive stress.  
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Chapter 4: Metabolic adaptation in 
the diaphragm following chronic 
sustained hypoxia 
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4.1 Chapter Introduction 
 
Mammals cannot survive prolonged periods of very severe hypoxia due to loss of ion 
homeostasis in the vital organs unless they have undergone graded acclimatisation 
[4,264,265]. Less oxygen results in perturbed cellular respiration, decreased ATP 
levels, slowdown of the Na
+
/K
+
 pump, and ion imbalance. Cellular pH drops with 
lactic acid production, the cell swells and membranes become leaky. Maintaining ion 
homeostasis requires the use of energy dependent ion pumps and so metabolic 
regulation in hypoxic vital organs is imperative. 
 
Skeletal muscle is considered amongst the most hypoxia-tolerant tissues [265] which 
is fascinating considering that skeletal muscle has high basal levels of mATPase 
activity as well as ATP-dependent ion pump activity [266]. These high ATPase 
activities accompanied with hypoxia should place tighter regulation on both ATP 
production and utilisation in this organ. Regulation of metabolism is arguably even 
more important in the diaphragm muscle during CH as the muscle is vital and more 
active. Increased ventilatory activity of the muscle will increase energy expenditure 
and demand through increased mATPase activity and increased H
+
 accumulation in 
the cytoplasm with subsequent requirement for removal. An increase in Na
+
/K
+
 
ATPase pump content has been observed in rat diaphragm exposed to six weeks of 
CH [22]. 
 
O2 is the ultimate electron acceptor in oxidative phosphorylation and required for 
ATP synthesis by this method, but hypoxia and HIF-1α signalling is typically 
associated with a shift toward glycolytic/anaerobic metabolism [95,267,268]. 
However, predominant glycolytic metabolism is unlikely to be able to support 
continuous diaphragm activity. The hypoxic ventilatory response may be viewed as a 
training effect and this should increase oxidative metabolism under normal 
circumstances [269]. Given the functional phenotype of the diaphragm following 
CH, metabolic adaptations are likely to occur to sustain/maintain functional integrity. 
 
Only a single study to date concerning metabolic enzyme activities in the diaphragm 
muscle of animal models of CH has been conducted [22] and no change was 
84 | P a g e  
 
observed. The study in question performed histochemistry on sections of rat 
respiratory muscle tissue followed by analysis of captured images to assess SDH 
activity. However, it has been reported that enzyme changes may be fibre/region 
specific within a muscle [87] and this is something we sought to explore further. 
[22]. Using the same tissue section images from [22], we measured SDH activity in 
individual fibres, plotted the results as a function of fibre cross sectional area and 
separated them into the most spatially distinct clusters using K-means cluster 
analysis in order to identify shifts in cluster fibre proportions or cluster centroids. We 
hypothesized that there would be an increase in the proportion of fibres in the higher 
SDH activity clusters because an increase in diaphragm activity and improved 
endurance is associated with increased oxidative capacity. 
  
It would be remiss to assume that the behaviour of a single protein is representative 
of an organelle, process, or pathway as a whole, especially when there is more than 
one stimulus and these stimuli being known to act upon different proteins (hypoxia 
vs. increased activity vs. redox stress) [270]. We have described redox remodelling 
of respiratory muscle metabolic enzymes in CH in Chapter 3, similar to COPD 
where redox modified metabolic enzyme activity changes occur [153]. The potential 
exists for significant physiological changes to metabolic enzyme activities in 
hypoxia through this mechanism [204] e.g. aconitase enzyme activity is correlated 
with oxidative stress [102,271,272]. In times of oxidative stress, it is also known that 
metabolic flux re-routing occurs to increase substrate availability for the pentose 
phosphate pathway to increase reducing equivalents for antioxidant usage [254]. We 
have also shown increased catalase activity in the diaphragm muscle after one, three 
and six weeks of CH (Chapter 3) and catalase is a necessary enzyme to decompose 
H2O2 that is produced in peroxisomes by β-oxidation, along with redox remodelling 
of proteins involved in lipid metabolism – FABP and G3PD. Indeed, β-oxidation 
would provide an alternate route of NADH and FADH to the respiratory chain 
complexes whilst facilitating NADPH production for antioxidant activity [273]. The 
second aim of this chapter was to measure metabolic activities of enzymes observed 
to undergo redox remodelling (chapter 3), as well as enzymes located at 
carbohydrate derivative flux gating points in respiratory and limb muscles after CH 
exposure (Fig. 4.1). We hypothesized that enzyme activity changes would be 
85 | P a g e  
 
indicative of favouring substrate flux into the pentose phosphate pathway, with 
decreased activity of glycolytic enzymes, as well as both decreased aconitase 
enzyme and CK enzyme activities for the diaphragm. Furthermore, we speculated 
that differential remodelling of metabolic enzymes would be observed in respiratory 
and limb muscles. 
 
In addition, we assessed HIF-1α content in the diaphragm and sternohyoid muscle 
after six weeks of CH ± chronic antioxidant supplementation. HIF-1α is a subunit of 
the HIF transcription factor complex that is constitutively expressed and degraded in 
normoxic conditions but degradation is prevented under hypoxic conditions. It 
promotes transcription of the cellular defensive response to hypoxia by forming a 
complex with the HIF-β subunit and consequent up-regulation of erythropoietin and 
haematocrit, glycolytic enzymes which produce ATP anaerobically etc. 
[95,267,274]. We know HIF-1α is basally and differentially expressed in skeletal 
muscle [7,13] and is involved in fast fibre type gene expression whereas the 
competing HIF-2α subunit is implicated in driving the slow fibre phenotype 
[14,15,144]. As discussed in chapter 1 and chapter 3, we consider the mitochondria 
as the primary site of both sensing hypoxia in the diaphragm and responding in the 
form of ROS production and altered redox remodelling. There is evidence to suggest 
that the transcription factor HIF-1α can be also modulated by ROS [148,164,275–
277] with some evidence implicating oxygen sensing at the mitochondria followed 
by ROS production and a role for the energy and stress sensors AMPK and MAPK 
proteins. One week of high altitude exposure has no effect on HIF-1α levels in 
human vastus lateralis [97] while two weeks of CH increased HIF-1α in rat 
gastrocnemius [278]. Training in hypoxia also induces HIF-1α mRNA transcription 
[279]. Potentially longer durations of hypoxia with/without the requirement of redox 
signalling are required for HIF-1α activation in diaphragm muscle. We know HIF-1α 
is activated to increase red blood production which occurs in our model. Thus, HIF 
may play a role in diaphragm adaptation to hypoxia and redox change and should 
duly be quantified. 
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Figure 4.1: Overview of metabolism pathways in skeletal muscle. Enzymes 
whose activity is measured in this thesis are highlighted with a green background. 
G6PD = glucose-6-phosphate dehydrogenase; GAPDH = glyceraldehdy-3-phosphate 
dehydrogenase; G3PD = glycerol-3-phosphate dehydrogenase; LDH = lactate 
dehydrogenase; SDH = succinate dehydrogenase; CK = creatine kinase 
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4.2 Chapter Results 
 
4.2.1 Section A: SDH activity at the fibre level  
The difference in SDH activity and the mitochondrial population (and ultimately 
fibre type composition) between the diaphragm and sternohyoid muscles is evident 
from the muscle section stained images for SDH activity in Fig. 4.2. Different 
structural and metabolic profiles may partly explain differential adaptations in these 
muscles. These differences can also be seen in Fig. 4.3 and Fig. 4.4 with the 
proportions of fibres at particular cross-sectional areas SDH activities distinctly 
different in diaphragm and sternohyoid muscles. The SDH activity correlation with 
fibre size can also be seen in Fig. 4.3 and Fig. 4.4. 
 
K-means cluster analysis is an unbiased way of separating the fibres in the most 
spatially distinct fibre clusters according to both SDH and fibre cross sectional area. 
Log scales are used to prevent skew in the large data sets. 
 
These data reveal no statistically significant differences in respective cluster 
centroids or the proportion of fibres associated with each cluster (Fig. 4.4) when 
normoxic and CH diaphragm and sternohyoid muscles were compared (29.8 ± 3.16 
vs. 29.5 ± 2.82, 34.83 ± 1.3 vs. 37.17 ± 3.0, 38.67 ± 3.22 vs. 33.5 ± 2.72 mean ± 
SEM percentage proportion of fibres in diaphragm clusters one, two, and three 
respectively; control vs. hypoxia; n=6 per group; Student’s two-tailed unpaired t test) 
(28.0 ± 3.66 vs. 28.0 ± 1.92, 29.8 ± 2.29 vs. 24.2 ± 1.56, 42.2 ± 4.99 vs. 48.0 ± 3.2 
mean ± SEM percentage proportion of fibres in sternohyoid clusters one, two, and 
three respectively; control vs. hypoxia; n=5 per group). In sternohyoid cluster 2, 
there is a decrease in the percentage proportion of fibres toward cluster 3 but this 
does not reach statistical significance (p=0.07). 
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SDH Histochemistry 
Diaphragm 
 
Sternohyoid 
 
Figure 4.2: 10μm transverse section of rat diaphragm (top) and sternohyoid 
(bottom) muscle stained for SDH activity. Oxidative fibre types are intensely 
stained compared to the pale glycolytic fibres. Scale represents = 200µm  
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Area Density Plots 
Diaphragm 
 
Sternohyoid 
 
Figure 4.3: Representative area-density plots for diaphragm (top) and 
sternohyoid (bottom). Using these data, K-means cluster analysis centroids for 
three clusters were determined for each plot with relative proportion of fibres in each 
defined cluster (see Fig. 4.4 below). 
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Cluster Centroids 
Diaphragm 
 
Sternohyoid 
 
 
Figure 4.4: Scatterplots of cluster centroids for diaphragm (top) and 
sternohyoid (bottom) in CH-treated (blue) and normoxic (red) rats. There was 
no significant difference in respective cluster centroids or the proportion of fibres 
associated with each cluster when normoxic and CH muscles were compared. 
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4.2.2 Section B: Metabolic enzyme activities and HIF-1 
Aconitase is the 2
nd
 enzyme of the TCA cycle and known to have its catalytic 
activity decreased in times of oxidative stress owing to its catalytic site iron-sulphur 
cluster. As shown in Fig. 4.5A, activity is significantly decreased after three and six 
weeks of CH while no change is observed after one week (0.397 ± 0.05 vs. 0.34 ± 
0.02, 0.43 ± 0.04 vs. 0.147 ± 0.02**, 0.455 ± 0.009 vs. 0.243± 0.042* mean ± SEM 
Units/mg protein; control vs. CH; diaphragm aconitase activity after one, three, and 
six weeks of CH respectively; n= 4-6 per group; *p<0.05, **p<0.01). 
 
CK, a mitochondrial and cytoplasmic enzyme that facilitates having a readily 
available but short-term supply of ATP when required, has an apparent bi-phasic 
response in hypoxia. CK activity is increased after one week of CH compared to 
control (p=0.059), but has significantly decreased activity after three and six weeks 
of CH (2.58 ± 0.14 vs. 3.42 ± 0.35#, 2.5 ± 0.37 vs. 1.31 ± 0.08*, 3.12 ± 0.28 vs. 1.89 
± 0.29* mean ± SEM Units/mg protein; control vs. CH; diaphragm CK activity after 
one, three, and six weeks of CH respectively; n= 4-6 per group; 
#
p=0.059 *p<0.05), 
as is illustrated in Fig. 4.5B. 
 
Aldolase is the 3
rd
 enzyme of the glycolysis pathway. Fig. 4.6A shows significantly 
decreased activity in the diaphragm after one and three weeks of CH and decreased 
activity (p=0.08) after six weeks of CH (0.104 ± 0.01vs. 0.07 ± 0.005*, 0.15 ± 0.01 
vs. 0.062 ± 0.003***, 0.13 ± 0.01 vs. 0.09 ± 0.01 mean ± SEM Units/mg protein; 
control vs. CH; diaphragm aldolase activity after one, three and six weeks of CH 
respectively; n=5-7 per group; *p<0.05, ***p<0.001).  
 
G3PD is an important link between carbohydrate and lipid metabolism directing 
substrate for lipid metabolism, gluconeogenesis or the mitochondrial glycerol-
phosphate shuttle. Interestingly, despite being oxidatively modified (Chapter 3), 
G3PD activity is significantly increased after one, three, and six weeks of CH as 
illustrated in Fig. 4.6B (0.57 ± 0.02 vs.1.09 ± 0.11***, 0.71 ± 0.07 vs. 1.24 ± 0.17*, 
0.48 ± 0.05 vs. 1.04 ± 0.15** mean ± SEM Units/mg protein; control vs. CH; 
diaphragm G3PD after one, three and six weeks of CH respectively; n=7-8 per 
group; *p<0.05, **p<0.01, ***p<0.001).  
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Figure 4.5: Diaphragm aconitase and creatine kinase activity after one, three, 
and six weeks of sustained hypoxia compared to normoxic controls. (A) 
Diaphragm aconitase activity (mean ± SEM) after one, three, and six weeks of 
sustained hypoxia expressed as Units/mg protein; n= 4-6 per group; (B) Diaphragm 
creatine kinase activity (mean ± SEM) after one, three, and six weeks of sustained 
hypoxia expressed as Units/mg protein; n= 4-6 per group; *p<0.05, **p<0.01, ns = 
not significant, Student’s t test and Mann-Whitney test as appropriate; Ctrl = 
normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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Figure 4.6: Diaphragm aldolase and G3PD activity after one, three, and six 
weeks of sustained hypoxia compared to normoxic controls. (A) Diaphragm 
aldolase activity (mean ± SEM) after one, three, and six weeks of sustained hypoxia 
expressed as Units/mg protein; n= 5-7 per group; (B) Diaphragm G3PD activity 
(mean ± SEM) after one, three, and six weeks of sustained hypoxia expressed as 
Units/mg protein; n= 7-8 per group; *p<0.05, **p<0.01, ***p<0.001; Student’s t 
test; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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G6PD is a metabolic enzyme that shuttles glucose-6-phosphate into the pentose 
phosphate pathway for NADPH production. G6PD activity, as shown in Fig. 4.7A 
and contrary to our hypothesis, is unchanged after one week of CH and significantly 
decreased after three and six weeks of CH (3.27 ± 0.35 vs. 2.88 ± 0.24, 3.01 ± 
0.39 vs. 1.54 ± 0.25**, 3.57 ± 0.60 vs. 1.15 ± 0.1274** mean ± SEM Units/mg 
protein; control vs. CH; diaphragm G6PD activity after one, three and six weeks of 
CH respectively; n=7-8 per group; **p<0.01). 
 
LDH, which converts pyruvate to lactate in anaerobic respiration, follows a similar 
pattern to G6PD of unchanged activity after one week of CH and significantly 
decreased activity after three and six weeks of CH as illustrated in Fig. 4.7B (0.63 ± 
0.034 vs. 0.586 ± 0.055, 0.73 ± 0.27 vs. 0.349.± 0.061, 0.756 ± 0.099 vs. 0.38 ± 
0.088* mean ± SEM Units/mg protein; control vs. CH; diaphragm LDH activity after 
one, three and six weeks of CH respectively; n=6-7 per group; *p<0.05). 
 
GAPDH is a key enzyme of the glycolytic pathway that we observe as oxidised in 
the diaphragm after six weeks of CH. As can be seen in Fig. 4.8A, GAPDH activity 
is increased (p=0.08) after one week of CH but is significantly decreased after three 
weeks of CH (0.013 ± 0.002 vs. 0.020 ± 0.002, 0.015 ± 0.0012 vs. 0.010 ± 0.0016* 
mean ± SEM Units/mg protein; control vs. CH; diaphragm GAPDH activity after 
one and three weeks of CH respectively; n=5-7 per group; *p<0.01). Note: Due to 
muscle tissue sample volume limitations, GAPDH activity at the six week time point 
could not be measured. 
 
Biphasic changes in GAPDH activity in the sternohyoid muscle after one and three 
weeks of CH are featured in Fig. 4.8B. GAPDH activity is significantly increased 
after one week of CH but significantly decreased after three weeks of CH (0.02 ± 
0.001 vs. 0.029 ± 0.003*, 0.026 ± 0.001 vs. 0.018 ± 0.001** mean ± Units/mg 
protein; SEM; control vs. CH; sternohyoid GAPDH activity after one and three 
weeks of CH respectively; n=6-7 per group; *p<0.05, **p<0.01). Note: Due to 
muscle tissue sample volume limitations, GAPDH activity at the six week time point 
could not be measured. 
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Figure 4.7: Diaphragm G6PD activity and LDH activity after one, three, and six 
weeks of sustained hypoxia compared to normoxic controls. (A) Diaphragm 
G6PD activity (mean ± SEM) after one, three, and six weeks of sustained hypoxia 
expressed as Units/mg protein; n= 7-8 per group; (B) Diaphragm LDH (mean ± 
SEM) after one, three, and six weeks of sustained hypoxia expressed as Units/mg 
protein; n= 6-7 per group; **p<0.01, ns = not significant, Student’s t test. Ctrl = 
normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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Figure 4.8: Diaphragm and sternohyoid GAPDH activity after one and three 
weeks of sustained hypoxia compared to normoxic controls. (A) Diaphragm 
GAPDH activity (mean ± SEM) after one and three of sustained hypoxia expressed 
as Units/mg protein; n= 5-7 per group; (B) Sternohyoid GAPDH activity (mean ± 
SEM) after one and three weeks of sustained hypoxia expressed as Units/mg protein; 
n= 6-7 per group; *p<0.05, **p<0.01; Student’s t test and Mann-Whitney test as 
appropriate; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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GAPDH activity in EDL (Fig. 4.9A) is increased after one and three weeks of CH 
compared to controls (0.02 ± 0.001 vs. 0.028 ± 0.001**, 0.018 ± 0.001 vs. 0.025 ± 
0.002* mean ± SEM Units/mg protein; control vs. CH; EDL GAPDH activity after 
one and three weeks of CH respectively; n=6-8 per group; *p<0.05, **p<0.01). 
Note: Due to muscle tissue sample volume limitations, GAPDH activity at the six 
week time point could not be measured. 
 
Similar to EDL muscle, there are significant increases in GAPDH activity in the 
soleus (Fig. 4.9B) after one and three weeks of CH (0.015 ± 0.002 vs. 0.021 ± 
0.001*, 0.013 ± 0.002 vs. 0.025 ± 0.005* mean ± SEM Units/mg protein; control vs. 
CH; soleus GAPDH activity after one and three weeks of CH respectively; n=7-8 per 
group; *p<0.05, **p<0.01). Note: Due to muscle tissue sample volume limitations, 
GAPDH activity at the six week time point could not be measured. 
 
LDH activity in the sternohyoid (Fig. 4.10A) is significantly increased after one 
week of CH while there is no change observed after three weeks of CH compared to 
controls (0.598 ± 0.125 vs. 0.938 ± 0.099*, 0.644 ± 0.111 vs. 0.438 ± 0.041 
Units/mg protein; mean ± SEM; control vs. CH; sternohyoid LDH activity after one 
and three weeks of CH respectively; n=5-8 per group; *p<0.05). Note: Due to 
muscle tissue sample volume limitations, LDH activity at the six week time point 
could not be measured. 
 
There is no change LDH activity in the EDL (Fig. 4.10B) after one or three weeks of 
CH (0.714 ± 0.033 vs. 0.683 ± 0.034, 0.865 ± 0.151 vs. 0.712 ± 0.177 mean ± SEM 
Units/mg protein; control vs. CH; EDL LDH activity after one and three weeks of 
CH respectively; n=6-7 per group). Note: Due to muscle tissue sample volume 
limitations, LDH activity at the six week time point could not be measured. 
 
Similarly, there is no change in soleus LDH activity after one week of CH compared 
to control (0.281 ± 0.027 vs.0. 299 ± 0.026 mean ± SEM Units/mg protein; control 
vs. CH; soleus LDH activity after one week of CH; n=7 per group). Note: Due to 
muscle tissue sample volume limitations, LDH activity at the three and six week 
time points could not be measured.  
98 | P a g e  
 
 
 
 
Figure 4.9: EDL and soleus GAPDH activity after one and three weeks of 
sustained hypoxia compared to normoxic controls. (A) EDL GAPDH activity 
(mean ± SEM) after one and three weeks of sustained hypoxia expressed as 
Units/mg protein; n= 6-8 per group; (B) Soleus GAPDH activity (mean ± SEM) after 
one and three of sustained hypoxia expressed as Units/mg protein; n= 7-8 per group; 
*p<0.05, **p<0.01; Student’s t test; Ctrl = normoxic control; Hypoxia = sustained 
hypoxia (FiO2 = 0.1). 
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Figure 4.10: Sternohyoid, EDL and soleus LDH activity after one and three 
weeks of sustained hypoxia compared to normoxic controls. (A) Sternohyoid 
LDH activity (mean ± SEM) after one and three weeks of sustained hypoxia 
expressed as Units/mg protein; n= 5-8 per group; (B) EDL LDH activity (mean ± 
SEM) after one and three of sustained hypoxia expressed as Units/mg protein; n= 6-7 
per group; (C) Soleus LDH activity (mean ± SEM) after one week of sustained 
hypoxia expressed as Units/mg protein; n= 7 per group; *p<0.05, ns = not 
significant; Student’s t test; Ctrl = normoxic control; Hypoxia = sustained hypoxia 
(FiO2 = 0.1). 
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As illustrated in Fig. 4.11A, six weeks of CH significantly increased HIF-1α content 
in diaphragm muscle compared to control and this was attenuated by chronic 
antioxidant supplementation with either tempol or NAC (1.714 ± 0.58 vs. 2.635 ± 
0.136*** vs. 1.557 ± 0.09
###
 vs. 1.926 ± 0.112
###
 mean ± SEM normalised relative 
luminescence units; control vs. hypoxia vs. tempol vs. NAC; diaphragm HIF-1α 
content after six weeks of CH; n=5-8 per group; One-way ANOVA: p<0.001; 
***p<0.001 vs. control, ###p<0.001 vs. hypoxia, Tukey’s multiple comparison test). 
 
In contrast to diaphragm, no significant changes were observed to HIF-1α content in 
sternohyoid muscle compared to controls (2.07 ± 0.22 vs. 2.279 ± 0.239 vs. 1.946 ± 
0.191 vs. 1.956 ± 0.154 mean ± SEM normalised relative luminescence units; control 
vs. hypoxia vs. tempol vs. NAC; sternohyoid HIF-1α content after six weeks of CH; 
n=5-8 per group). 
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Figure 4.11: Diaphragm and sternohyoid HIF1-α content after six weeks of 
sustained hypoxia ± chronic antioxidant supplementation or normoxia. (A) 
Diaphragm HIF1-α content mean ± SEM Units/mg protein; n= 5-8 per group; (B) 
Sternohyoid HIF1-α content mean ± SEM Units/mg protein; n= 5-7 per group; 
***p<0.001 vs. control, ###p<0.001 vs. hypoxia Tukey’s multiple comparison test; 
Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); RLU = relative 
luminescence units.   
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4.3 Chapter Discussion 
The main findings of this chapter are 1) SDH activity does not change at a fibre level 
in rat diaphragm following CH; 2) redox remodelling in the mouse diaphragm is 
associated with decreased aconitase, aldolase, and CK activities; 3) there may be an 
increased reliance on fatty acid metabolism or the glycerol-phosphate shuttle in the 
CH diaphragm; 4) differential muscle metabolic enzyme activity remodelling is 
observed in respiratory and in limb muscles; and 5) HIF-1α content is significantly 
increased in the diaphragm following six weeks of CH and is attenuated by 
antioxidant supplementation. 
 
4.3.1 SDH activity at the fibre level  
There is a trend towards a significant decrease in proportion of fibres in the 2
nd
 
hypoxic sternohyoid cluster compared to control. The shift is in favour of decreased 
oxidative capacity as there is an increased mean proportion of fibres in the 3
rd
 cluster 
whose centroid coordinates are of lower SDH activity and higher FCSA. 
Hypertrophy is observed in the fast glycolytic fibres of rat sternohyoid following CH 
[22] so this trend potentially follows that while FCSA increases the SDH content and 
thus mitochondrial content does not. No change is observed in the diaphragm despite 
fibre atrophy of the slow oxidative fibre types in this model. This suggests that 
mitochondria are also decreasing proportionally with fibre size. Decreased 
mitochondrial content in the diaphragm has also been observed in mice after four 
weeks of CH [80].  
 
Mitochondria have previously been observed to be more abundant in the diaphragm 
sub-sarcolemma around capillaries following CH. Fig. 4.2 presents with more 
intense staining observed at the cell boundaries. This localisation and crowding of 
mitochondria may interfere with catalytic activity by this method. 
  
It should be noted that there may be differences in mouse and rat diaphragm muscle 
metabolic adaptation to CH as differences in pressure generation for different 
ventilatory activities have been observed [280,281]. 
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4.3.2 Metabolic enzyme activities and HIF-1 
Aldolase – a glycolysis enzyme, aconitase – a TCA cycle enzyme, and CK – a 
phosphagen system enzyme, all present with decreased activities after six weeks of 
CH. The diaphragm is adopting a strategy that reduces carbohydrate derivative flux 
in hypoxia. This is not uncommon in other mammalian hypoxia tolerant tissues as is 
observed in diving, burrowing, hibernating and high altitude mammals [265,282–
287]. Decreasing metabolic activity lends to decreasing ROS production by 
mitochondria. Correlation with cellular homeostasis, functional integrity and 
understanding how to achieve this strategy of decreased carbohydrate derivative flux 
will be important for understanding and managing clinical hypoxia [284]. 
Understanding how the diaphragm muscle can increase work per unit time despite 
decreased utilisation of carbohydrate will be further important to muscle physiology. 
As these enzymes undergo redox remodelling (chapter 3), ROS are potentially 
candidates for this adaptation. 
 
Aconitase is a readily oxidised enzyme with a ferrous catalytic site that facilitates 
oxidation-induced decreased catalytic activity which is observed after three and six 
weeks of CH in the diaphragm. With loss of activity, aconitase has been observed to 
take on a regulatory role in transcription of proteins involved in iron up-take, storage 
and utilisation in the cell nucleus [288] as well as stabilising mitochondrial DNA 
[289]. Aldolase expression is HIF responsive although HIF alone is not enough to 
drive transcription [290]. However, while aldolase activity is decreased after six 
weeks of CH and HIF-1α content is increased, there is a suggestion that activity may 
be increasing again with the six week CH group presenting with higher activities 
compared to the one and three week CH groups. CK is an enzyme that co-localises 
with the cross-bridge. CK deficient mice lack the ability for burst activity in muscle 
and graded deficiencies result in graded burst reductions [242,291]. Burst deficiency 
likely occurs due to an inability to generate a bulk volume of ATP close to the cross-
bridge sufficient for widespread and strong contractions. This is perhaps required by 
the diaphragm muscle to quickly overcome/prevent periods of dyspnoea and may be 
important in chronic respiratory disease. Loads on this muscle are relatively low with 
resting-state breathing. Whilst CK activity is significantly decreased after six weeks 
of CH in the diaphragm muscle, the increased activity of the muscle may keep 
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creatine phosphate stores depleted to such an extent that CK is relatively inactive and 
susceptible to oxidation rather than oxidation targeting this enzyme. Although we do 
not have CK activity measurements for the sternohyoid muscle, given the oxidation 
observed in chapter 3 it is likely that similar activity changes occur. Correlating 
decreased burst activity for this muscle would be of physiological significance given 
that more forceful contractions are required in this muscle to maintain upper airway 
patency. This would also be important in progression of OSA where upper airway 
muscle function is perturbed [292,293]. 
 
G6PD and LDH are metabolic enzymes located at key substrate flux gating points. 
Conflicting with our hypothesis of substrate flux into the pentose phosphate 
pathway, G6PD is significantly decreased after three and six weeks of CH in the 
diaphragm. Perhaps, the physiological significance of this is to reduce O2 
consumption and ROS production at the NADPH oxidase complex although this is 
speculative as NADPH from the pentose phosphate pathway is utilised in antioxidant 
defence mechanisms. Six weeks of CH does not increase NADPH dehydrogenase 
activity in rat diaphragm muscle [22]. Interestingly, G6PD expression can be HIF-
regulated although this is slower than other glycolytic enzymes, depends on redox 
status also and may not be activated in CH [274,294]. LDH expression is also HIF 
regulated [290] however there is no evidence to suggest activity begins to rise again 
after three weeks of CH. HIF alone is not sufficient to drive LDH expression and so 
different transcriptional regulators may be required for aldolase and LDH genes. Just 
as we observe decreased activities of key metabolic pathway enzymes, the substrate 
flux gating point enzymes of G6PD and LDH are also decreased suggesting that 
substrate flux is not diverted elsewhere and metabolic flux itself is decreasing. 
 
However, increased G3PD (another enzyme located at a metabolic junction) activity 
after one, three, and six weeks of CH along with increased catalase activity (Chapter 
3) is suggestive of increased utilisation of fatty acids as metabolic substrate. 
Certainly, the high altitude pika diaphragm muscle relies more on β-oxidation than 
does the diaphragm from the sea-level pika [295]. COPD severity is also correlated 
with β-oxidation enzyme activity [165]. The contribution of increased G3PD activity 
to the glycerol-3-phosphate shuttle is potentially important as mice lacking G3PD 
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are unable to maintain normal ATP levels with exercise [296]. Metabolic substrate 
utilisation by the heart during hypoxia, to maintain ATP synthesis while minimizing 
cellular damage by ROS, is intricately regulated [256,297] and there may be 
complex mechanisms involved to maintain diaphragm functional integrity as the 
diaphragm is also a vital tissue.  
 
A differential muscle response is also observed in terms of metabolic enzyme 
activities. GAPDH activity is increased in the diaphragm muscle after one week of 
CH but decreased after three weeks of CH. This is indicative of an early glycolytic 
shift in the diaphragm but ROS predominates thereafter to decrease activity. The 
initial glycolytic shift may be stronger in fast fibre respiratory muscles as both 
GAPDH and LDH activity increase in the sternohyoid muscle after one week but are 
decreased after three weeks of CH. In contrast, GAPDH activity is significantly 
increased after one and three weeks of CH in both EDL and soleus muscles. 
Furthermore, no decrease in LDH activity was detected. These data indicate that 
limb muscles favour a glycolytic shift with progressive hypoxia compared to the 
hypometabolism in the respiratory muscles. These differences further highlight the 
diaphragm muscle as being unique in terms of adaptation to CH. 
 
It is known that idle enzymes are more readily oxidised and this perhaps is an 
integral part of the cellular ROS buffering capacity so that working enzymes remain 
free of redox modification (also discussed briefly in chapter 3). It may be that many 
of these metabolic enzymes are more prone to oxidation when the animal is placed in 
hypoxic conditions and this may be responsible for the metabolic activity changes 
observed in respiratory muscles.  
 
In control conditions, HIF-1α content is less in diaphragm muscle compared to 
sternohyoid, perhaps reflecting its fibre type composition. Despite this, and unlike 
the lack of change in the sternohyoid, HIF-1α content is increased with six weeks of 
CH. Differential roles for HIF-1α may be important in muscles of different fibre type 
compositions and differential regulation of energy homeostasis [7]. Increased ROS 
are potentially a requirement for increased HIF-1α in the diaphragm given that 
chronic supplementation with tempol or NAC attenuated the increase in HIF-1 
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content in the diaphragm but did not affect HIF-1α content in the sternohyoid 
muscle. A role for ROS in regulation of HIF is also suggested in the literature 
[148,164,275–277]. Furthermore, greater specificity is also required than simply 
ROS alone as protein oxidation is also observed in the sternohyoid muscle. The role 
of increased HIF-1α in the diaphragm after six weeks of CH is difficult to discern 
given that glycolytic enzyme activities are decreased however we have discussed 
that HIF alone is not sufficient to stimulate expression of several of these enzymes. 
Regardless, HIF-1α content is increased and likely to play a role in diaphragm 
adaptation to CH given that it may drive expression of hundreds of potential target 
genes that contain hypoxia-responsive elements [298]. The HIF-1:HIF-2 ratio may 
also be important in hypoxic adaptation in the diaphragm [144]. 
 
4.3.3 Conclusion 
The diaphragm in hypoxia adopts a strategy of decreased carbohydrate derivative 
flux with increased reliance on fatty acid oxidation that is differential to other 
muscles - owing to the data from the high altitude pika, adaptation of the COPD 
diaphragm, the mRNA differences within the respiratory muscles in regard to 
metabolic substrate utilisation [165,257,295], and the data presented here with global 
decreased enzyme activities apart from G3PD and catalase (chapter 3). 
Gluconeogenesis would also be an option given that there is muscle fibre atrophy 
and thus protein catabolism but carbohydrate pathway metabolic enzymes activities 
are decreased. Fatty acid metabolism enzyme activities and reaction products need to 
be measured in respiratory and limb muscles to confirm their role. 
 
The diaphragm is also more active compared to limb muscles and so there is a 
requirement for processes to facilitate both hypometabolism and functional integrity 
– muscle atrophy is discussed in the following chapter. 
 
There is an extensive and interesting comparative physiology literature on 
metabolism in hypoxia-sensitive and hypoxia-tolerant animals, some of which has 
been discussed already. One group proposes a two-phase response of hypoxia 
tolerant systems to an oxygen lack. The first is a defence against hypoxia which 
involves balanced suppression of ATP-demand and ATP-supply pathways to 
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stabilize adenylate levels while ATP turnover rates greatly decline. ATP demands 
must also be down-regulated and translational arrest is one such mechanism. Rescue 
mechanisms then occur if the period of oxygen deprivation is extended by 
preferentially regulating the expression of several proteins, and hypoxia tolerant cells 
use significant gene-based metabolic reprogramming. Hypometabolic steady states 
may be prerequisite for surviving prolonged hypoxia [299]. 
 
Protein phosphorylation has been identified as a reversible mechanism for the 
regulated suppression of metabolism and thermogenesis during mammalian 
hibernation. Phosphatase subfamilies are differentially augmented in the hibernating 
squirrel and these augmentations are organ specific [300]. ROS may also be involved 
in triggering phosphorylation changes [224]. 
 
 
Figure 4.12: Achieving hypoxia tolerance as described by Ramirez et al., (2007). 
Failures to reduce metabolic activity, prevent cellular injury, and/or maintain 
functional integrity is detrimental to hypoxia tolerance (53). 
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Chapter 5: Atrophy in the 
diaphragm after chronic sustained 
hypoxia 
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5.1 Chapter Introduction 
 
Muscle atrophy is a decrease in muscle volume or muscle constituents due to 
decreased cell volume and/or decreased protein component of the cell. It occurs in 
catabolic periods that present in various diseases such as COPD, heart failure, and 
cancer [71,81,83,301–304] to provide amino acids to other organs (muscles contain 
the majority of the body’s protein). It can occur in conditions where the muscles 
themselves become stressed and/or deconditioned e.g. denervation, chronic 
unloading, prolonged bed-rest, hypogravity, mechanical ventilation, starvation, 
hypoxia, oxidative stress [16,22,46,89,90,94,277,305–309]. Increased contractile 
activity stimulates protein turnover [310] preventing ‘wear and tear’ of sarcomere 
proteins. Unfortunately, muscle atrophy lends itself to poor prognosis in 
pathophysiological states [311]. Thus, pathways controlling muscle mass and protein 
turnover are being increasingly researched as potential therapeutic avenues [86]. 
Atrophy of the diaphragm muscle is perhaps more dangerous because it contributes 
to respiratory failure as is observed in COPD, cachexia, muscular dystrophy, and 
other myopathies where diaphragm wasting is observed [48,49,152,312,313].  
 
Skeletal muscle mass is controlled by balancing protein synthesis with degradation. 
Atrophy can therefore present as an inactive process – simply decreased protein 
synthesis. Of course, protein synthesis and degradation signalling are intrinsically 
interlinked and will shortly be discussed. Active atrophy processes in muscle include 
protein degradation by the proteasome complex or by the lysosome. The difference 
between these active processes is that individual proteins and small complexes are 
degraded by the proteasome (microphagy) while whole intracellular organelles such 
as mitochondria may be imported into the lysosome and degraded therein 
(macrophagy), although microphagy can also occur at the lysosome. 
 
Atrophy is either rapid or slow in onset depending on conditions experienced by the 
muscle cell. Slow atrophy of muscle is typically associated with disuse or 
denervation [314] and we might expect slow atrophy in deconditioned limb muscles 
in animal models of CH. However, atrophy occurs rapidly (appreciably measurable 
within a few hours) in diaphragm muscles of mechanically ventilated rats [16]. 
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Rapid onset atrophy is typically observed in fasting states, sepsis and diseases such 
as cancer cachexia where systemic factors such as circulating glucocorticoids or 
inflammatory factors are likely to play a role [315–320]. Atrophy is also linked with 
oxidative stress/signalling [90,150,308,320–323]. Interestingly, metabolic 
suppression also appears to be a common feature of atrophying muscles [320]. 
Importantly, muscle fibre atrophy in the diaphragm following CH [22,67] will 
impact upon muscle function. Elucidating the molecular mechanism and signalling 
of atrophy in the diaphragm following CH will open potential therapeutic avenues to 
prevent weakness in hypoxia.  
 
Severe hypoxia has been shown to progressively increase chymotrypsin-like 
proteasome activity, but not lysosome activity, in rat gastrocnemius muscle after 
three, seven, and fourteen days of hypoxia exposure [94]. These changes occurred 
alongside progressive muscle fibre atrophy observed by histology and progressive 
oxidative stress in the muscle. Increased proteasome activity has also been reported 
in the COPD diaphragm muscle [85] and increased proteasome subunit mRNA 
expression is common to several atrophy producing states [320]. Furthermore, 
proteasome activity is redox sensitive – chymotrypsin-like activity in particular has 
been detected to be very sensitive to ROS and antioxidant treatment 
[16,150,217,321], and degradation of oxidised proteins does not require 
ubiquitination, ATP consumption, or regulation by the 19S “gating” subunit [322]. 
We sought to measure chymotrypsin-like activity of the 20S proteasome in CH 
respiratory and limb muscles to determine if proteasome activity is increased as an 
active atrophy process. Furthermore, if this process is redox driven, comparable 
results to the muscle specific protein oxidation will be observed.  
 
Atrophy signalling is driven by FOXO3a localisation to the nucleus to transcribe 
atrophy promoting atrogin mRNAs such as Murf-1 and MAFbx. FOXO3a, in 
hypertrophic conditions, will be prevented from transcribing mRNA in the nucleus 
by Akt phosphorylation [88] and can also be inhibited by PGC1- [324] (Fig 5.1). 
PGC-1 mRNA and protein have been observed to be reduced in diaphragm muscle 
of mice exposed to four weeks of CH [80]. FOXO3a transcription activity is also 
associated with increased catalase activity [90,325] (chapter 3). The MyoD family of 
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transcription factors, inflammatory cytokines, catecholamines, and MAPK proteins 
are also involved in modulating the atrophy signal by interaction with the Akt 
pathway or affecting gene transcription in the nucleus [90,315–320,326]. 
Hypertrophy signalling and protein synthesis is predominantly driven by circulating 
growth factors binding to the insulin-like growth factor (IGF)-1 receptor with 
progressive activation of phosphatidylinositol-3-kinase (PI3K), Akt, mTOR and 
S6RP promoting both protein transcription and translation [327]. However, there are 
various stimuli which can impact upon increasing translation such as hypoxia, 
oxidative stress, contractile activity, and free cytoplasmic amino acids to name a few 
[328]. Bonaldo and Sandri (2013) provide a comprehensive list of the phenotype of 
transgenic and K/O mice for genes involved in anabolic and catabolic pathways in 
skeletal muscle [89]. These pathways can further regulate themselves e.g. FOXOs 
inhibit mTOR complex 1 (mTORC1) formation in times of energy stress and 
mTORC2 is shown to facilitate Akt activation [329,330]. Akt and its downstream 
targets constitute a junction for many signalling proteins in both hypertrophy and 
atrophy regulation in skeletal muscle as well as being an important pathway 
themselves. Thus, they are potential candidates of therapeutic manipulation in 
muscle wasting conditions. However, it should be noted that they affect other 
biological processes and prevention of protein turnover may be, in the long term, 
detrimental to cell health [331]. Regardless, very little is known about the activation 
of these pathways in the atrophied diaphragm muscles of mice exposed to CH. Thus, 
we sought to quantify the content of phospho-Akt, phospho-mTOR, and phospho-
FOXO3a in the diaphragm muscle after one, three and six weeks of CH. 
Furthermore, we quantified phospho-GSK-3β, phospho-p70S6K, and phospho-S6RP 
which are important downstream targets of Akt and mTOR. Indeed, several of these 
targets have also been observed to be regulated by hypoxia dominant to Akt [328]. 
Quantification of these phosphorylated proteins will aid the full delineation of Akt 
and other signalling proteins involved in CH-induced diaphragm atrophy signalling. 
We hypothesized that hypoxia would promote increased atrophy signalling and 
decreased hypertrophy signalling. 
 
MAPKs represent a large family of protein kinases that regulate various cell 
signalling cascades and stress responses. They are known to strongly interact with 
112 | P a g e  
 
ROS and the Akt signalling cascade, differentially depending on the specific MAPK 
protein, in regulation of cell growth. The p38 MAPK increases MAFbx mRNA 
levels in rat soleus unloading experiments via ROS production [90]. ERK1/2 
MAPKs phosphorylate TSC2 at a site independent of Akt to promote mTORC1 
formation [332]. JNK MAPK is observed to modulate FOXO3a to promote 
mitophagy [333]. Furthermore, there are strong associations between increased 
muscle activity and MAPK activation and the pattern of muscle activation lends to 
differential MAPK signalling. Prolonged activity is known to activate ERK 1/2 and 
p38 while JNK activation appears to have greater association with peak force 
generation and mechanical stress [334–336]. Hypoxia has also been shown to 
differentially activate MAPK proteins although this is in-vitro and ex-vivo in rat 
neurons. In Section C of this chapter we measure MAPK pathway protein 
phosphorylation content after six weeks of CH – specifically phospho-ERK 1/2 
(Thr202/204, Tyr185/187), phospho-JNK (Thr183, Tyr185) and phospho-p38 
(Thr180, Tyr182).  
 
We should note here that studies involving pair feeding and amino acid 
supplementation had no effect on atrophy and/or atrophy signals measured in CH 
limb muscles with or without exercise [94,337]. In rats exposed to three weeks of 
CH, ~60% of muscle mass is lost independent of hypophagia [338].  
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Figure 5.1: Hypertrophy/atrophy signalling in muscle. A simplified schematic of 
intracellular signalling proteins involved in controlling muscle mass and protein 
turnover. Note: specific downstream effects for several of these proteins are not 
shown as the effect can vary depending upon the sequence and combination of 
transcription factor activation but some are discussed in the text. Also, positive and 
negative regulatory activities are not shown, only the fact that a downstream effect 
occurs. Furthermore, many cross-talk signals between stimuli and proteins described 
in non-muscle tissues are omitted for simplification of the diagram. This does not 
mean they are not active in skeletal muscle however. Phosphorylated content of the 
cytosolic proteins in the black boxes are assessed in this chapter. 
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5.2 Chapter Results 
 
5.2.1 Section A: Chymotrypsin-like Proteasome Activity 
Chymotrypsin-like activity of the 20S proteasome in diaphragm muscle is shown in 
Fig. 5.2A and sternohyoid and limb muscles in Fig. 5.2B. Activity in diaphragm 
muscle is unchanged after one week of CH but significantly increased compared to 
controls after six weeks (26.12 ± 3.25 vs. 29.85 ± 2.78, 28.69 ± 1.41 vs. 39.68 ± 
3.627* mean ± SEM AMC substrate generation (pmol/min/mg protein); control vs. 
CH; diaphragm chymotrypsin-like proteasome activity after one and six weeks of 
CH respectively; n= 7-8 per group; *p<0.05). Note: Due to muscle tissue sample 
volume limitations, activity at the three week time point could not be measured. 
 
 
After six weeks of CH, activity is unchanged in sternohyoid, increased in EDL 
(p=0.08), and significantly increased in soleus muscle (30.82 ± 1.88 vs. 34.36 ± 1.16, 
13.02 ± 2.48 vs. 19.43 ± 2.36, 16.92 ± 2.41 vs. 33.49 ± 5.71* mean ± SEM AMC 
substrate generation (pmol/min/mg protein); control vs. CH; sternohyoid, EDL, and 
soleus chymotrypsin-like proteasome activity after six weeks of CH respectively; n= 
4-8 per group; *p<0.05). Note: Due to muscle tissue sample volume limitations, 
activity at the one and three six week time points could not be measured. 
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Figure 5.2: Chymotrypsin-like proteasome activity in diaphragm, sternohyoid, 
EDL, and soleus after sustained hypoxia compared to normoxic controls. (A) 
Diaphragm chymotrypsin-like proteasome activity (mean ± SEM) after one and six 
weeks of normoxia or sustained hypoxia expressed as pmol AMC substrate 
generation/min/mg protein; n=7-8 per group; (B) Sternohyoid, EDL, and soleus 
chymotrypsin-like proteasome activity (mean ± SEM) after six weeks of normoxia or 
sustained hypoxia expressed as pmol AMC substrate Generation/min/mg protein; 
n=4-8 per group; *p<0.05, ns=not significant; Student’s t-test; Ctrl = normoxic 
control; Hypoxia = sustained hypoxia (FiO2 = 0.1).   
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5.2.2 Section B: Akt signalling cascade  
Phospho-mTOR content in diaphragm muscle is shown in Fig. 5.3A and phospho-
FOXO3a content in Fig. 5.3B. Phospho-mTOR content is significantly increased 
after one week of CH and significantly decreased after three weeks of CH. Content is 
decreased (p=0.06) after six weeks albeit not statistically significant (92.11 ± 16.04 
vs. 146.5 ± 13.36*, 169.4 ± 8.72 vs. 37.21 ± 4.28***, 94.78 ± 9.03 vs. 74.04± 6.49 
mean ± SEM normalised relative luminescence units; control vs. CH; diaphragm 
phospho-mTOR content after one, three and six weeks of CH respectively; n= 7-8 
per group; *p<0.05, ***p<0.001).  
 
Phospho-FOXO3a changes are also bi-phasic. Phospho-FOXOs3a content is 
increased after one week of CH (p=0.08) but significantly decreased after three and 
six weeks of CH (325.7 ± 24.91 vs. 393.3 ± 26.68, 373.6 ± 33.78 vs. 287.1 ± 14.4*, 
350.4 ± 23.13 vs. 283.4± 6.53* mean ± SEM normalised relative luminescence units; 
control vs. CH; diaphragm phospho-FOXO3a content after one, three and six weeks 
of CH respectively; n= 7-8 per group; *p<0.05). 
 
Phospho-Akt content in diaphragm muscle is shown in Fig. 5.4A and phospho-GSK-
3β content in Fig. 5.4B. Phospho-Akt content is unchanged after one week of CH 
and decreased after three (p=0.06) and six (p=0.07) weeks of CH but does not reach 
statistical significance (22.12 ± 1.69 vs. 25.71 ± 2.76, 21.98 ± 2.6 vs. 16.81 ± 0.69, 
18.87 ± 1.08 vs. 16 ± 0.97 mean ± SEM normalised relative luminescence units; 
control vs. CH; diaphragm phospho-Akt content after one, three and six weeks of 
CH respectively; n= 7).  
 
Phospho-GSK-3β changes are bi-phasic. Phospho-GSK-3β content is significantly 
increased after one week of CH but decreased after three (p=0.055) and six weeks 
(p=0.054) of CH (31.3 ± 1.93 vs. 47.58 ± 3.33**, 43.95 ± 4.68 vs. 32.25 ± 2.917, 
26.18 ± 1.74 vs. 32.53 ± 2.422 mean ± SEM normalised relative luminescence units; 
control vs. CH; diaphragm phospho-GSK-3β content after one, three and six weeks 
of CH respectively; n= 7 per group; **p<0.01). 
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Figure 5.3: Diaphragm phospho-mTOR and phospho-FOXO3a content after 
one, three and six weeks of sustained hypoxia compared to normoxic controls. 
(A) Diaphragm phospho-mTOR content (mean ± SEM) after one, three, and six 
weeks of normoxia or sustained hypoxia expressed as normalised relative 
luminescence units; n=7-8 per group; (B) Diaphragm phospho-FOXO3a content 
(mean ± SEM) after one, three, and six weeks of normoxia or sustained hypoxia 
expressed as normalised relative luminescence units; n=7-8 per group; *p<0.05, 
***p<0.001; Student’s t-test; Ctrl = normoxic control; Hypoxia = sustained hypoxia 
(FiO2 = 0.1); RLU = relative luminescence units. 
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Figure 5.4: Diaphragm phospho-Akt and phospho-GSK-3β content after one, 
three and six weeks of sustained hypoxia compared to normoxic controls. (A) 
Diaphragm phospho-Akt content (mean ± SEM) after one, three, and six weeks of 
normoxia or sustained hypoxia expressed as normalised relative luminescence units; 
n=7 per group; (B) Diaphragm phospho-GSK-3β content (mean ± SEM) after one, 
three, and six weeks of normoxia or sustained hypoxia expressed as normalised 
relative luminescence units; n=7 per group; **p<0.01, ns=not significant; Student’s 
t-test; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); RLU = 
relative luminescence units.  
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Phospho-p70S6K content in diaphragm muscle is shown in Fig. 5.5A and phospho-
S6RP content in Fig. 5.5B. Phospho-p70S6K content is unchanged after one week of 
CH, significantly decreased after three weeks of CH, and decreased (p=0.08) after 
six weeks of CH but not significantly (6.85 ± 0.68 vs. 7.76 ± 0.27, 6.81 ± 0.48 vs. 
5.2 ± 0.25*, 6.43 ± 0.3 vs. 5.47 ± 0.41 mean ± SEM normalised relative 
luminescence units; control vs. CH; diaphragm phospho-p70S6K content after one, 
three and six weeks of CH respectively; n= 7-8 per group; *p<0.05).  
 
Phospho-S6RP changes are also bi-phasic. Phospho-S6RP content is significantly 
increased after one week of CH but not different from control levels after three and 
six weeks of CH (54.21 ± 15.58 vs. 131.3 ± 16.07**, 42.1 ± 5.8 vs. 54.03 ± 12.98, 
44.39 ± 8.74 vs. 33.23 ± 4.99 mean ± SEM normalised relative luminescence units; 
control vs. CH; diaphragm phospho-S6RP content after one, three and six weeks of 
CH respectively; n= 7 per group; **p<0.01). 
120 | P a g e  
 
 
Figure 5.5: Diaphragm phospho-p70S6K and phospho-S6RP content after one, 
three and six weeks of sustained hypoxia compared to normoxic controls. (A) 
Diaphragm phospho-p70S6K content (mean ± SEM) after one, three, and six weeks 
of normoxia or sustained hypoxia expressed as normalised relative luminescence 
units; n=7 per group; (B) Diaphragm phospho-S6RP content (mean ± SEM) after 
one, three, and six weeks of normoxia or sustained hypoxia expressed as normalised 
relative luminescence units; n=7 per group; *p<0.05, **p<0001, ns=not significant; 
Student’s t-test and Mann-Whitney test as appropriate. Ctrl = normoxic control; 
Hypoxia = sustained hypoxia (FiO2 = 0.1); RLU = relative luminescence units. 
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5.2.3 Section C: MAP Kinases 
As illustrated in Fig. 5.6A, six weeks of CH increased diaphragm phospho-p38 
content compared to control and this was significantly attenuated by chronic 
antioxidant supplementation with either tempol or NAC (2.606 ± 0.26 vs. 3.996 ± 
0.56 vs. 2.215 ± 0.3
#
 vs. 2.112 ± 0.3
#
 mean ± SEM normalised relative luminescence 
units; control vs. hypoxia vs. tempol vs. NAC; diaphragm phospho-p38 content after 
six weeks of CH; n=5-8 per group; One-way ANOVA: p<0.01, 
#
p<0.05 vs. hypoxia 
Tukey’s multiple comparison test). 
 
Fig. 5.6B illustrates changes in diaphragm phospho-JNK content after six weeks of 
CH ± chronic antioxidant supplementation. One-way ANOVA reveals the means are 
trending towards being significantly different while a multiple comparisons test 
highlights that six weeks of CH + chronic NAC supplementation significantly 
decreases phospho-JNK content compared to control (73 ± 13.22 vs. 66.27 ± 10.22 
vs. 53.05 ± 8.93 vs. 28.38 ± 5.076* mean ± SEM normalised relative luminescence 
units; control vs. hypoxia vs. tempol vs. NAC; diaphragm phospho-JNK content 
after six weeks of CH; n=5-8 per group; One-way ANOVA: p<0.01, 
#
p<0.05 vs. 
hypoxia Tukey’s multiple comparison test). 
  
As illustrated in Fig. 5.6C, six weeks of CH ± chronic antioxidant supplementation 
has no effect on diaphragm phospho-ERK1/2 content (56.4 ± 16.92 vs.63.38 ± 16.08 
vs. 51.35 ± 12.16 vs. 39.7 ± 14.92
###
 mean ± SEM normalised relative luminescence 
units; control vs. hypoxia vs. tempol vs. NAC; diaphragm phospho-JNK content 
after six weeks of CH; n=5-8 per group; One-way ANOVA: ns). 
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Figure 5.6: Diaphragm phospho-MAPK contents after six weeks of sustained 
hypoxia ± chronic antioxidant supplementation or normoxia. (A) Diaphragm 
phospho-p38 content (mean ± SEM) expressed as normalised relative luminescence 
units; n=5-8 per group; (B) Diaphragm phospho-JNK content (mean ± SEM) 
expressed as normalised relative luminescence units; n=5-8 per group; (C) 
Diaphragm phospho-ERK 1/2 content (mean ± SEM) expressed as normalised 
relative luminescence units; n=5-8 per group;*p<0.05 vs. control, #p<0.05 vs. 
hypoxia Tukey’s multiple comparison test. Ctrl = normoxic control; Hypoxia = 
sustained hypoxia (FiO2 = 0.1); RLU = relative luminescence units. 
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As illustrated in Fig. 5.7A, six weeks of CH ± chronic antioxidant supplementation 
has no effect on sternohyoid phospho-p38 content (1.576 ± 0.14 vs. 1.279 ± 0.176 
vs. 1.235 ± 0.079 vs. 1.241 ± 0.29 mean ± SEM normalised relative luminescence 
units; control vs. hypoxia vs. tempol vs. NAC; sternohyoid phospho-p38 content 
after six weeks of CH; n=5-7 per group; One-way ANOVA: ns). 
  
As illustrated in Fig. 5.7B, six weeks of CH significantly decreased sternohyoid 
phospho-JNK content compared to control and chronic antioxidant supplementation 
with either tempol or NAC could not prevent this (104.1 ± 14.47 vs. 63.64 ± 9.496* 
vs. 65.33 ± 6.65* vs. 48.22 ± 4.7** mean ± SEM normalised relative luminescence 
units; control vs. hypoxia vs. tempol vs. NAC; sternohyoid phospho-JNK content 
after six weeks of CH; n=5-7 per group; One-way ANOVA: p<0.01, 
*
p<0.05 vs. 
Control and **p<0.01 vs. Control, Tukey’s multiple comparison test). 
  
Fig. 5.7C illustrates changes in sternohyoid phospho-ERK1/2 content after six weeks 
of CH ± chronic antioxidant supplementation. The Kruskal-Wallis test reveals the 
means are significantly different with hypoxia decreasing phospho-ERK1/2 
compared to control and this was decreased further with antioxidant 
supplementation. However, Dunn’s multiple comparisons test revealed no significant 
differences between pairs (17.2 ± 2.95 vs. 12.28 ± 1.94 vs. 9.367 ± 0.956 vs. 8.752 ± 
1.832 mean ± SEM normalised relative luminescence units; control vs. hypoxia vs. 
tempol vs. NAC; sternohyoid muscle phospho-ERK1/2 content after six weeks of 
CH; n=5-7 per group; Kruskal-Wallis test: p<0.05).  
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Figure 5.7: Sternohyoid phospho-MAPK contents after six weeks of sustained 
hypoxia ± chronic antioxidant supplementation or normoxia. (A) Sternohyoid 
phospho-p38 content (mean ± SEM) expressed as normalised relative luminescence 
units; n=5-7 per group; (B) Sternohyoid phospho-JNK content (mean ± SEM 
expressed as normalised relative luminescence units; n=5-7 per group; (C) 
Sternohyoid phospho-ERK 1/2 content (mean ± SEM) expressed as normalised 
relative luminescence units; n=5-7 per group;*p<0.05 vs. control, **p<0.01 vs. 
hypoxia, Tukey’s or Dunn’s multiple comparison test as appropriate; Ctrl = 
normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1), RLU = relative 
luminescence units.  
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5.3 Chapter Discussion 
 
The main findings of this chapter are 1) chymotrypsin-like activity of the 20S 
proteasome is significantly increased in diaphragm and soleus muscles after six 
weeks of CH – similar to protein carbonyl content (chapter 3). Furthermore, basal 
proteasome activity is greatest in sternohyoid>diaphragm>soleus>EDL which is 
similar to basal protein carbonyl content in these muscles; 2) six weeks of CH 
decreases phospho-FOXO3a, phospho-mTOR and increases phospho-p38 MAPK 
content while antioxidants attenuate increased phospho-p38 MAPK content – 
suggestive that these are signalling proteins driving hypoxia – and ROS – induced 
atrophy; 3) atrophy signalling is temporally modulated; and 4) atrophy signalling is 
differential in diaphragm and sternohyoid muscles despite protein oxidation in both 
muscles (chapter 3). 
 
5.3.1 Chymotrypsin-like Proteasome Activity  
Chymotrypsin-like proteasome activity, which is redox sensitive, is increased in the 
six week CH mouse diaphragm and soleus muscles. Increased proteasome activity 
may be redox regulated or may be due to increased proteasome complex formation 
which would occur in turn with increased atrophy signalling (also potentially due to 
protein oxidation). Interestingly, these changes follow suit with slow oxidative fibre 
type muscles being prone to CH-induced protein carbonylation. Furthermore, basal 
proteasome activity measurements in the different muscles follow suit with basal 
protein carbonyl contents being greatest in sternohyoid>diaphragm>soleus>EDL 
muscles. Increased chymotrypsin-like proteasome activity will facilitate degradation 
of oxidatively damaged proteins, turnover of harder-working contractile apparatus 
proteins, and will contribute to muscle fibre atrophy in the CH animal model. 
 
The higher respiratory muscle chymotrypsin-like proteasome activity in control 
conditions is perhaps not surprising given the continuous work of breathing but both 
highest carbonyl content and proteasome activity in the fast fibre type sternohyoid 
over diaphragm is unexpected. Perhaps sternohyoid proteasome activity is at 
approximately maximum capacity in C57Bl6/J control conditions and does not 
increase to a statistically significant extent after six weeks of CH as a result. Indeed, 
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the mean CH-diaphragm chymotrypsin-like proteasome activity is not much higher 
than mean activity in control-sternohyoid. 
 
We cannot rule out lysosomal activity changes as mitochondrial degradation is 
observed in mouse hypoxic diaphragm alongside decreased PGC-1α and increased 
BNIP-3 [80]. Increased lysosomal activity more than likely does occur in accordance 
with these observations. PGC-1α has a role in FOXO suppression (although 
literature is conflicting) while BNIP-3 targets mitochondria for lysosome 
degradation [80,324,333,339,340]. 
 
5.3.2 Akt signalling cascade 
Decreased phospho-mTOR and phospho-FOXO3a content after three and six weeks 
of CH are indicative of placing a brake on protein translation and facilitating the 
transcription of pro-atrophy genes respectively. Downstream of mTOR, phospho-
p70S6K follows suit and is decreased after three and six weeks. Downstream of 
p70S6K, phospho-S6RP is not different from controls, suggestive of phosphorylation 
from alternate pathways that maintains basal translational activity. S6RP can be 
phosphorylated by the p70 and p90 ribosomal S6 protein kinases, casein kinase 1, 
and signals from MAPK pathways, as well as dephosphorylated by the protein 
phosphatase 1 (PP1) [91,341]. Of course, changes in phospho-p70S6K and phospho-
S6RP need not necessarily be measurable together with such temporal precision e.g. 
decreases in p70S6K occur in the mechanically ventilated diaphragm before 
decreases in protein synthesis are observed [16]. 
 
Akt is a modulator of both hypertrophy and atrophy depending on its 
phosphorylation state. It is upstream of mTOR and FOXO3a and results in 
phosphorylation of both when activated. Akt phosphorylation occurs when 
circulating growth factors such as IGF-1 bind to their receptors to initiate a cell 
growth signalling cascade through the Akt protein. We hypothesized that phospho-
Akt content would remain unchanged after CH exposure and that oxidative stress 
(chapter 3) in the muscle is responsible for the observed muscle fibre atrophy 
[22,67]. No significant changes in phospho-Akt content were detected; however 
content changes follow a similar pattern as phospho-mTOR and phospho-FOXO3a. 
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The decrease in phospho-Akt after three and six weeks of CH may be 
physiologically relevant over this extended period of time to enhance the signal of 
decreased protein synthesis and degradation signalling through mTOR and FOXO3a 
regulation. Basal protein turnover in muscle is very high, potentially more-so in 
respiratory muscles effecting the hypoxic ventilatory response, and so a large net 
protein loss over a prolonged period of moderately decreased Akt signalling may 
occur. However, Akt is unlikely to be the predominant contributor to these processes 
at the specific time-points given the larger and statistically significant changes 
observed to the downstream mTOR and FOXO3a in CH. Very severe hypoxia is 
observed to have no apparent effect on growth factor or catecholamine signalling in 
rat limb muscle [94]. 
 
Akt mediated activation of mTOR is indirect [342,343] through TSC2 and this 
presents a site of manipulation of mTOR signalling that is downstream of Akt. 
Indeed, REDD1 and AMPK has been shown to inhibit mTOR signalling through 
TSC2 [338,344,345]. REDD1 in particular is significantly increased in rat soleus 
muscle after three weeks of CH [338]. Phospho-Akt content is also significantly 
decreased in this study. However, there are no data on the effect of REDD1 at an 
earlier exposure time. Furthermore, REDD1 was not significantly increased in 
hypoxaemic COPD patient vastus lateralis compared to non-hypoxaemic patients 
[338].  
 
Further elucidation of the Akt signal strength may be delineated by measuring 
phosphorylation of its downstream target GSK-3β. GSK-3β is a serine/threonine 
kinase that was first discovered as a regulatory protein for glycogen synthase but is 
now recognised as a key regulator of numerous protein functions ranging from 
metabolic proteins to structural proteins and transcription factors [346]. Indeed, 
phospho-GSK-3β content is significantly increased after one week of CH unlike 
phospho-Akt, but follows a similar trend of decreased content as phospho-Akt, 
similarly not statistically significant, after three and six weeks of CH. There is a 
regulatory mechanism other than Akt involved at the one week CH time-point. 
 
Like several of these signalling proteins, GSK-3β also regulates feedback control, 
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over mTOR [347]. Phosphorylation events by GSK-3β, for the most part, result in 
deactivation of a protein’s activity [319,346–348]. Furthermore, pre-phosphorylation 
of several GSK-3β substrates is required (priming) before being phosphorylated by 
GSK-3β – in effect an integration of two signalling pathways. Phosphorylation of 
GSK-3β can result in increases or decreases in its activity so it is under tight 
regulation in the cell. GSK-3β phosphorylation at serine 9, the content of which was 
measured in this study, decreases its activity, thus enhancing activity of its 
downstream targets.  
 
Specific GSK inhibitors have been observed to attenuate muscle atrophy in a guinea-
pig model of LPS-induced atrophy [319]. GSK k/o mice exhibit accelerated 
sarcopenia of cardiac and skeletal muscle and premature death [347]. In the latter 
study, GSK deletion induced marked mTOR activation and suppression of atrophy 
signals. It appears that short-term inhibition of GSK can facilitate muscle growth but 
long-term inhibition results in reduced degradation of damaged and miss-folded 
proteins. With regard to this study, increased phospho-GSK-3β measured after one 
week of CH will be inhibiting muscle growth in and around this period. Phospho-
GSK-3β returns to control levels after three and six weeks which may facilitate 
mTOR signalling thereafter. Of course phospho-mTOR levels have already 
decreased at these later stages. Potentially, phospho-mTOR activity stimulating 
growth occurs earlier than the one week time-point and GSK-3β becomes activated 
to negatively regulate this process. Following this, phospho-p70S6K and phospho-
S6RP content are significantly decreased and unchanged respectively after three 
weeks of CH. Regulation of GSK-3β, and indeed atrophy signalling as a whole, may 
also play a role in developing the decreased carbohydrate derivative flux strategy 
observed in the CH-mouse diaphragm [302,320,349,350] as well as that of 
regulating Ca
2+
 handling proteins [320]. We observed both metabolic enzyme 
suppression and redox-modulation and expression changes to Ca
2+
 handling proteins 
in respiratory muscle (chapters 3 and 4). Indeed, just as AMPK feeds information 
about the energetic state of the cell into the growth signalling pathways [344,345], it 
is likely that there would be feedback about growth signalling into energetic 
maintenance. Furthermore, GSK-3β activity is known to regulate HIF-1 expression 
[351,352]. 
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Regarding regulation of GSK-3β, exposure of muscle to an oxidative stress and 
insulin significantly reduces GSK-3β phosphorylation at serine9 compared to 
exposure to insulin alone, almost certainly through decreased Akt phosphorylation 
which also occurs [353]. Phospho-GSK-3β is increased after one week of CH but 
returns to control levels by three weeks. A similar finding is observed after four 
weeks of CH in mouse soleus muscle [354]. Similar to phospho-Akt, GSK-3β is 
trending toward being significantly decreased after three weeks of CH. However, it 
is unlikely phospho-Akt is the only upstream effector signal acting upon GSK-3β, 
especially early in the hypoxia stimulus. 
 
Increased phospho-mTOR, phospho-FOXO3a, and phospho-S6RP after one week of 
CH suggests there is an early hypertrophic signal, potentially resulting from 
increased activity of the muscle or an acute ROS stimulus (ROS has been observed 
to promote adaptation to exercise) [355], that changes in favour of atrophy over time. 
Both increased synthesis and degradation of proteins in rat limb muscle after two 
weeks of hypoxia exposure has been reported [94]. Given that phospho-mTOR and 
phospho-FOXO3a content changes (which are increased after one week and 
decreased after three weeks) are unlikely to be completely attributable to phospho-
Akt and thus may be dephosphorylated at different rates, the potential exists for 
synthesis and degradation signals to overlap at some point. Some studies present 
high altitude-induced protein synthesis in human limb muscles but this may be a 
training effect of ascent to high altitude [356,357]. One study reports that myofibril 
and sarcoplasmic protein synthesis rates are differentially augmented in human limb 
muscles. This is not surprising given that contractile proteins are among the most 
stable in the cell and turnover can take up to ten days. Interestingly, in all of these 
studies, protein synthesis rates are measured over a relatively short period of time 
(hours-days). We observe a large and statistically significant increase in phospho-
S6RP content after one week of CH. This is likely to be an effect of hypoxia per se 
given that it is also observed in limb muscles by the aforementioned high altitude 
studies. 
 
Doucet et al., (2010) [83] present increased mRNA expression of Murf1, MafBx1, 
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and FOXO1 in COPD patient vastus lateralis muscle compared to same patient 
COPD diaphragm muscles, while phospho-p70S6K protein content was significantly 
greater in diaphragm compared to vastus lateralis. Moreover, these findings suggest 
that atrophy signalling is either being attenuated in the diaphragm (possibly due to 
increased activity), potentiated in the limb muscle (possibly due to deconditioning), 
or both, but only with respect to the other COPD muscle studied. When the 
diaphragm/vastus ratios for the signalling factors were compared between COPD and 
control patients, the ratios suggest greater susceptibility to degradation in COPD 
limb and greater susceptibility to protein synthesis in diaphragm. The implications of 
this study is that local factors are important and diaphragm contractility and/or limb 
deconditioning is likely to be important. Interestingly, the PaO2 of patients in this 
study is not as severe as in other COPD studies. Atrophy of the COPD diaphragm 
does occur however and literature discrepancies relating to atrophy/hypertrophy 
signalling in COPD patients have been postulated to be due to the severity of 
hypoxemia [83,338]. This is also important for our findings in this study as there are 
likely to be changes in diaphragm tissue hypoxia overtime due to typical 
acclimatisation characteristics such as increased red blood cell content and changes 
in blood flow. However, we have not measured tissue hypoxia in this study. 
 
5.3.3 MAP Kinases 
Six weeks of CH increases phospho-p38 content in the diaphragm. P38 activity in 
muscle is strongly associated with promoting atrophy [90,326]. In fact, one study 
suggests p38 signalling is required for hypoxia signalling via mitochondrial ROS 
production [148], which is consistent with our hypothesis of ROS being pivotal in 
diaphragm adaptation to CH. Phospho-p38 increases are attenuated by antioxidant 
supplementation further highlighting that this effect of CH is ROS regulated. Both 
tempol and NAC have been shown to attenuate stress-induced activation of p38 
[358]. No change in phospho-p38 content is observed in sternohyoid muscle. The 
reason for this is unclear however it supports findings from other groups that other 
local factors are important for driving muscle atrophy [83] in COPD. Furthermore, 
this may be key as to why ROS in the sternohyoid does not induce degradation of 
this muscle [22], just as inactive p38 is associated with longevity [359]. ROS 
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induced activation of p38 occurs through apoptosis-stimulating kinase (ASK1 – a 
MAP3K) [359–361] activation after release by oxidation of a bound thioredoxin. 
 
Phospho-JNK is decreased by six weeks of CH in diaphragm and more-so in the 
sternohyoid, with antioxidant treatment (especially NAC) further serving to decrease 
phospho-JNK content. JNK is also activated by the upstream MAP3K ASK1 [361]; 
however differential regulation of p38 and JNK occurs at the MAP2K level and is 
potentially influenced by contractile activity and mechanical stress [362]. 
Furthermore, ROS activation of phosphatases can differentially regulate MAPK 
protein activation [363]. Interestingly, both JNK and p38 have been shown to export 
FOXO proteins from the nucleus which is contradictory to atrophy [364], thus, it is 
likely to be a specific combination of activated p38, JNK, FOXO, Akt and other 
signalling kinases and phosphatases that are requisite for the muscle fibre atrophy 
response. Given the greater decrease of phospho-JNK content in the sternohyoid 
following CH, basal levels of phospho-JNK are potentially important for CH-
induced muscle fibre atrophy in the diaphragm.  
 
Phospho-ERK1/2 content may also be involved in this response too as it is 
unchanged in the diaphragm after six weeks of CH ± antioxidant supplementation 
but decreased in the sternohyoid and more-so with antioxidant treatment. ROS 
induced activation of ERK1/2 in skeletal muscle may require Ca
2+
 signalling [365]. 
ERK1/2 also activates mTOR through a parallel mechanism to Akt but converging 
on TSC2 [332] and so ERK1/2 may be more important early in hypoxia adaptation.  
 
The MAPK proteins are typically associated with cell life versus death signalling. 
We know the diaphragm muscle atrophies with CH and COPD but it does remain 
functional [22,43,67,70,86,366]. In the clinical setting, patients may present with 
respiratory disease where hypoxia is featured and although breathing may be 
difficult and clinical outcome is correlated with inspiratory pressure generating 
capacity [47], it is only in severe cases that mechanical ventilation is required. Here 
we present differential MAPK responses in different muscles that will facilitate 
differential atrophic responses but ultimately the combination of these do not result 
in apoptosis. 
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5.3.4 Conclusion 
We conclude that hypoxia increases the activity of diaphragm muscle degradation 
processes and atrophy signalling differential to other respiratory and limb muscles. 
Oxidative fibre types are potentially more prone to active degradation. Furthermore, 
atrophy signalling in the diaphragm results in temporal changes in phospho-
FOXO3a, phospho-mTOR, and phospho-S6RP content indicating both 
transcriptional and translational regulation of muscle cell size. Increased p38 MAPK 
is the likely candidate for driving this response in diaphragm given its redox 
regulation and association with atrophy signalling. We hypothesize that contractile 
activity, hypoxia, oxidative stress, and the cellular energetic state contribute to CH-
hypertrophy/atrophy changes in diaphragm muscle through the modulatory effects 
on the signalling proteins presented in this chapter. 
 
Atrophy is often associated with functional and metabolic abnormalities [302,320]. 
We should note that atrophy may not be entirely maladaptive in periods of hypoxia 
and oxidative stress. Muscle atrophy will also serve to clear damaged proteins, 
reduce O2 diffusion distances, and increase amino acid bioavailability. Less ATP is 
required for active atrophy than for protein synthesis. However, now that we have a 
greater appreciation of the molecular mechanisms that underpin muscle fibre atrophy 
in hypoxia, we can begin to assess different therapeutic avenues e.g. acute GSK-3β 
inhibition improves muscle growth during sepsis [319]. Given the associations 
between oxidative stress and active atrophy, and the fact that antioxidant 
administration can attenuate p38 activation and proteolysis [321], antioxidants may 
be useful as adjunct therapies in hypoxia-induced respiratory muscle fibre atrophy. 
Antioxidants are observed to increase phosphorylation of p70S6K [16]. Interestingly, 
antioxidants have been shown to prevent release of myofibrils from the sarcomere in 
the mechanically ventilated rat diaphragm, suggesting that ROS promote sarcomeric 
degradation [321]. The early hypertrophic adaptations are potentially regulated by 
the antioxidant response in the diaphragm (chapter 3). 
 
Key proteins still need to be turned over in basal conditions, especially in working 
muscle. Exposure to hypoxia results in a hypoxic ventilatory response that over time 
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plateaus at a lower rate. Other pathophysiological states resulting in atrophy show 
some increased gene expression of translational control proteins [320] and we may 
be observing this early in the hypoxia response of the diaphragm muscle as a 
protective mechanism. 
 
Given the onset times and direction of fibre type shifts and muscle volume in 
respiratory and limb muscles from the same COPD patients, local factors appear 
dominant to systemic factors in driving changes in muscle mass [83,105]. However, 
glucocorticoids, inflammatory mediators, and catecholamines may also play a role in 
driving respiratory muscle fibre atrophy in CH and cannot be ruled out without 
further studies. If they do, perhaps hepatic gluconeogenesis is inappropriately 
activated in hypoxia as is the case in diabetes [339]. 
 
We should note that translation of these data from inbred animal models to the 
human situation is difficult given that genetic differences account for large 
variability in muscle performance and structural quality in elite athletes, elderly 
populations, diseased states and there is also the possibility of sex differences [367]. 
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Chapter 6: Diaphragm function 
after chronic sustained hypoxia ± 
antioxidant supplementation  
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6.1 Chapter Introduction 
 
Diaphragm functional (mal)adaptations in animal models of CH as assessed ex vivo 
include weakness with maintained/improved endurance [22,67], similar to COPD 
patients [45,56], and are differential in respiratory and in limb muscles [22,67] 
(discussed in chapter 1). However, there are discrepancies in the literature on 
diaphragm performance after CH which appear to depend on different ex vivo bath 
temperatures used in the studies [22,26,65]. We have presented in previous chapters 
protein redox remodelling, a ROS sensitive decreased carbohydrate derivative flux 
strategy, and evidence of ROS sensitive atrophy signalling and mechanism in mouse 
diaphragm muscle, differential to other respiratory and limb muscles, after six weeks 
of CH. While we might associate these molecular adaptations with muscle weakness, 
they would typically be considered contrary to improved diaphragm endurance. 
However, diaphragm functional performance following six weeks of CH has only 
been characterised in rat and not mouse models. It is clear that further assessment of 
diaphragm function after CH is required. We sought to assess mouse diaphragm and 
sternohyoid muscle function after six weeks of CH. Given the redox changes 
observed, we hypothesized that six weeks of CH would be detrimental to mouse 
diaphragm performance. 
 
Isotonic muscle function, i.e. the ability of the muscle to shorten and at various 
speeds against loads <100%, is vital to diaphragm function in vivo. Isometric 
contraction, whereby the muscle does not shorten, would fail to produce the requisite 
thoracic pressure changes for breathing. Only isometric contractile performance of 
diaphragm muscle bundles following CH has been assessed to date. Furthermore, 
isotonic and isometric contractions differ greatly at the cellular level such that 
isotonic performance cannot be predicted from isometric readings [368]. Thus, and 
more specifically, we sought to assess mouse diaphragm and sternohyoid isotonic 
muscle function after six weeks of CH. We hypothesized that six weeks of CH 
would be detrimental to power generating capacity of the diaphragm. 
  
The overall hypothesis for this thesis is that redox remodelling is pivotal for 
diaphragm muscle adaptation to CH. We have provided evidence of this at a 
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molecular level. We sought to assess mouse diaphragm and sternohyoid muscle 
isotonic function after six weeks of CH ± chronic antioxidant supplementation with 
either tempol or NAC. Antioxidants have been shown to improve skeletal muscle 
isometric performance and alleviate hypoxia-induced impairment [170,171,369]. 
Tempol is a membrane permeable superoxide dismutase mimetic while NAC is 
precursor to the endogenous antioxidant glutathione. As mitochondria are the likely 
producers of the redox stress, we hypothesize that tempol supplementation will be 
most beneficial in tempering diaphragm muscle weakness in hypoxia because tempol 
can permeate into the mitochondria and exert antioxidant effects at ROS source. 
 
The sternohyoid muscle, whose functional performance is studied here in parallel to 
the diaphragm muscle, presents with similar protein redox changes as diaphragm 
(chapter 3). However, resultant molecular signalling pathway changes and atrophy 
mechanism changes (chapter 5, [22]) are differential in these muscles. Thus, 
antioxidant supplementation may induce changes in sternohyoid muscle performance 
that are differential to diaphragm. There is a paucity of information concerning 
sternohyoid muscle function following CH exposure that needs to be addressed, 
especially given that COPD patients are more prone to upper airway dysfunction and 
developing OSA [53,54]. Moreover, as is the case with the diaphragm muscle, the 
existing literature on sternohyoid muscle performance ex vivo after CH is conflicting. 
Previous work from our laboratory describes no change in rat sternohyoid muscle 
force or endurance after six weeks of CH and studied at 30
o
C [22] while another 
study reports decreased endurance at 25
o
C [26]. However, isotonic performance 
assessment may prove differential to isometric conditions given that a significant 
redox stress is also observed in the sternohyoid following six weeks of CH (chapter 
3) and isotonic and isometric contractions differ greatly at the cellular level [368]. 
 
Diaphragm performance is reported in section A and sternohyoid in section B. EDL 
and soleus limb muscles were not studied as the duration of time they would be 
bathed in Krebs solution ex vivo while diaphragm and sternohyoid function was 
assessed would result in too great functional deterioration to be of scientific merit. 
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6.2 Chapter Results 
 
6.2.1 Section A: Diaphragm 
Diaphragm muscle twitch contractile kinetics are shown in Fig. 6.1. There are no 
significant changes in diaphragm TTP (Fig. 6.1A) (15 ± 0.8 vs. 15.8 ± 1.1 vs. 17.2 ± 
3.9 vs. 12.9 ± 0.6 mean ± SEM ms; control vs. CH vs. CH + tempol vs. CH + NAC; 
diaphragm TTP after six weeks of CH respectively; n=5-8 per group) or T50 (Fig. 
6.1B) (21 ± 0.9 vs. 20.5 ± 2.9 vs. 25.5 ± 4.7 vs. 16.5 ± 2.09 mean ± SEM ms; control 
vs. CH vs. CH + tempol vs. CH + NAC; diaphragm T50 after six weeks of CH 
respectively; n=5-8 per group) after six weeks of CH ± chronic antioxidant 
supplementation. 
 
As illustrated in Fig. 6.2, six weeks of CH ± chronic antioxidant supplementation has 
no effect on peak specific twitch force (Fig. 6.2A) (3.35 ± 0.2 vs. 2.14 ± 0.15 vs. 
2.17 ± 0.31 vs. 2.95 ± 0.8 mean ± SEM N/cm
2
; control vs. CH vs. CH + tempol vs. 
CH + NAC; diaphragm peak specific twitch force after six weeks of CH 
respectively; n=5-8 per group). However, peak specific tetanic forces (Fig. 6.2B) are 
significantly different after one-way ANOVA. Tukey’s multiple comparison test 
reveals that peak specific tetanic force is significantly decreased after CH and CH + 
tempol but unchanged in the NAC treated group (20.6 ± 0.82 vs. 13.7 ± 1.5** vs. 
11.26 ± 0.99*** vs. 22.02 ± 1.3
### ttt
 mean ± SEM N/cm
2
; control vs. CH vs. CH + 
tempol vs. CH + NAC; diaphragm peak specific tetanic force after six weeks of CH 
respectively; n=5-8 per group; **p<0.01 vs. control; ***p<0.001 vs. control; 
###
p<0.001 vs. CH; 
ttt
p<0.001 vs. CH + tempol; One-way ANOVA followed by 
Tukey’s multiple comparison test). 
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Figure 6.1: Diaphragm isometric twitch kinetics after six weeks of sustained 
hypoxia ± chronic antioxidant supplementation or normoxia. (A) Diaphragm 
time to peak twitch tension (mean ± SEM) expressed as time (ms); n=5-8 per group; 
(B) Diaphragm twitch half relaxation time (mean ± SEM) expressed as time (ms); 
n=5-8 per group; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 
0.1); Tempol = sustained tempol + sustained hypoxia; NAC = sustained NAC + 
sustained hypoxia.  
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Figure 6.2: Diaphragm peak specific twitch force and tetanic force after six 
weeks of sustained hypoxia ± chronic antioxidant supplementation or normoxia. 
(A) Diaphragm peak specific twitch force (mean ± SEM) expressed as Force/CSA 
(N/cm
2
); n=5-8 per group; (B) Diaphragm peak specific tetanic force (mean ± SEM) 
expressed as Force/CSA (N/cm
2
); n=5-8 per group; **p<0.01 vs. Ctrl; ***p<0.001 
vs. Ctrl; 
###
p<0.001 vs. Hypoxia; 
tttp<0.001 vs. Tempol, Tukey’s multiple 
comparison test; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); 
Tempol = sustained tempol + sustained hypoxia; NAC = sustained NAC + sustained 
hypoxia.  
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Diaphragm muscle peak specific shortening velocity is shown in Fig. 6.3A and peak 
specific shortening in Fig. 6.3B. There are no significant changes in diaphragm peak 
specific shortening velocity (5.99 ± 0.5 vs. 5.62 ± 0.58 vs. 4.85 ± 0.75 vs. 6.53 ± 
0.42 mean ± SEM Lo/s; control vs. CH vs. CH + tempol vs. CH + NAC; diaphragm 
peak specific shortening velocity after six weeks of CH respectively; n=5-8 per 
group) or diaphragm peak specific shortening (0.53 ± 0.04 vs. 0.46 ± 0.01 vs. 0.41 ± 
0.07 vs. 0.51 ± 0.08 mean ± SEM L/Lo; control vs. CH vs. CH + tempol vs. CH + 
NAC; diaphragm peak specific shortening after six weeks of CH respectively; n=5-8 
per group) after six weeks of CH ± chronic antioxidant supplementation. 
 
As illustrated in Fig. 6.4A, six weeks of CH ± tempol significantly decreases 
diaphragm peak specific power but no change is observed after CH + NAC treatment 
(18.91 ± 2.3 vs. 10.2 ± 1.14* vs. 8.74 ± 1.19** vs. 19.02 ± 2.1
# tt
 mean ± SEM 
Watts/cm
2
; control vs. CH vs. CH + tempol vs. CH + NAC; diaphragm peak specific 
power after six weeks of CH respectively; n=5-8 per group; *p<0.05 vs. control; 
**p<0.01 vs. control; 
#
p<0.05 vs. CH; 
tt
p<0.01 vs. CH + tempol; One-way ANOVA 
followed by Tukey’s post-hoc test). Peak specific work (Fig. 6.4B) follows a similar 
pattern as power (2.04 ± 0.33 vs. 1.11 ± 0.1* vs. 0.9 ± 0.12** vs. 1.87 ± 0.2
t
 mean ± 
SEM Watts/cm
2
; control vs. CH vs. CH + tempol vs. CH + NAC; diaphragm peak 
specific power after six weeks of CH respectively; n=5-8 per group; *p<0.05 vs. 
control; **p<0.01 vs. control; 
t
p<0.05 vs. CH + tempol; One-way ANOVA followed 
by Tukey’s multiple comparison test). 
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Figure 6.3: Diaphragm peak specific shortening velocity and shortening after 
six weeks of sustained hypoxia ± chronic antioxidant supplementation or 
normoxia. (A) Diaphragm peak specific shortening velocity (mean ± SEM) 
expressed as optimal lengths/Time (Lo/s); n=5-8 per group; (B) Diaphragm peak 
specific shortening (mean ± SEM) expressed as length/Optimal length (L/Lo); n=5-8 
per group; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); 
Tempol = sustained tempol + sustained hypoxia; NAC = sustained NAC + sustained 
hypoxia.  
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Figure 6.4: Diaphragm peak specific power and work after six weeks of 
sustained hypoxia ± chronic antioxidant supplementation or normoxia. (A) 
Diaphragm peak specific power (mean ± SEM) expressed as Watts/CSA (cm
2
); n=5-
8 per group; (B) Diaphragm peak specific work (mean ± SEM) expressed as 
Joules/CSA (cm
2
); n=5-8 per group; *p<0.05 vs. Ctrl; **p<0.01 vs. Ctrl; 
#
p<0.05 vs. 
Hypoxia; 
t
p<0.05 vs. Tempol;
 ttp<0.01 vs. Tempol, Tukey’s multiple comparison 
test; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol = 
sustained tempol + sustained hypoxia; NAC = sustained NAC + sustained hypoxia. 
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Diaphragm muscle specific shortening velocity after incremental loads from 0-100% 
of peak specific force is shown in Fig. 6.5. A two-way ANOVA reveals a significant 
effect of the treatment (p<0.001) and, as expected, the load (p<0.01), but there is no 
interaction. 
 
Diaphragm muscle specific shortening after incremental loads from 0-100% of peak 
specific force is shown in Fig. 6.6. Similar to shortening velocity, two-way ANOVA 
reveals a significant effect of both treatment (p<0.05) and load (p<0.001) but there is 
no interaction.  
 
Specific work (Fig. 6.7) and power (Fig. 6.8) after incremental loads from 0-100% of 
peak specific force however present with significant effects of treatment (p<0.001), 
load (p<0.001), and treatment⋅load interaction (p<0.01). Two-way ANOVA 
followed by Bonferroni’s post-hoc test reveals six weeks of CH ± tempol 
significantly decreases peak specific work across loads 20-40% but NAC treatment 
prevents this. Similar results are observed for peak specific power. 
 
Treatment (p<0.001) and time (p<0.001) have a significant effect on diaphragm 
isotonic fatigue tolerance for all parameters measured – specific shortening velocity 
(Fig. 6.9), specific shortening (Fig. 6.10), specific work (Fig. 6.11) and specific 
power (Fig. 6.12) but there is no treatment⋅time interaction. Bonferroni’s post-hoc 
test however reveals significant differences in specific work and power between 
control and CH + tempol over the initial 20s and between CH + tempol and CH + 
NAC at the 10s time point. In all cases the CH + tempol value is significantly 
decreased. Significant differences in specific work are also observed from 0-30s in 
the control vs. CH + tempol groups. 
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Figure 6.5: Diaphragm shortening velocity-load after six weeks of sustained 
hypoxia ± chronic antioxidant supplementation or normoxia. Diaphragm specific 
shortening velocity (mean ± SEM) expressed as optimal lengths/Time (Lo/s) as a 
function of load expressed as a percentage of peak force (force/peak force*100); 
n=5-8 per group; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 
0.1); Tempol = sustained tempol + sustained hypoxia; NAC = sustained NAC + 
sustained hypoxia. 
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Figure 6.6: Diaphragm shortening-load after six weeks of sustained hypoxia ± 
chronic antioxidant supplementation or normoxia. Diaphragm specific shortening 
(mean ± SEM) expressed as length/optimal length (L/Lo) as a function of load 
expressed as a percentage of peak force (force/peak force*100); n=5-8 per group; 
Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol = 
sustained tempol + sustained hypoxia; NAC = sustained NAC + sustained hypoxia.  
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Two-Way ANOVA followed by Bonferroni’s post-hoc 
test. 
All treatments compared at all loads. 
Ctrl vs. Hyp Ctrl vs. Temp Hyp vs. NAC Temp vs. NAC 
20% p<0.05 
 
20% P<0.001 
 
25% P<0.01 
 
20% P<0.01 
 
25% p<0.05 
 
25% P<0.001 
 
30% P<0.01 
 
25% P<0.001 
 
30% p<0.05 
 
30% P<0.001 
 
35% P<0.01 
 
30% P<0.001 
 
35% p<0.05 
 
35% P<0.001 
 
40% p<0.05 
 
35% P<0.001 
 
40% p<0.05 
 
40% P<0.01 
 
 40% P<0.01 
 
 
Figure 6.7: Diaphragm work-load after six weeks of sustained hypoxia ± 
chronic antioxidant supplementation or normoxia. Diaphragm specific work 
(mean ± SEM) expressed as Joules/CSA (cm
2
) as a function of load expressed as a 
percentage of peak force (force/peak force*100); n=5-8 per group; Ctrl = normoxic 
control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol = sustained tempol + 
sustained hypoxia; NAC = sustained NAC + sustained hypoxia. 
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Two-Way ANOVA followed by Bonferroni’s post-hoc 
test. 
All treatments compared at all loads. 
Ctrl vs. Hyp Ctrl vs. Temp Temp vs. NAC 
30% p<0.05 
 
20% p<0.01 
 
20% p<0.01 
 
35% p<0.05 
 
25% p<0.01 
 
25% p<0.001 
 
40% p<0.05 
 
30% p<0.001 
 
30% p<0.001 
 
  
 
35% p<0.001 
 
 
  
 
40% p<0.01 
 
 
 
Figure 6.8: Diaphragm power-load after six weeks of sustained hypoxia ± 
chronic antioxidant supplementation or normoxia. Diaphragm specific power 
(mean ± SEM) expressed as Watts/CSA (cm
2
) as a function of load expressed as a 
percentage of peak force (force/peak force*100); n=5-8 per group; Ctrl = normoxic 
control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol = sustained tempol + 
sustained hypoxia; NAC = sustained NAC + sustained hypoxia. 
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Figure 6.9: Diaphragm Fatigue Tolerance: Shortening velocity after six weeks 
of sustained hypoxia ± chronic antioxidant supplementation or normoxia. 
Diaphragm specific shortening velocity (mean ± SEM) expressed as optimal 
lengths/Time (Lo/s) as a function of time (s) with fatiguing stimulation; n=5-8 per 
group; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol 
= sustained tempol + sustained hypoxia; NAC = sustained NAC + sustained hypoxia. 
 
 
149 | P a g e  
 
 
Figure 6.10: Diaphragm Fatigue Tolerance: Shortening after six weeks of 
sustained hypoxia ± chronic antioxidant supplementation or normoxia. 
Diaphragm specific shortening (mean ± SEM) expressed as length/optimal length 
(L/Lo) as a function of time (s) with fatiguing stimulation; n=5-8 per group; Ctrl = 
normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol = sustained 
tempol + sustained hypoxia; NAC = sustained NAC + sustained hypoxia. 
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Two-Way ANOVA followed by Bonferroni’s post-hoc 
test. 
All treatments compared at all times. 
Ctrl. Vs. Temp 
0s p<0.001 
10s p<0.01 
20s p<0.05 
30s p<0.05 
 
Figure 6.11: Diaphragm Fatigue Tolerance: Work after six weeks of sustained 
hypoxia ± chronic antioxidant supplementation or normoxia. Diaphragm specific 
work (mean ± SEM) expressed as Joules/CSA (cm
2
) as a function of time (s) with 
fatiguing stimulation; n=5-8 per group; Ctrl = normoxic control; Hypoxia = 
sustained hypoxia (FiO2 = 0.1); Tempol = sustained tempol + sustained hypoxia; 
NAC = sustained NAC + sustained hypoxia. 
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Two-Way ANOVA followed by Bonferroni’s post-hoc 
test. 
All treatments compared at all times. 
Ctrl vs. Temp Temp vs. NAC 
0s p<0.01 
 
10s p<0.05 
 
10s p<0.01 
 
  
 
20s p<0.05 
 
  
 
 
Figure 6.12: Diaphragm Fatigue Tolerance: Power after six weeks of sustained 
hypoxia ± chronic antioxidant supplementation or normoxia. Diaphragm specific 
power (mean ± SEM) expressed as Watts/CSA (cm
2
) as a function of time (s) with 
fatiguing stimulation; n=5-8 per group; Ctrl = normoxic control; Hypoxia = 
sustained hypoxia (FiO2 = 0.1); Tempol = sustained tempol + sustained hypoxia; 
NAC = sustained NAC + sustained hypoxia. 
 
 
152 | P a g e  
 
6.2.2 Section B: Sternohyoid 
Sternohyoid muscle twitch contractile kinetics are shown in Fig. 6.13. There are no 
significant changes in sternohyoid TTP (Fig. 6.13A) (9.42 ± 0.31 vs. 10.08 ± 0.37 vs. 
10.6 ± 1.12 vs. 10.3 ± 0.4 mean ± SEM ms; control vs. CH vs. CH + tempol vs. CH 
+ NAC; sternohyoid TTP after six weeks of CH respectively; n=5-7 per group) or 
T50 (Fig. 6.13B) (11 ± 1.18 vs. 1.67 ± 0.4 vs. 13.9 ± 3.04 vs. 11.7 ± 1.52 mean ± 
SEM ms; control vs. CH vs. CH + tempol vs. CH + NAC; sternohyoid T50 after six 
weeks of CH respectively; n=5-7 per group) after six weeks of CH ±chronic 
antioxidant supplementation. 
 
As illustrated in Fig. 6.14, six weeks of CH ± chronic antioxidant supplementation 
has no effect on peak specific twitch force (Fig. 6.14A) (2.5 ± 0.39 vs. 1.56 ± 0.19 
vs. 1.88 ± 0.66 vs. 2.99 ± 0.85 mean ± SEM N/cm
2
; control vs. CH vs. CH + tempol 
vs. CH + NAC; sternohyoid peak specific twitch force after six weeks of CH 
respectively; n=5-7 per group). However, peak specific tetanic forces (Fig. 6.14B) 
are significantly different after one-way ANOVA. Peak specific tetanic force is 
decreased after CH and CH + tempol and Tukey’s post-hoc test comparing all means 
to each other reveals that CH + NAC significantly increases peak specific force 
compared to CH (12.32 ± 1.49 vs. 7.98 ± 0.58 vs. 11 ± 0.26 vs. 16.03 ± 2.3
##
 mean ± 
SEM N/cm
2
; control vs. CH vs. CH + tempol vs. CH + NAC; sternohyoid peak 
specific tetanic force after six weeks of CH respectively; n=5-7 per group; 
##
p<0.01 
vs. CH; One-way ANOVA followed by Tukey’s multiple comparison test). 
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Figure 6.13: Sternohyoid isometric twitch kinetics after six weeks of sustained 
hypoxia ± chronic antioxidant supplementation or normoxia. (A) Sternohyoid 
time to peak twitch tension (mean ± SEM) expressed as time (ms); n=5-7 per group; 
(B) Sternohyoid twitch half relaxation time (mean ± SEM) expressed as time (ms); 
n=5-7 per group; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 
0.1); Tempol = sustained tempol + sustained hypoxia; NAC = sustained NAC + 
sustained hypoxia. 
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Figure 6.14: Sternohyoid peak specific twitch force and tetanic force after six 
weeks of sustained hypoxia ± chronic antioxidant supplementation or normoxia. 
(A) Sternohyoid peak specific twitch force (mean ± SEM) expressed as Force/CSA 
(N/cm
2
); n=5-7 per group; (B) Sternohyoid peak specific tetanic force (mean ± SEM) 
expressed as Force/CSA (N/cm
2
); n=5-7 per group; 
##p<0.01 vs. Hypoxia, Tukey’s 
multiple comparison test; Ctrl = normoxic control; Hypoxia = sustained hypoxia 
(FiO2 = 0.1); Tempol = sustained tempol + sustained hypoxia; NAC = sustained 
NAC + sustained hypoxia.  
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Sternohyoid muscle peak specific shortening velocity is shown in Fig. 6.15A and 
peak specific shortening in Fig. 6.15B. There are no significant changes in 
sternohyoid peak specific shortening velocity (5.4 ± 0.71 vs. 5.19 ± 0.93 vs. 6.11 ± 
0.72 vs. 6.05 ± 0.4 mean ± SEM Lo/s; control vs. CH vs. CH + tempol vs. CH + 
NAC; sternohyoid peak specific shortening velocity after six weeks of CH 
respectively; n=5-7 per group) or sternohyoid peak specific shortening (0.27 ± 0.03 
vs. 0.33 ± 0.05 vs. 0.43 ± 0.04 vs. 0.42 ± 0.07 mean ± SEM L/Lo; control vs. CH vs. 
CH + tempol vs. CH + NAC; sternohyoid peak specific shortening after six weeks of 
CH respectively; n=5-7 per group) after six weeks of CH ± chronic antioxidant 
supplementation. 
 
As illustrated in Fig. 6.16A, There are no significant changes in sternohyoid peak 
specific power (11.7 ± 1.81 vs. 8.36 ± 1.45 vs. 11.15 ± 1.33 vs. 15.54 ± 2.94 mean ± 
SEM Watts/cm
2
; control vs. CH vs. CH + tempol vs. CH + NAC; sternohyoid peak 
specific power after six weeks of CH respectively; n=5-7 per group). Peak specific 
work (Fig. 6.16B) follows a similar pattern as power however one-way ANOVA 
comparing all groups approaches statistical significance (p=0.08) (0.6 ± 0.09 vs. 0.62 
± 0.08 vs. 0.76 ± 0.09 vs. 0.95 ± 0.11 mean ± SEM Watts/cm
2
; control vs. CH vs. 
CH + tempol vs. CH + NAC; sternohyoid peak specific power after six weeks of CH 
respectively; n=5-7 per group). 
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Figure 6.15: Sternohyoid peak specific shortening velocity and shortening after 
six weeks of sustained hypoxia ± chronic antioxidant supplementation or 
normoxia. (A) Sternohyoid peak specific shortening velocity (mean ± SEM) 
expressed as optimal lengths/Time (Lo/s); n=5-7 per group; (B) Sternohyoid peak 
specific shortening (mean ± SEM) expressed as length/Optimal Length (L/Lo); n=5-7 
per group; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); 
Tempol = sustained tempol + sustained hypoxia; NAC = sustained NAC + sustained 
hypoxia.  
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Figure 6.16: Sternohyoid peak specific power and work after six weeks of 
sustained hypoxia ± chronic antioxidant supplementation or normoxia. (A) 
Sternohyoid peak specific power (mean ± SEM) expressed as Watts/CSA (cm
2
); 
n=5-7 per group; (B) Sternohyoid peak specific work (mean ± SEM) expressed as 
Joules/CSA (cm
2
); n=5-7 per group; Ctrl = normoxic control; Hypoxia = sustained 
hypoxia (FiO2 = 0.1); Tempol = sustained tempol + sustained hypoxia; NAC = 
sustained NAC + sustained hypoxia. 
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Sternohyoid muscle specific shortening velocity after incremental loads from 0-
100% of peak specific force is shown in Fig. 6.17. A two-way ANOVA reveals a 
significant effect of load (p<0.01), but not treatment and there is no interaction. 
 
Sternohyoid muscle specific shortening after incremental loads from 0-100% of peak 
specific force is shown in Fig. 6.18. Similar to shortening velocity, two-way 
ANOVA reveals a significant load effect (p<0.001). There is also a significant 
treatment effect (p<0.001) but there is no interaction. However, Bonferroni’s post-
hoc test reveals significantly increased specific shortening in CH + tempol compared 
to control and CH + NAC compared to control at 0-10% and 0% loads respectively. 
 
Specific work (Fig. 6.19) and power (Fig. 6.20) after incremental loads from 0-100% 
of peak specific force however present with significant effects of treatment 
(p<0.001), load (p<0.001), and but no treatment-load interaction. Bonferroni’s post-
hoc test reveals increased peak specific work after six weeks of CH + NAC 
compared to control and CH in loads 25, 40, 60% and 25, 30% respectively. 
 
Shortening velocity, shortening, work and power were measured during the fatigue 
trial. Time had a significant effect on each parameter studied (p<0.001) as we would 
expect. Treatment effects were observed for shortening (p<0.001), work (p<0.001), 
and power (p<0.001), but not shortening velocity. It is clear from Fig. 6.21 that the 
rate of shortening velocity fatigue is the same in all groups. Differences in 
sternohyoid rate of shortening fatigue is observed between normoxia and CH + 
tempol groups as CH + tempol shortening is significantly greater than control at time 
0s (p<0.01) but not significantly different at later time points – indicating that the 
rate of fatigue for tempol with shortening is faster than for normoxia. Similar results 
are observed for work fatigue whereby CH + NAC work fatigues faster than 
normoxia and hypoxia alone. CH + NAC power production fatigues faster than 
hypoxia alone. 
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Figure 6.17: Sternohyoid shortening velocity-load after six weeks of sustained 
hypoxia ± chronic antioxidant supplementation or normoxia. Sternohyoid 
specific shortening velocity (mean ± SEM) expressed as optimal lengths/Time (Lo/s) 
as a function of load expressed as a percentage of peak force (force/peak force*100); 
n=5-7 per group; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 
0.1); Tempol = sustained tempol + sustained hypoxia; NAC = sustained NAC + 
sustained hypoxia. 
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Two-Way ANOVA followed by Bonferroni’s post-hoc 
test. 
All treatments compared at all loads. 
Ctrl vs. Temp Ctrl vs. NAC 
0% p<0.01 
 
0% p<0.05 
 
5% p<0.01 
 
  
 
10% p<0.05 
 
  
 
 
Figure 6.18: Sternohyoid shortening-load after six weeks of sustained hypoxia ± 
chronic antioxidant supplementation or normoxia. Sternohyoid specific 
shortening (mean ± SEM) expressed as length/optimal length (L/Lo) as a function of 
load expressed as a percentage of peak force (force/peak force*100); n=5-7 per 
group; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol 
= sustained tempol + sustained hypoxia; NAC = sustained NAC + sustained hypoxia.  
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Two-Way ANOVA followed by Bonferroni’s post-hoc 
test. 
All treatments compared at all loads. 
Ctrl vs. NAC Hyp vs. NAC 
25% p<0.05 
 
25% p<0.05 
 
40% p<0.05 
 
35%  p<0.05 
 
60% p<0.05 
 
  
 
 
Figure 6.19: Sternohyoid work-load after six weeks of sustained hypoxia ± 
chronic antioxidant supplementation or normoxia. Sternohyoid specific work 
(mean ± SEM) expressed as Joules/CSA (cm
2
) as a function of load expressed as a 
percentage of peak force (force/peak force*100); n=5-7 per group; Ctrl = normoxic 
control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol = sustained tempol + 
sustained hypoxia; NAC = sustained NAC + sustained hypoxia. 
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Figure 6.20: Sternohyoid power-load after six weeks of sustained hypoxia ± 
chronic antioxidant supplementation or normoxia. Sternohyoid specific power 
(mean ± SEM) expressed as Watts/CSA (cm
2
) as a function of load expressed as a 
percentage of peak force (force/peak force*100); n=5-7 per group; Ctrl = normoxic 
control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol = sustained tempol + 
sustained hypoxia; NAC = sustained NAC + sustained hypoxia. 
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Figure 6.21: Sternohyoid Fatigue Tolerance: Shortening velocity after six weeks 
of sustained hypoxia ± chronic antioxidant supplementation or normoxia. 
Sternohyoid specific shortening velocity (mean ± SEM) expressed as optimal 
lengths/Time (Lo/s) as a function of time (s) with fatiguing stimulation; n=5-7 per 
group; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol 
= sustained tempol + sustained hypoxia; NAC = sustained NAC + sustained hypoxia. 
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Two-Way ANOVA followed by Bonferroni’s post-hoc 
test. 
All treatments compared at all times. 
Ctrl. Vs. Temp 
0s p<0.01 
 
Figure 6.22: Sternohyoid Fatigue Tolerance: Shortening after six weeks of 
sustained hypoxia ± chronic antioxidant supplementation or normoxia. 
Sternohyoid specific shortening (mean ± SEM) expressed as length/optimal length 
(L/Lo) as a function of time (s) with fatiguing stimulation; n=5-7 per group; Ctrl = 
normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol = sustained 
tempol + sustained hypoxia; NAC = sustained NAC + sustained hypoxia. 
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Two-Way ANOVA followed by Bonferroni’s post-hoc 
test. 
All treatments compared at all times. 
Ctrl vs. NAC Hypoxia vs. NAC 
0s p<0.05 
 
10s p<0.01 
 
 20s P<0.05 
 
 
Figure 6.23: Sternohyoid Fatigue Tolerance: Work after six weeks of sustained 
hypoxia ± chronic antioxidant supplementation or normoxia. Sternohyoid 
specific work (mean ± SEM) expressed as Joules/CSA (cm
2
) as a function of time (s) 
with fatiguing stimulation; n=5-7 per group; Ctrl = normoxic control; Hypoxia = 
sustained hypoxia (FiO2 = 0.1); Tempol = sustained tempol + sustained hypoxia; 
NAC = sustained NAC + sustained hypoxia. 
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Two-Way ANOVA followed by Bonferroni’s post-hoc 
test. 
All treatments compared at all times. 
Hypoxia. Vs. NAC 
10s p<0.01 
20s p<0.05 
30s p<0.05 
 
Figure 6.24: Sternohyoid Fatigue Tolerance: Power after six weeks of sustained 
hypoxia ± chronic antioxidant supplementation or normoxia. Sternohyoid 
specific power (mean ± SEM) expressed as Watts/CSA (cm
2
) as a function of time 
(s) with fatiguing stimulation; n=5-7 per group; Ctrl = normoxic control; Hypoxia = 
sustained hypoxia (FiO2 = 0.1); Tempol = sustained tempol + sustained hypoxia; 
NAC = sustained NAC + sustained hypoxia. 
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6.3 Chapter Discussion 
 
The main findings of this chapter are 1) six weeks of CH is detrimental to diaphragm 
power generating capacity; 2) tempol supplementation has no mitigating effect on 
CH-induced diaphragm weakness; 3) NAC supplementation in CH significantly 
improves diaphragm power generating capacity to an equivalent level to control; 4) 
both the six weeks of CH group and CH + tempol group improve diaphragm isotonic 
fatigue tolerance at 33% load compared to control; and 5) both tempol and NAC 
supplementation in CH improve sternohyoid work-load and power-load relationships 
compared to CH and control conditions. 
 
6.3.1 Diaphragm 
There are no changes in diaphragm contractile kinetics after six weeks of CH and 
this is consistent with previous studies [22,26,65]. Furthermore, this is suggestive 
that changes in Ca
2+ 
release/re-uptake from the SRs are not occurring in the 
diaphragm after six weeks of CH and no change is observed to SECRA isoform areal 
density in rat diaphragm after six weeks of CH [22]. These data suggest that hypoxia 
does not contribute to the SERCA fast-to-slow isoform transitions which are 
observed in COPD diaphragm alongside fibre type transitions from fast-to-slow 
[119], or at least other important factors of the disease are required alongside 
hypoxia to elicit this adaptation e.g. increased load. The increased force required to 
overcome increased load in COPD will increase muscle metabolic demand, thus 
slower relaxation of the muscle to facilitate matching blood perfusion with metabolic 
demand could be deemed a positive adaptation.  
 
Peak force is decreased after six weeks of CH compared to controls, in agreement 
with previous findings in animal models of CH [22,65] and of COPD [86]. A similar 
effect is observed with peak work and power but not peak shortening or shortening 
velocity. Given that isotonic factors contributing to work and power are unchanged, 
decreased force generating capacity explains these changes in work and power. 
Diaphragm weakness is associated with dyspnoea and poor prognosis in respiratory-
related diseases with progression resulting in respiratory failure [370] so this effect 
of CH is clinically relevant. CH in respiratory-related diseases such as COPD is 
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potentially causal and/or progressive to observed diaphragm muscle weakness 
[44,56]. There is a role for ROS in effecting these CH-induced performance 
deteriorations given that NAC supplementation alleviates CH-induced functional 
weakness. This is potentially the mechanism driving diaphragm weakness in COPD 
as decreased force is observed in type I and type IIa fibres [44,56] and we have 
described increased susceptibility of muscles with a higher complement of slow 
oxidative fibre types to CH-induced protein redox remodelling and degradation.  
 
Curiously, while NAC was inotropic in CH, supplementation with tempol was not. 
We suggest two reasons why this might be so. Firstly, these antioxidants are 
administered in the animals’ drinking water during the CH trial and thus must be 
delivered into muscle to carry out their effects. NAC, which contains a cysteine 
amino acid and is a precursor to GSH, supplements circulating cysteine and GSH 
levels. GSH is not a protein and not translated in muscle cells and so GSH/cysteine 
is transported into tissues from the blood and synthesized in the cell. NAC 
supplementation increases [GSH] and decreases protein carbonyls in human vastus 
lateralis muscle [371]. Tempol is a SOD mimetic and SOD enzymes are synthesized 
in the muscle cells themselves, thus, it is unlikely that muscle cells have transporters 
to facilitate tempol up-take. Tempol is membrane permeable however, and can pass 
into muscle down its concentration gradient. Simply, there may be more 
NAC/GSH/cysteine influx into the diaphragm supplementing antioxidant defences 
than tempol. However, chronic in vivo tempol supplementation has previously been 
shown to have inotropic effects on muscle function [189]. Furthermore, in chapter 5 
we report that both tempol and NAC supplementation decreased phospho-p38 
content to a comparable level as control – indicative that tempol is exerting effects 
within the diaphragm. Our second hypothesis follows that as tempol is membrane 
permeable and can permeate into the mitochondria preventing ROS damage at the 
source, this will also serve to prevent ROS signalling (e.g. turnover of mitochondrial 
proteins – chapter 3; increased phospho-p38 MAPK – chapter 5), many of which 
may be important in diaphragm adaptation to CH. NAC may be more limited to 
supplementing antioxidant defences in the myoplasm and preventing oxidation of 
sarcomere localised proteins that are important to function directly such as CK, actin, 
and α-crystallin-B-chain. In a rat model of chronic intermittent hypoxia, both tempol 
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and NAC supplementation improved diaphragm endurance in CIH but only NAC 
improved force [189]. 
 
As six weeks of CH affects force generating capacity but not shortening velocity, 
there is likely to be a variable intrinsic to maximum force production, but not 
maximum shortening velocity [368], that is a target for redox remodelling either 
directly or downstream of ROS. Certainly oxidation of actin is known to affect acto-
myosin interaction (shown in chapter 3) and a similar mechanism may be involved 
after CH exposure. Metabolic changes will not be driving this; peak performance 
capacity is determined before fatiguing stimulation is performed. Muscle atrophy is 
potentially causal because we determine specific force based on CSA of excised 
tissue and not CSA of individual muscle fibres; force is proportional to FCSA. 
However, if cross-bridges in parallel are decreased then shortening velocity would 
also be decreased. Differences in muscle content (e.g. collagen infiltration) are 
unlikely as previous structural studies on the diaphragm do not present evidence of 
muscle injury [22,80]. Therefore, the mechanism affecting force but not shortening 
velocity is likely to be involved in the contractile apparatus. Potentially, redox 
modifications place cross-bridges in different states of activation under pre-load. 
 
Breathing, for the most part, is against low loads, thus there is a reserve of power 
available to the diaphragm for physiological function. If, for example, breathing 
required 8 Watts/cm
2
 (arbitrary value) power generation by the diaphragm, breathing 
at optimum velocity for power production provides ~57% power generating capacity 
reserve in control animals but only ~20% in CH animals according to our ex vivo 
data. Furthermore, producing 8 Watts/cm
2
 can be achieved at a much slower 
shortening velocity in control than CH animals. This will facilitate greater voluntary 
control of breathing in controls and be important in development of dyspnoea in 
respiratory-related disease where hypoxia is featured. The CH diaphragm muscle is 
clearly at a disadvantage if load increases due to e.g. airway obstruction as observed 
in COPD. NAC supplementation could ameliorate this weakness in COPD as it does 
in CH.  
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Work and power in control diaphragms are significantly greater than CH + tempol 
diaphragms observed over the initial 30s of the fatigue trial. After 30s, no significant 
differences are observed suggesting that the rate of isotonic fatigue is faster in the 
control diaphragm. A fatigue index of the isotonic parameter measured after one 
minute of fatiguing stimulation as a function of the initial value reveals significantly 
increased fatigue tolerance in the CH + tempol group compared to control for 
shortening velocity and power but not shortening or work. Taken together, these data 
suggest that ROS differentially impact the fatigue tolerance of the isotonic factors of 
work and power with shortening velocity more susceptible than total shortening. As 
NAC improves peak force, peak work, and peak power, its fatigue tolerance is also 
diminished to control levels – in fact CH + NAC fatigue tolerance may be worse 
than in control later in the fatigue trial. 
 
A potential limitation of the fatigue test in this study is that while initial shortening 
and shortening velocities for the fatigue tolerance test are quite different across 
groups, and this accounts for the statistical differences in work and power over the 
initial 30s, the maximum shortening and shortening velocity at 33% load are not 
significantly different from each other according to the previous isotonic-load 
relationships – indicative that significant fatigue has occurred already. This would 
mean that the CH + tempol group is more prone to fatigue. However, we are still 
considering fatigue tolerance of the different groups after the same protocol and time 
spent in the muscle bath ex vivo. Furthermore, peak force was re-determined after the 
step protocol and 100% load was reset accordingly. Thus, regardless of fatigue over 
the course of the preparation, 33% load was adjusted and accurate to each muscle at 
the beginning of the fatigue tolerance test. In addition, 33% is representative of the 
load at which peak power is generated in control animals but not in e.g. CH + tempol 
treated animals (peak power is generated at ~60% load, Fig.6.8) 
 
Maintained or improved fatigue tolerance of the diaphragm is reported in animal 
models of CH [22,67] and in COPD [45]. In the ex vivo studies, fatiguing stimulation 
was carried out at 40Hz where isometric force production was not different between 
control and CH muscles. The 33% load used in this study biases the test in favour of 
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the weaker CH ± tempol treated groups. Percentage load here is muscle specific, thus 
shortening against 33% load is a lower absolute load for weaker muscles.  
 
6.3.2 Sternohyoid 
Similar to diaphragm, CH has no effect on sternohyoid contractile kinetics which is 
consistent with other studies [22,26] and suggestive that changes in Ca
2+ 
release/re-
uptake from the SRs are not occurring in the sternohyoid.  
 
Taking the peak parameter data and isotonic function-load relationships together, CH 
is detrimental to sternohyoid force, has no effect on shortening velocity, and 
improves total shortening. As six weeks of CH affects sternohyoid force generating 
capacity but not shortening velocity, we arrive at a similar scenario as in diaphragm 
whereby there is likely to be a variable intrinsic to maximum force production, but 
not maximum shortening velocity [368], that is a target for redox remodelling either 
directly or downstream of ROS. Differential to diaphragm however, CH improves 
sternohyoid shortening-load and consequently work-load relationships. Were this 
effect attenuated by antioxidants, we would credit redox remodelling as the 
mechanism of adaptation; however antioxidants potentiate CH-induced increased 
shortening and work. We have discussed increased susceptibility of slow oxidative 
fibre types to redox remodelling, thus increased shortening capability is potentially 
an effect specific to fast glycolytic muscles. 
 
Decreased force is contrary to the effects of CH on sternohyoid function reported in 
rat [22,26], however the temperature used in the latter muscle bath studies were 30
o
C 
and 25
o
C respectively, both lower than the 35
o
C used in this study. Hypoxia-induced 
sternohyoid dysfunction is thought to contribute to OSA which is characterised by 
recurrent airway collapse [292]. Decreased force generating capacity may be 
detrimental to the bracing function of the muscle potentially increasing susceptibility 
to airway collapse. Clearly, antioxidant supplementation is a therapeutic strategy to 
increase sternohyoid work and power.  
 
ROS affect force production in both sternohyoid and diaphragm muscles with 
consequences for power generating capacity of these muscles. However, differential 
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muscle isotonic contractile parameter adaptations indicate muscle specific effects of 
CH on function. This follows suit with differential molecular adaptations presented 
in previous chapters. However, given that NAC supplementation is beneficial to 
performance in both muscles, it may be especially useful as an adjunct therapy in the 
COPD-OSA overlap syndrome. 
 
Fatiguing stimulation had no effect on sternohyoid shortening velocity but treatment 
effects were observed for shortening, work and power. CH + tempol shortening was 
significantly greater than control at time zero but not thereafter suggesting fatigue 
tolerance is decreased in the sternohyoid of the CH + tempol group. CH + NAC 
work is significantly greater than both CH alone and control at time 10-20s and 0s 
respectively but not thereafter. This highlights differences in the mechanism of 
action of tempol and NAC on the sternohyoid in CH. Tempol has greater effect on 
shortening while NAC has a greater effect on force. In a rat model of chronic 
intermittent hypoxia, both tempol and NAC supplementation improved diaphragm 
endurance in CIH but only NAC improved force [189]. A similar effect of NAC is 
observed for power fatigue tolerance – NAC has no effect on shortening velocity and 
so increases force generating capacity to increase power. Increased power generating 
capacity decreases fatigue tolerance. A fatigue index of the work and power 
measured after one minute of fatiguing stimulation as a function of the initial value 
reveals decreased fatigue tolerance of the CH + antioxidant groups compared to CH 
alone. With respect to this, antioxidants may be detrimental to the sternohyoid 
muscle function in keeping the airway open in CH. 
 
6.3.3 Conclusion 
In support of our hypotheses, six weeks of CH is detrimental to mouse diaphragm 
isotonic performance and this is mitigated by NAC supplementation. Contrary to our 
hypothesis, tempol had no effect in alleviating CH-induced diaphragm weakness. 
 
Six weeks of CH exposure predominantly affects diaphragm force production which 
in turn has consequences for the muscle’s ability to perform work and generate 
power. This is a ROS related phenomenon as it was attenuated by NAC. Some CH-
induced ROS may promote positive adaptations in the diaphragm because tempol 
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had no effect on functional performance in CH. NAC supplementation may be a 
viable adjunct therapy to improve diaphragm performance in respiratory-related 
diseases where hypoxia is featured and redox stress occurs. Six weeks of CH also 
affects sternohyoid force generating capacity and both tempol and NAC 
supplementation attenuate this. CH-induced ROS in the sternohyoid muscle may be 
progressive to the development of upper airway dysfunction and OSA that often 
occurs in COPD patients [53,54]. 
 
The strength and site of action of antioxidant supplements is important with regard to 
improving muscle performance in times of stress as they may block redox signalling 
that could be important for both positive and negative adaptations rather than 
negative adaptations alone. Identifying how CH and ROS can be detrimental to 
diaphragm muscle force but not isotonic shortening or shortening velocity will 
facilitate greater specificity in identifying and selecting therapeutic strategies to 
combat respiratory muscle dysfunction. 
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Chapter 7: Summary & Conclusions 
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7.1 Summary 
 
Our laboratory has previously described CH-induced structural and functional 
(mal)adaptations in the diaphragm muscle, similar to COPD patients, and differential 
in respiratory and limb muscles. Trans-thoracic pressure generating capacity is 
correlated with survival in COPD so adaptations in the diaphragm following CH are 
clinically relevant. COPD is predicted to be the 3
rd
 leading cause of death globally 
and there is no cure. Elucidating the molecular mechanisms that underpin diaphragm 
adaptations to CH is important for shaping therapeutic strategies. We hypothesized 
that redox remodelling is pivotal in driving these adaptations for several reasons: 1) 
CH promotes ROS formation at the mitochondria; 2) mitochondrial remodelling has 
been described in the diaphragm following CH; respiration rates decreased compared 
to limb muscles; evidence of mitophagy is observed; and ROS are produced by and 
contribute to mitochondrial damage; 3) evidence of ROS damage has been observed 
in skeletal muscle of COPD patients and after high altitude expeditions; 4) 
contractile activity promotes ROS formation and contractile activity increases in the 
diaphragm with reflex hyperventilation; and 5) ROS are known to affect muscle at 
metabolic, structural, and functional levels with adaptations described for each in the 
diaphragm following CH. 
 
We utilised a mouse model exposed for one, three, and six weeks to CH (FiO2=0.1) 
or normoxia for molecular study of the diaphragm. The sternohyoid and limb 
muscles were studied in parallel as a reference. A second cohort exposed to six 
weeks of CH ± chronic antioxidant supplementation was used for functional and 
molecular analysis of the diaphragm. 
 
In chapter three we have highlighted a role for ROS in promoting both bi-phasic and 
progressive protein redox changes in diaphragm. These changes are differential in 
respiratory and in limb muscles and occur regardless of increased endogenous 
antioxidant defences. These data are also indicative that both of the harder-working 
respiratory muscles have an increased susceptibility to protein redox remodelling as 
do muscles with a greater complement of slow oxidative fibre types. Following this, 
we took our investigation of protein redox changes further using a redox proteomics 
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approach and identified proteins that undergo structural and expression changes 
following six weeks of CH. It quickly became clear that extensive metabolic enzyme 
remodelling was occurring, the stress was reaching the level of the cross-bridge, and 
numerous stress response proteins were affected. These findings prompted us to 
assess metabolic enzyme activities, atrophy signalling and mechanism, and 
ultimately function after six weeks of CH + antioxidant supplementation. 
 
Chapter four describes metabolic remodelling in the diaphragm. For the most part, 
decreased activities of redox remodelled proteins and others at key substrate flux 
gating points from the glycolysis, TCA cycle and phosphagen metabolic systems are 
observed. Clearly, a decreased carbohydrate derivative flux strategy is adopted, not 
an uncommon hypoxia response as is described in the comparative physiology 
literature, and will serve to put tighter regulation on ATP levels, limit ROS 
production from mitochondria, and limit cellular acidosis. Some of these changes are 
bi-phasic, which, taken together with bi-phasic adaptations observed in protein redox 
remodelling, suggest differential early and late responses to hypoxia at the molecular 
level. There is also a differential muscle response. Furthermore, we provide some 
evidence to suggest the diaphragm may increase reliance on fatty acid metabolism 
which is also reported in the high altitude literature. HIF-1α content is increased in 
the diaphragm after six weeks of CH and this increase is attenuated by antioxidant 
supplementation and will contribute to gene expression changes. HIF-1α content 
remained unchanged in the sternohyoid muscle suggesting a muscle specific 
activation. 
 
Atrophy signalling changes and a redox sensitive atrophy mechanism are reported in 
chapter 5. Both active and passive atrophy signalling occur through increased 
phospho-FOXO3a content and decreased phospho-mTOR content. Moreover, these 
changes are not driven by Akt, but rather increased phospho-p38 content. P38 
MAPK is known to be ROS sensitive and to promote atrophy in times of redox 
stress. Supplementation with the antioxidants tempol or NAC in CH decreased 
phospho-p38 content in diaphragm to a comparable level as control. Phosphorylated 
p38, JNK and ERK1/2 MAPK content changes were differential in diaphragm and 
sternohyoid muscles and likely underpin the differential muscle fibre atrophy 
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responses to CH. Bi-phasic changes overtime are further indicative of different early 
and late adaptive strategies in CH. Redox sensitive chymotrypsin-like activity of the 
20S proteasome is also increased in the diaphragm after six weeks of CH as a 
mechanism of muscle fibre atrophy. Proteasome activity changes after six weeks of 
CH correlate with protein carbonylation as the muscles with the greater complement 
of slow oxidative fibres present with the greatest change. 
 
In chapter six we assessed isotonic function of the mouse diaphragm after six weeks 
of CH ± chronic antioxidant supplementation. Six weeks of CH decreases diaphragm 
power generating capacity. Decreased force is driving this as shortening velocity was 
unaffected. Chronic supplementation with tempol had no effect on performance 
while NAC restored power to a comparable level as control. These data are 
indicative of redox modification/s at the level of the cross-bridge that affects force 
production but not shortening velocity in the diaphragm muscle after six weeks of 
CH. Potentially some ROS are required for redox signalling, and tempol, being a 
membrane permeable superoxide mimetic, is blocking ROS at source, while NAC is 
exerting greater effects in the myoplasm of the cell conferring protection to the 
cross-bridge apparatus whilst permitting some redox signalling.  
 
7.2 Limitations 
 
I appreciate that no research method is without limitations and that the scientific 
method can only ever be supportive of a hypothesis or prove it false. We hypothesize 
that redox remodelling is pivotal in driving diaphragm adaptation to CH. Our data on 
molecular and functional remodelling is in support of this hypothesis. However, no 
animal model can truly mimic the human scenario; the durations of the hypoxia 
stimulus are snapshots of the change from control at those particular time-points and 
oscillations may occur between those time points – just as bi-phasic changes are 
observed for several of the metabolic signalling proteins studied between control and 
six weeks of CH; and ex vivo muscle functional performance assessment is 
potentially different to in vivo performance. 
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There are also inherent limitations of techniques used in this study: Extracellular 
matrix (ECM) proteins may be contributing to the redox proteomics data as the ECM 
is not removed from the muscle. One way around this would be to use single fibres 
from the muscle however this asks a different question. We are interested in the 
muscle bundle as a whole which takes away confounding factors such as differences 
in fibre recruitment during the trial. Ideally all fibres would have to be taken into 
account and this is not feasible. Given the location and function of the majority of 
the proteins identified to be remodelled e.g. several metabolic proteins which are 
present at much higher quantities in muscle than in the ECM, we hypothesize that 
the contribution of ECM proteins is minimal. A second limitation of this approach is 
that higher molecular weight proteins are not accounted for. They are known to be 
difficult to transfer from isoelectric focusing strips into polyacrylamide gel for 
electrophoresis. Furthermore, if they do transfer across the strip-gel interface, there is 
a high abundance of high molecular weight proteins in muscle and thus the signal 
from these is likely to present as saturated and beyond the specification of our 
measurement tools. An increased amount of saturated protein signals might also 
mask proteins with very low signals. However, we do use a molecular mass range 
that incorporates the greatest proportion of different muscle proteins. For isotonic 
fatigue assessment, we contracted the muscles at 33% load as we and other groups 
observe 33% to be the approximate load at which peak power occurs. However, the 
load at which peak power occurs is decreased in the CH + tempol group as we 
observe from the power-load relationship. Therefore, the fatigue data is not a 
comparison of peak power fatigue, but simply power fatigue at 33% load. If fatigue 
data is presented as a percentage of the initial power measured, then the percentage 
decrease in power highlights the CH + tempol group as being most fatigue tolerant. 
 
Limitations in the conclusions drawn from the evidence: while we suggest that the 
diaphragm increases reliance on fatty acid oxidation, the evidence to support this, 
with the exception of catalase, comes from our data on protein activities that do not 
strictly take part in the beta-oxidation pathway but can support substrate flux through 
this cascade, as well as from the literature on other models of hypoxia. FOXO3a, 
unlike the other atrophy signalling proteins assessed, is actually exported from the 
nucleus and prevented from driving atrophy when it is phosphorylated. Therefore, 
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measuring a decrease in phospho-FOXO3a content will not strictly be driving 
atrophy as decreased FOXO3a protein content, phosphorylated or not, could account 
for this observation. However, coupled with the other changes in the Akt and MAPK 
cascades, the muscle fibre atrophy phenotype that has been described, and the 
increased catalase activity, we hypothesize that decreased phospho-FOXO3a is 
representative of increased non-phosphorylated FOXO3a protein which will drive 
the fibre atrophy response. 
 
Finally, more protein can be extracted from the diaphragm muscle than the other 
muscles used in this study. Therefore sternohyoid and limb muscles have not been 
used as a reference in all experiments described. Furthermore, when sample volumes 
were running low, some samples were pooled so further experiments could be 
performed. This in turn decreases the statistical power of some experiments. 
 
7.3 Future Studies 
 
First and foremost, do the molecular mechanisms driving mouse diaphragm 
adaptation to CH translate to human disease where hypoxia is featured? A molecular 
investigation of human diaphragm from hypoxic patients and correlation of the 
magnitude of redox stress with PaO2 would further determine the extent of the 
translational aspect of this research. Our laboratory is now collaborating with the 
local university hospital to obtain human biopsy samples to address this.  
 
NAC treatment from the onset of the hypoxic insult proved favourable to diaphragm 
function but many respiratory-related diseases where hypoxia is featured are detected 
at later stages of disease. It would be beneficial to know if NAC treatment beginning 
several weeks after the onset of the hypoxia trial can attenuate or reverse the redox 
stress and muscle dysfunction. 
 
Future experiments considering muscle fibre atrophy should further record muscle 
weights to determine if muscle atrophy is commensurate with the observed changes 
in body weight. 
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From a scientific perspective, elucidating the mechanism behind CH- and ROS-
induced decreased diaphragm force production but not shortening velocity would be 
interesting. Purification of actin and myosin from mouse diaphragm after CH 
treatment by chromatography followed by MS analyses to determine sites and types 
of protein structural remodelling would provide clues as to how this effect 
materialises. 
 
Another interesting avenue of study would be to determine if these changes can be 
reversed by a subsequent chronic re-oxygenation protocol following the chronic 
sustained hypoxia exposure. Given the diaphragm adaptations described in this thesis 
are redox-sensitive, they are potentially reversible. This is would be of physiological 
importance to high altitude expeditions in particular where re-oxygenation occurs 
with descent to sea level. 
  
Lastly, and of great importance for both research and clinical settings where 
antioxidants are in use, the question remains as to whether chronic tempol 
supplementation in CH blocks redox signalling events in the diaphragm and in doing 
so counters potential beneficial antioxidant effects, such as those observed with 
NAC. If this proves to be the case, then the strength of the antioxidant supplement as 
well as its target site of action becomes very important in shaping therapeutic 
strategies that utilise antioxidants.  
 
7.4 Conclusions & Implications 
 
We conclude that CH induces protein redox changes in the diaphragm muscle that 
drive a decreased carbohydrate derivative flux phenotype and promote muscle fibre 
atrophy. Moreover, these molecular adaptations contribute to decreased diaphragm 
functional performance after CH, but, importantly, they can be prevented by 
treatment with the antioxidant NAC but not tempol. These findings indicate that 
NAC may be a useful adjunct therapy in respiratory-related diseases where hypoxia 
is featured. However, care must be taken when considering exogenous antioxidants 
as therapeutic options with regard to their strength and site of action because 
important redox signalling cascades that result in positive adaptions may be blocked 
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e.g. tempol is membrane permeable and will exert stronger antioxidant effects than 
NAC at the mitochondria. CH-induced adaptations depend on contractile activity, 
muscle fibre-type composition and duration of exposure and skeletal muscles cannot 
be considered as a single organ when describing CH-induced changes. Adaptation to 
CH is temporally modulated and insight drawn from early defensive strategies may 
not be relevant to longer durations of CH. The redox proteomics approach utilised in 
this study can be extended to other models of disease characterised by 
oxidative/reductive stress. 
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Appendix I 
Animal model data for group 1 exposed to one, three and six weeks of CH or 
normoxia. 
 
 
 
 
 
Figure 8.1: C57Bl6/J percentage haematocrit after one, three and six weeks of 
sustained hypoxia compared to normoxic controls. Haematocrit (mean ± SEM) 
after one, three, and six weeks of normoxia or sustained hypoxia expressed as a 
percentage of total blood volume; n=8 per group; ***p<0.001; Student’s t-test; Ctrl 
= normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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Figure 8.2: C57Bl6/J body weights after one, three and six weeks of sustained 
hypoxia compared to normoxic controls. Body weights (mean ± SEM) after one, 
three, and six weeks of normoxia or sustained hypoxia expressed in grams (g); n=8 
per group; Ctrl = normoxic control; CH = sustained hypoxia (FiO2 = 0.1). 
 
 
 
Figure 8.3: C57Bl6/J right ventricle/left ventricle (+ septum) weights after one, 
three and six weeks of sustained hypoxia compared to normoxic controls. Right 
ventricle/left ventricle (+ septum) weights (mean ± SEM) after one, three, and six 
weeks of normoxia or sustained hypoxia; n=8 per group; **p<0.01, ***p<0.001, 
ns=not significant; Student’s t-test; Ctrl = normoxic control; Hypoxia = sustained 
hypoxia (FiO2 = 0.1). 
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Figure 8.4: C57Bl6/J right ventricle/100g body weight after one, three and six 
weeks of sustained hypoxia compared to normoxic controls. Right 
ventricle/(100g) body weight (mean ± SEM) after one, three, and six weeks of 
normoxia or sustained hypoxia; n=8 per group; ***p<0.001, ns=not significant; 
Student’s t-test; Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1). 
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Animal model data for group 2 exposed six weeks or normoxia or CH ± 
antioxidant supplementation. 
 
 
 
 
Figure 8.5: C57Bl6/J percentage haematocrit after six weeks of sustained 
hypoxia ± chronic antioxidant supplementation or normoxia. Haematocrit (mean 
± SEM) expressed as a percentage of total blood volume; n=5-8 per group; 
***p<0.001 vs. Ctrl; One-way ANOVA, Tukey’s multiple comparison test; Ctrl = 
normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol = sustained 
tempol + sustained hypoxia; NAC = sustained NAC + sustained hypoxia. 
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Figure 8.6: C57Bl6/J right ventricle/left ventricle (+ septum) weights after six 
weeks of sustained hypoxia ± chronic antioxidant supplementation or normoxia. 
Right ventricle/left ventricle (+ septum) weights (mean ± SEM); n=5-8 per group; 
Ctrl = normoxic control; Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol = 
sustained tempol + sustained hypoxia; NAC = sustained NAC + sustained hypoxia. 
 
 
Figure 8.7: C57Bl6/J right ventricle/body weight (100g) after six weeks of 
sustained hypoxia ± chronic antioxidant supplementation or normoxia. Right 
ventricle/body weights (mean ± SEM); n=5-8 per group; *p<0.05 vs. Ctrl; Kruskal-
Wallis test, Dunn’s multiple comparison test; Ctrl = normoxic control; Hypoxia = 
sustained hypoxia (FiO2 = 0.1); Tempol = sustained tempol + sustained hypoxia; 
NAC = sustained NAC + sustained hypoxia. 
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Figure 8.8: C57Bl6/J body weights after six weeks of sustained hypoxia ± 
chronic antioxidant supplementation or normoxia. Body weights (mean ± SEM) 
expressed in grams (g); n=5-8 per group; Ctrl = normoxic control; Hypoxia = 
sustained hypoxia (FiO2 = 0.1); Tempol = sustained tempol + sustained hypoxia; 
NAC = sustained NAC + sustained hypoxia. 
 
 
Figure 8.9: C57Bl6/J water consumption after six weeks of sustained hypoxia ± 
chronic antioxidant supplementation or normoxia. Water consumption (mean ± 
SEM) expressed in ml/mouse/day; water contained 1mM tempol and 1% NAC for 
tempol and NAC groups respectively; n=5-8 per group; Ctrl = normoxic control; 
Hypoxia = sustained hypoxia (FiO2 = 0.1); Tempol = sustained tempol + sustained 
hypoxia; NAC = sustained NAC + sustained hypoxia. 
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